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ABSTRACT 
For over a decade, diquaternary ammonium gemini surfactants have shown promise as 
non-viral gene delivery agents in both in vitro and in vivo systems. Their continued development, 
however, requires an understanding of their biological fate. The absence of identification and 
quantification methods that can achieve that goal is what drove the development of simple and 
rapid mass spectrometry (MS)-based methods; the focus of my Ph.D. dissertation.  
Prior to the development of these MS-based methods, an understanding of the gas phase 
behavior of diquaternary ammonium gemini surfactants is required. The development of a 
universal fragmentation pathway for gemini surfactants was achieved using low resolution and 
high resolution MS instruments. Single stage (MS), tandem stage (MS/MS and quasi-multi-stage 
(quasi MS
3
) mass spectrometry analysis allowed for the confirmation of the molecular 
composition and structure of each gemini surfactant through the identification of common and 
unique mass to charge values. Understanding the fragmentation behavior allowed for the specific 
identification and/or quantification of gemini surfactants by MS-based methods; including liquid 
chromatography low resolution tandem mass spectrometry (LC-LR-MS/MS), fast 
chromatography low resolution tandem mass spectrometry, fast chromatography high resolution 
mass spectrometry, desorption electrospray ionization low resolution mass spectrometry and 
matrix assisted laser desorption ionization high resolution mass spectrometry. 
We hypothesized that a LC-LR-MS/MS method would be the most effective quantitative 
method for the quantification of N,N-bis(dimethylhexadecyl)-1,3-propane-diammonium 
dibromide (G16-3) within PAM212 cellular lysate; achieving the lowest lower limit of 
quantification (LLOQ). Although the LC-LR-MS/MS method achieved a LLOQ suitable for 
analysis of G16-3 within PAM212 cell lysate, its limitations made it an inefficient method. In 
comparison, the four alternative mass spectrometry methods were faster, more efficient and less 
expensive than a conventional LC-LR-MS/MS method for the post transfection quantification of 
G16-3 within PAM212 cell lysate to be determined; 1.45 ± 0.06 μM. Future application of the 
universal fragmentation pathway and each MS-based quantification method will be beneficial for 
the future development of diquaternary ammonium gemini surfactants to further understand their 
post transfection fate. 
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CHAPTER 1 
INTRODUCTION 
1.1 Biopharmaceutical therapeutics 
 The combination of technological innovations and a better understanding of biological 
systems are altering the manner by which diseases are being diagnosed and treated as evident in 
the steady approval of new biological drugs.1 The increase in approval rates can be attributed to 
the success of biopharmaceutical therapeutics that aim to directly mimic the function of the 
deficient or erroneous biological molecule(s) without inducing toxicity. The first commercially 
approved biopharmaceutical agent was insulin, which, along with its analogues, is utilized for the 
treatment of both type I & II diabetes mellitus.2, 3 These biopharmaceuticals provide medical 
glycemic control and they remain the prevailing therapeutic agents utilized for the treatment of 
both type I & II diabetes mellitus after 31 years of marketing biosynthetic human insulin.2, 3 
Insulin’s efficacy in the treatment  of diabetes was instrumental in the development of future 
biopharmaceuticals, demonstrating the viability of using replacement proteins, instead of small 
drug molecules, in the treatment of diseases. For example, interferon-α proteins have replaced 
corticosteroids for the treatment of Behcet's disease inducing long-lasting remission and 
significantly improving prognosis.4 Progress, such as this, has stimulated the use of biological 
agents, including both proteinaceous and genetic material, for the treatment of a plethora of 
ailments.1 
Although proteinaceous biopharmaceuticals are the dominant biological therapeutic, 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are also being utilized and developed 
for therapeutic purposes.  For example, the RNA sequence Macugen®, an anti-vascular 
endothelial growth factor (VEGF), is able to block extracellular VEGF, inhibiting its activity and 
preventing age-related macular degeneration.5 Intravitreous injection of Macugen® has reduced 
the risk of visual-acuity loss and induced visual improvement without producing an increased 
risk of complications associated with intraocular drug injection.5 Gene therapy’s ability to treat a 
disease state by reducing adverse effects associated with conventional therapies is one of the 
desired benefits. For example, a mycobacterial cell wall-DNA complex has been effectively 
employed as an anti-tumor agent for the treatment of bladder cancer in patients, achieving 
treatment rates comparable to the conventional treatment of bacillus Calmette-Guerin (BCG).6  
However, unlike BCG the adverse reactions were lower and did not limit treatment options.6 The 
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development and application of such biopharmaceuticals have demonstrated how they are able to 
alleviate disease symptoms in a safe and efficacious manner. 
1.2 Genetic Biopharmaceuticals 
 Theoretically, DNA and RNA can treat disease states and/or restore normal cellular 
function through the correction of a monogenic genetic mutation, insertion of a specific gene, or 
blockage of gene overexpression. Gene therapy can be utilized to permanently restore normal 
cellular function if the gene is effectively inserted into the chromosome and subsequently 
transcribed into the desired messenger RNA producing the desired protein(s). Conversely, 
transient restoration of normal cellular function can occur if the genetic material is transported 
into the nucleus, producing the desired biological outcomes without being inserted into the 
chromosome.7, 8 In order for the genetic material to be expressed, it should escape cellular 
degradation and be efficiently delivered into the nucleus. Although this can be achieved using 
several physical methods, many genetic biopharmaceuticals currently under development utilize 
a delivery vector; preventing degradation of the genetic material and enabling its cellular 
uptake/targeting. 
Vectors can be classified as either viral, which involves replacing the genetic information 
within the viral capsid with a therapeutic gene(s),8 or non-viral, utilizing either physical methods 
[electroporation, sonoporation, etc.] or chemical methods [lipoplexes, nanoparticles, etc.] to 
facilitate the transfection of the genetic material into the cells. Although both vector classes have 
surmounted many hurdles in their application to gene delivery, the task of delivering the genetic 
material remains a large technical challenge. Viral gene therapy achieves gene delivery, with an 
efficacy greater than non-viral gene therapy.8 In addition, some viral vectors are capable of 
introducing the gene directly into the chromosome.9, 10 For example, treatment of immune 
dysfunction through gene therapy resulted in eight of nine patients achieving permanent gene 
expression following ex vivo retrovirus-mediated transfer of γ chain to autologous CD34+ bone 
marrow cells.11 Patient follow up demonstrated that the T cells were still producing the 
transduced gene 10 years after undergoing the ex vivo treatment. However, this viral gene 
therapy has been correlated with a risk of acute leukemia as well as an undesired immune 
response.11  
3 
 
Native defense mechanisms of cytokines and lymphocytes induce an immune response 
through the recognition of viral peptide antigens, inducing detrimental side effects, including 
death.12, 13 The risks associated with viral gene therapy have spurred the exploration of non-viral 
methods of gene delivery. 
1.3 Carriers Utilized for Non-viral Gene Delivery 
 Although non-viral gene therapy is less effective than viral vectors in the delivery of 
genetic material, it is a safer and less complex alternative.14-16 The ability to chemically modify 
non-viral vectors, preserving their benefits and addressing their deficiencies, is applicable not 
only to reducing their toxicity, but also for improving their efficiency, biodegradability,17 
handling capacity,18 and production mechanisms,19 all of which are properties that play a key role 
in achieving safe and sustained transgene expression.  
A critical feature of many successfully applied non-viral gene delivery vectors is their 
cationic nature;20 first introduced by Felgner et al.21 as well as Wu and Wu22 in 1987. The 
cationic nature of the delivery vectors allows them to form ion pair interactions with the 
polyanionic backbone of genetic material, shielding the genetic material from degradation while 
allowing for their cellular uptake and release.20 The ion pair interaction facilitates the compaction 
and encapsulation of both small and large (>130kDa) DNA or RNA within a simple delivery 
vector.23   
 Despite being less toxic than viral vector, a result of their reduced propensity for 
inducing an immunogenic effect,24 cationic non-viral delivery vectors do impart some toxicity 
due to their cationic nature.25-27 For example, polycationic polymers, polyethylenimine,28 and 
poly[N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide] modified with polyethylene glycol (PEG-
P[ASP]DET), demonstrated  excellent gene compaction efficiencies but were found to inflict 
cellular damage through interactions with anionic molecules(Figure 1.1A).27 To reduce these 
interactions, chondroitin sulfate was included in the formulation, neutralizing the cationic region 
after plasmid release and preventing the interaction of PEG-P[ASP]DET with anionic molecules 
(Figure 1.1B).27 The inclusion of chondroitin sulfate within the non-viral gene delivery 
formulation demonstrates the flexibility of their composition. In fact, modifications to non-viral 
delivery systems comprised of cationic and neutral lipids have allowed for their application to 
the treatment of various cancers; including head,29 neck,29 kidney,30 and ovarian cancers.31 In 
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addition, non-viral vectors were successfully utilized through the use of targeting ligands, 
enhancing their efficacy and specificity as well as reducing their overall toxicity.32, 33 
1.3.1 Lipid-based Non-viral Vectors 
 Lipid-based non-viral vectors encapsulate the genetic material within lipoplex structures, 
shielding it from degradation by deoxyribonuclease or ribonuclease34, 35 and facilitating the 
interaction of the surface of the lipoplex with cellular surfaces.36 Such capabilities can lead to the 
effective delivery of genetic material, with the potential for a 10-fold increase in the stability of 
the encapsulated genetic material in comparison to unprotected genetic material.20, 37 The 
formation of a lipoplex facilitates stabilization, however, the stability is enhanced through an 
increase in the ratio of the lipid’s positive charge to the genetic material's negative charge.37 
Additional innovations are required in order to further improve the encapsulation and efficient 
delivery of lipoplexes, including altering their size (1-500 nm)38 and composition (anionic or 
cationic lipid, protein composite lipid, etc.).39 
 Uptake, a key consideration for the efficacy of a lipoplex formulation, is largely affected 
by its size and composition. The transfection of C2C12 pluripotent mesenchymal precursor cell 
lines by cationic lipoplexes with a mean diameter of 130 nm resulted in a 2 fold increase in 
internalization of the plasmid in comparison to lipoplexes with a mean diameter of 253 nm.40 
Similarly, a decrease in the mean diameter of polyethylene glycol (PEG) phosphatidyl-
ethanolamine lipoplexes has led to an increase in delivery efficacy and gene expression.38 In 
addition, the circulation time was improved, contributing to the efficient delivery and targeting 
of lipoplexes containing PEG bearing lipids.41, 42 The inclusion of PEG increases the surface 
hydrophilicity of the liposome and reduces the probability of the liposome interacting with 
opsons, which cause liposomal degradation and removal.43  
Additional modifications to the lipid structure have the potential to enhance the 
compaction of genetic material, reduce cellular toxicity, and improve cellular targeting. Gemini 
surfactants, dimeric surfactant entities, are one class of surfactant molecule that is being 
developed for lipid-based gene delivery. A variety of structural modifications are employed by 
gemini surfactants to improve their transfection efficiency and specificity. 
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Figure 1.1 Chondroitin sulfate is able to alleviate tissue damage (ϟ) attributed to cationic non-
viral gene carriers. The use of cationic non-viral vectors has been associated with cellular and 
tissue damage due to their non-specific interactions with anionic molecules. For example, the 
application of PEG-P[ASP]DET as non-viral vectors has been shown to induce damage 
(bolts) of the membrane due to their polycationic nature  (A). The inclusion of chondroitin 
sulfate, a poly anionic compound, during vector production resulted in a reduction in the 
observed membrane damage because chondroitin sulfate was found to interact with the 
cationic region of PEG-P[ASP]DET (B). 
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1.3.2 Gemini surfactants 
 The term gemini surfactant was proposed by Fredric Menger in 199144 for molecules 
comprised of two hydrophobic alkyl chains with polar heads separated by a spacer region linking 
each polar head (Figure 1.2A).45  Menger solely included bis-surfactants that had a rigid spacer 
composed of a benzene or stilbene system (Figure 1.2B) in his original definition, however, it 
has since been extended to include all bis-surfactants joined by a rigid or flexible spacer 
molecules, including both anionic (Figure 1.2D) and cationic molecules (Figure 1.2D).45 
Conventional surfactants have a single hydrophobic tail connected to polar/ionic head group. The 
inclusion of two hydrophobic tail regions attached to the polar head groups creates an 
amphiphilic compound that, when introduced into solution, self-assemble.45, 46 The self-assembly 
of the gemini surfactants molecules results from hydrophobic/hydrophilic segregation facilitated 
by the hydrophobic tail regions as well as the polar headgroups and/or spacer regions.47 The 
presence of two hydrophobic tail regions as well as the symmetry of gemini surfactants makes 
their surface activity stronger than conventional surfactants and more importantly the critical 
micelle concentration (CMC) is remarkably lower than other surfactants.45  
Gemini surfactants that are asymmetric,48 possessing more than two polar groups and/or 
tails, have also been synthesized.49, 50 However, the great majority of gemini surfactants are 
symmetrical, with identical polar head groups and tail regions.51 The acceptable variations in the 
structure of the spacer, polar head groups, and hydrophobic tails regions allow for an endless 
number of possible structures and physicochemical properties.  A benefit of the structural 
variations of gemini surfactants is their numerous applications; including the construction of high 
porosity materials,52 antibacterial regimens,53, 54 analytical processes,55 and drug delivery 
systems.56-59 The cationic nature of diquaternary ammonium gemini surfactants makes them 
adeptly suited to encapsulate genetic materials and facilitate their transfection. The interaction 
between the cationic regions of the gemini surfactant and the anionic phosphate backbone of the 
DNA sequence results in the successful encapsulation of DNA.60 In addition, the amphiphilic 
nature of gemini surfactants results in the self-assembly of cationic lipoplexes at concentrations 
greater than the gemini surfactants CMC.44 A multitude of gemini compounds are currently 
assessed for their DNA delivery efficiency, however, those discussed in this dissertation are 
symmetrical diquaternary ammonium compounds.61 
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1.3.3 Diquaternary ammonium gemini surfactants  
 The molecular structure of diquaternary ammonium gemini surfactants and their DNA 
complexes are well-characterized; a result of their usage as gene delivery agents for the past 
decade and a half.46, 56, 62, 63 These gemini surfactants can be categorized into one of four 
individual families based upon the composition of their spacer region; alkyl spacers (Figure 
1.3A), secondary and tertiary amines within alkyl spacers (Figure 1.3B), ether linkages between 
alkyl spacers (Figure 1.3C), or hydroxyl functional groups attached to alkyl spacers (Figure 
1.3D). Studies involving diquaternary ammonium gemini surfactants demonstrate that they 
provide a viable method for non-invasive gene delivery. For example, the transfection of a 
plasmid, cytomegalovirus immediate early promoter green fluorescent protein, into COS-7 cells 
utilizing (2S, 3R)-2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-dimethylammonium)butane 
Figure 1.2 Structural characteristics of Gemini surfactants. Gemini Surfactants are comprised of 
two hydrophobic tail regions, attached to one another through a spacer region that binds to each 
tail regions terminal polar head group (A). Examples of gemini surfactants include those with a 
benzene spacer similar to N,N-bisdodecyl-4,4'-ethene-1,2-phenyldiphosphate (B), an anionic 
spacer region similar to 2,2'-{oxybis[(3-dodecoxypropane-1,2-diyl)oxy]}diacetic acid (C) or a 
cationic spacer region similar to N,N-bis(dimethyldodecyl)-1,16-hexadecanediammonium (D). 
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dibromide gemini surfactants was just as efficient as Lipofectin™ and other commercially 
available cationic lipids.64-66 
In addition to cellular studies, the topical application of interferon-γ (IFNγ) genes 
encapsulated within di(dimethyldodecyl)-1,3-propanediammonium:1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine (DOPE) and di(dimethylhexadecyl)-1,3-propanediammonium (G16-
3):DOPE vectors produced 250% and 450% increase in levels of IFNγ in the epidermis 
compared to unprotected IFNγ genes within a mouse animal model.56, 57 The use of neutral helper 
lipids, including DOPE, as stabilizing agents enhanced gene delivery capability of gemini 
surfactant nanoparticles67, 68 while still allowing for the gemini-DNA complexes to be 
administrated topically or systematically (via oral, mucosal, or injectable forms). 51 These 
findings demonstrate that the usage of this class of gemini surfactants is a viable method for non-
invasive gene delivery.   
 All of the studies previously reported were exclusively concerned with improving both 
the transfection efficiency of gemini surfactant nanoparticles while reducing toxicity. 
Conclusions were based on the correlations between the encapsulation efficiency, transfection 
efficiency, cell viability, gemini surfactant structure and lipoplex composition. However, no 
study was conducted to monitor the adsorption, distribution, metabolism, and excretion of the 
nanoparticles and their contents. An understanding of each of these characteristics is vital to 
achieving approval for a new drug application. Therefore, qualitative and quantitative analytical 
methods are needed to further advance the use of diquaternary ammonium gemini surfactants. 
Mass spectrometry is uniquely suited to quantify gemini surfactants due to the two permanent 
positive charges on the polar head regions of the gemini surfactants. In addition, innovations in 
both ionization sources and mass analyzers are stimulating the development and application of 
specific, selective, and sensitive high-throughput mass spectrometry methods to the 
quantification of both drug(s) and carrier molecules.  
1.4 Mass spectrometry’s application to pharmaceutical analysis 
Each stage in the drug development process requires qualitative and quantitative analysis, a task 
commonly achieved using mass spectrometry (MS) because of its ability to identify novel 
analytes through the determination of their molecular composition.69, 70 Superior analytical 
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information supplied by MS has been applied to the analysis of the metabolites and degradation 
products of drug molecules; streamlining the process of drug discovery and development.71, 72 In 
addition, recent advances in both ionization sources and mass analyzers have enlarged mass 
spectrometry’s role within the preclinical and clinical assessment of pharmaceuticals.73 
Figure 1.3 The general structure of first and second generation quaternary ammonium gemini 
surfactants as categorized based upon their spacer composition; Alkyl chain (A), 2° & 3° 
amine (‘R’ = hydrogen or methyl)  (B), polyethoxylated (C), and hydroxyl (D) substituted 
alkyl chains. "t" = number of carbons in chain. "s" = fuctional groups in the spacer region 
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Revolutionary steps during development of mass analyzers, included the invention of 
quadrupole mass analyzers74 and tandem mass spectrometry (MS/MS);75 allowing for the 
structural details of analytes to be determined based upon their fragmentation behavior. Recent 
advances in mass analyzer technology have allowed for a reduction in the total time of analysis 
while providing more detailed and comprehensive analytical data. For example, analyte 
quantification can be achieved using high resolution-mass spectrometry (HR-MS) that can 
differentiate ions based upon minor structural variations.76-78 The ability to achieve very precise 
mass to charge ratio (m/z) measurements enables analytes to be distinguished from one another 
based on their unique molecular composition.78, 79 Similarly, advances in ionization have resulted 
in improved analytical outcomes. For example, the development of electrospray ionization (ESI) 
allowed for liquid chromatography (LC) to be easily coupled to MS,80, 81 while the invention of 
desorption electrospray ionization (DESI) allowed for analytes to be ionized and introduced into 
the mass spectrometer under ambient conditions with minimal or no sample preparation.82  
The continued advancement of MS technology has culminated in commercial products 
that are better equipped to promptly identify/quantify small drug molecules within complex 
matrices; including high-field asymmetric waveform ion mobility spectrometry (FAIMS),83 
multistage mass spectrometry (MS
n
),84 direct analysis in real time (DART),85 and matrix assisted 
laser desorption ionization (MALDI).86 Applying these MS technologies to the field of 
pharmaceutical sciences allows for the rapid acquisition of accurate and precise analytical data 
that assists in assessing the efficacy and viability of both drugs and formulations. However, the 
sensitivity, specificity, and selectivity of these modern MS instruments still rely upon the 
principles of MS proposed by E. Goldstein87 and J.J. Thomson.88 
1.5 Historical perspectives on mass spectrometry 
 The cathode ray tube experiments of both E. Goldstein87 and J.J. Thomson88 demonstrated 
that the path of ions traveling through the cathode ray tube could be deflected using magnetic 
and electric fields; providing the initial principle of MS.89 Through an understanding of this 
principle, ionic atoms and isotopes produced by cathode ray apparatus were separated by 
magnetic and electric fields based upon differences in their masses and a nominal charge of 1; 
allowing for the identification of naturally occurring isotopes.88, 89 The dominant use of MS for 
the separation of isotopes continued till the 1956 when R. Gohlke and F. McLafferty used MS to 
11 
 
detect and identify analytes separated by gas chromatography.90 The ability to identify molecular 
ions led to the subsequent use of MS for the qualitative identification of organic molecules. In 
addition, it stimulated the development of MS technology, including J.H. Futrell’s development 
of MS/MS,75 K.R. Jennings application of collision induced dissociation (CID),91 M. Yasmashita 
and J.B. Fenn’s invention of the ESI81 as well as the invention of laser desorption ionization by 
K. Tanaka;92 amongst a multitude of others. 
 Prior to the advent of MS/MS, MS analysis had only been able to provide m/z 
information on ions produced during the ionization process, severely limiting the ability to 
deduce information on their molecular structure. Therefore, the discoveries of MS/MS and CID 
were critical because they allowed for MS analysis to be applied to the inference of structural 
information of any ion. CID involves accelerating ions through a potential difference, causing 
them to collide with neutral gas molecules and one another within the acceleration region. As the 
ions collided with the neutral species, their ions kinetic energy is transformed into internal 
energy.91 The elevated internal energy of the ions causes them to fragment into smaller ions that 
are detected following m/z analysis.91 Originally deemed a nuisance because they increased the 
spectrum’s background, fragment ions produced through CID became desired with the advent of 
MS/MS. However, structural information about the precursor ion could only be inferred when 
CID was observed either in the region prior to the first analyzer or between the analyzers.74  The 
principles of CID and MS/MS, however, were not fully embraced until the development of triple 
quadrupole low resolution tandem mass spectrometers (QQQ-LR-MS/MS).74  
 Another milestone in the history of MS is the invention of ESI, an ionization source that 
facilitates the evaporation of solvent at atmospheric conditions; revolutionizing how analytes are 
introduced into the mass spectrometer.81 Prior to the invention of ESI, many ionization 
techniques required that sample to be converted into the gas phase or placed under vacuum prior 
to ionization (a two-step process); limiting the types of samples that could be analyzed. ESI 
eliminated the need for a two-step process and allowed for the analysis of analytes that could not 
be ionized by traditional ionization methods because they were either heat sensitive or non-
volatile.93 Conversely, desorption ionization (DI) techniques, produced ions from analytes 
present on a solid substrate.92, 94 The novelty of both techniques is the simplicity of how liquid 
and solid samples are introduced into the gaseous phase and the soft manner by which molecules 
are ionized. Soft ionization of an analyte prevents its dissociation into fragment ions, thereby 
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reducing the total number of ions present within the spectrum and allowing for the identification 
of intact analytes.  
The simplification of data provided by both ionization and ion separation/fragmentation 
techniques advanced the application of MS for quantitative purposes. The most significant 
outcome of these advancements was the ability to directly couple LC with MS. LC-MS is 
extensively utilized for the analytical assessment of drug molecules because it provides rich 
analytical information in a specific, sensitive, selective, and rapid manner.95, 96 
1.6 Liquid chromatography-mass spectrometric quantification of pharmaceuticals 
 The development of ESI in the 1980s and the subsequent adoption of LC-MS initiated 
mass spectrometry’s journey to the forefront of analytical chemical analysis.97, 98 It provided a 
way to directly convert the liquid effluent of LC to gas phase ions by passing them through a 
high voltage emitter, positioning LC-MS as the gold standard of analysis for numerous fields.70, 99 
The specificity, selectivity, and sensitivity of MS as well as its ability to differentiate and 
monitor a large number of analytes has made it the method of choice for qualitative and 
quantitative analysis of drugs, metabolites, and endogenous molecules within pharmaceutical 
formulations and biological matrices.100-102  LC-MS has become the analytical technique of 
choice within the pharmaceutical industry,69 surmounting many traditional detection methods 
(including diode array detection, fluorescence detection, and electron impact detection).103  
 Both high and low resolution MS instruments can be coupled to LC and have been 
utilized for quantitative purposes.  By coupling LC with HR-MS (i.e., LC-HR-MS), the analyte 
can be specifically identified by its exact mass measurement and isotopic signature.69 Both the 
atomic composition and universal isotopic distribution of an ion facilitates the determination of 
its empirical formula.  On the other hand, low resolution mass spectrometers, comprised of two 
or more mass analyzers, can also provide a high degree of specificity by performing MS/MS 
analysis by LC-LR-MS/MS.104 Monitoring an analyte’s specific LC retention time as well as its 
specific m/z, isotopic signature, and/or MS/MS signature makes LC-HR-MS and LC-LR-MS/MS 
more specific than traditional quantitative methods that relied solely upon LC separation and 
general  
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absorbance and/or emission properties of an analyte. Due to its capabilities, MS minimizes the 
interference produced by co-eluting molecules.105 
  An illustrative example of the ability of LC-LR-MS/MS to differentiate between closely 
related, co-eluting molecules is the identification of 14 structurally-related anti-malarial drugs, 
including amodiaquine and N-desethyl-amodiaquine. As shown in Table 1.1, these structures 
differ solely by an ethyl functional group but possess nearly identical physical and ultraviolet 
(UV) absorbance properties.106 The specificity provided by MS/MS removes the need for 
baseline separation of analytes, allowing for the co-elution and quantification of numerous 
analytes at the same time.107, 108 By eliminating the need to achieve baseline LC separation of 
analytes, LC-MS/MS can be utilized to quantitatively analyze hundreds of drugs in a shorter time 
period. This provides several benefits over LC coupled to conventional detectors, including 
reducing the total time of analysis, increasing the number of analytes that can be monitored and 
enhancing the limits of quantification due to an increase in specificity provided by MS. 
 MS and specifically MS/MS can also minimize matrix interferences and eliminate 
additional peaks by monitoring the m/z values of the precursor ion and/or fragment ions that are 
Table 1.1 A comparison of the structural and physical characteristics of Amodiaquine and N-
desethyl-amodiaquine
106 
Amodiaquine N-desethyl-amodiaquine 
N
NH
Cl
OH
N
CH3
CH3
 
N
NH
Cl
OH
NH
CH3
 
Monoisotopic mass of 355.1451 Da Monoisotopic mass of 327.1138 Da 
Molecular Formula of C20H22ClN3O Molecular Formula of C18H18ClN3O 
UV absorption occurs at 340 nm UV absorption occurs at 340 nm 
MRM transition of 356.3 m/z  283.0 m/z MRM transition of 328.3 m/z  283.0 m/z 
MRM (Multiple Reaction Monitoring)  
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unique for the analyte(s) of interest.109 For example, the quantitative analysis of phenytoin (PH) 
and carbamazepine (CAZ) within tablets using LC separation achieved superior accuracy when 
using mass spectrometry detection in comparison to UV detection (Figure 1.4).110 Such results 
are attributed to endogenous molecules interfering with conventional detection methods, a result 
of the absence of specificity in the absorption properties monitored, potentially compromising 
quantitative data due to co-eluting molecules. Therefore, concessions must be made when using 
UV detection for either selectivity or sensitivity in order to improve the other.  
Despite superior performance, LC-HR-MS and LC-LR-MS/MS still suffer from the 
inherent disadvantages of LC and ESI. Firstly, the amount of time required to both develop and 
run a method can be quite lengthy due to the need to achieve adequate peak shape and minimize 
ion suppression. Therefore, numerous alterations to a method are needed, resulting in lengthy 
periods of time for column equilibration/cleaning. Secondly, the developed method can be quite 
complex, typically requiring different mobile phases and gradients to achieve the desired analyte 
separation/peak shape. A single flaw in this complex system can cause the peak to drift, 
broadened, and/or split; potentially inducing a false negative or positive reading for an 
analyte(s). Such drawbacks of the separation of analytes by LC prompted the development of 
additional MS-based quantification methods that do not require LC separation; particularly for 
the analysis of a relatively small number of analytes within the sample.  
1.7 Alternative Mass Spectrometry Based Quantification Methods 
 Traditionally, quantitative mass spectrometric analysis relied heavily upon both 
chromatography and sample preparation techniques, ensuring optimal results. The advent of new 
ionization techniques, mass analyzers, and electronics have allowed for enhanced sampling rates 
and enhanced specificity/accuracy for ion separation, selection, and detection. It has provided 
ways to circumvent the need for extensive chromatography, method development, and/or sample 
preparation.112 For example, the development of flow injection analysis (FIA), fast liquid 
chromatography (FC), DESI, and MALDI have advanced the application of high-throughput  
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analysis of pharmaceuticals, achieving results that are comparable to conventional 
chromatographic methods. These techniques are discussed below as they relate to quantitative 
workflows.   
1.7.1 Fast liquid chromatography and flow injection analysis mass spectrometric analysis 
  The case for chromatographic separation prior to mass spectrometric detection is 
typically required for the identification and/or quantification of a large number of analytes and 
unknowns.113-115 However, for applications that require the quantification of a single or small 
number of analytes, high throughput methods such as FIA can achieve results comparable to LC-
MS with a reduction in the total time of analysis. An additional benefit is the reduced cost 
 
 
 
 
 
Figure 1.4 A chromatographic comparison of Mass Spectrometric (A & B) and ultraviolet 
detection (C) detection methods utilized for the quantification of phenyltoin (PH) and 
carbamazepine (CAZ). Adapted and used with permission from reference 110. 
 
 
Figure 1.4 A chromatographic comparison of Mass Spectrometric (A & B) an ultraviolet 
detection (C) detection methods utilized for the quantification of PH and CAZ. Adapted and 
used with permission from reference 110. 
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Figure 1.4 A chromatographic comparison of Mass Spectrometric (A & B) and ultraviolet 
detection (C) detection methods utilized for the quantification of phenyltoin (PH) and 
carbamazepine (CAZ). Adapted and used with permission from reference 110. 
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associated with consumables required for analysis/separation. Two methods that are used to 
reduce the time of analysis are FIA, which introduces the liquid sample into the instrument as a 
injected plug (i.e., no analytical column),116 or FC, which uses a short column to produce 
chromatographic peaks. The nonspecific and simplistic nature of FIA-MS and FC-MS methods, 
compared to many LC-MS methods, means they are flexible in their application to a plethora of 
analytes.117 
 The adoption of FIA and FC-based MS quantification is related to the ability of MS to 
differentiate between closely related ions, both in composition and/or structure. The presence of 
structural variations between different molecules, including minute variations such as structural 
isomers, minimizes the probability of analyte cross-talk and false positives during MS analysis. 
For example, the quantification of un-related drugs of abuse (bezoylecgonine, amphetamine, and 
codeine) analyzed by FIA-LR-MS/MS was achieved in the forty-five second period of analysis 
and provided results that formed the presence of individual drugs.118 No interference was 
detected when the drugs were spiked in both serum and urine matrices and provided a limit of 
detection (LOD) below 2 ng/mL.118 FIA-LR-MS/MS analysis can also be used when structurally 
similar analytes are introduced simultaneously with no interference detected for either analyte. 
For example, the introduction of dihydrocodeine and hydrocodone (analogues of codeine) did 
not result in any interference for the transitions being monitored for codeine.118 Identical results 
were also achieved when ecgonine methylester and methamphetamine were introduced.118 This 
demonstrates the ability of FIA-LR-MS/MS to be a sensitive and specific method for quantitative 
analysis.  
 The most definitive advantage FIA has over methods that utilize chromatographic 
separation is speed; allowing up to 100 samples to be analyzed within a one hour period.118, 119 
The rapid analysis of samples is directly beneficial for quality control purposes as it allows for 
near instantaneous feedback on the composition and uniformity of pharmaceutical formulations. 
Assessing the uniformity of pharmaceutical formulations containing caffeine and creatine using 
FIA was shown to be both accurate and precise; achieving results that are within the United 
States Food and Drug Administration’s (USFDA) requirements for bioanalytical validation.119 
Attainment of the required validation parameters demonstrates the applicability of FIA to the 
rapid assessment of the active ingredient of a formulation. An added benefit of FIA is the 
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short period of time that analytes interact with the carrier solute, allowing for the assessment of 
analytes with varying solubility profiles.119   
Conversely, variations in matrices can have deleterious effects on analyte analysis by 
interfering with ionization or detection of analytes; diminishing limits of detection/quantification 
or reducing the linear range of a quantitative method. The use of FC instead of FIA can alleviate 
these problems by addressing the issue of ion suppression. FC also prevents the co-elution of 
analytes molecules that may induce ion suppression.120 It should be noted, however, that 
variations between matrices and the introduction of molecules that induce ion suppression can 
occur during all MS assays; including LC, FIA, and FC. Therefore, sample preparation prior to 
MS analysis is a critical step that can improve the analytical outcome of all methods that utilize 
mass spectrometry detection. 
 Application of FIA to pharmaceutical research allows for the realization of real time in 
vivo and in vitro monitoring of analytes. Near instantaneous feedback provides information on 
Figure 1.5 A Bland-Altman comparative plot of the LC-LR-MS/MS and FIA-LR-MS/MS 
results attained for the quantification of imatinib within the plasma of cancer patients. The 
Bland–Altman plot showed mean difference of -1.46 ng/mL and standard deviation of 
28.9 ng/mL. Used with permission from reference 125. 
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synthetic pathways, monitoring of specific chemical changes and the fate of drug candidates.121 
The validation of a FIA-LR-MS/MS method for quantification of topiramate in human plasma 
provided information on its biological fate and transformation.122 The FIA-MS method yielded 
comparable accuracy, precision and reproducibility to that of capillary electrophoresis UV 
detection, gas chromatography flame ionization detection and LC-LR-MS/MS.122-124 In addition, 
the number of samples analyzed within a one hour period was superior to conventional LC-LR-
MS/MS methods.122  
 Reducing the time of analysis has a two important benefits as it reduces the demand upon 
the instrument through a reduction in run time and reduces the overall cost of the analysis. The 
cost of analysis benefits from a reduction in solvent usage, however, it may also gain an 
economical advantage through the use of less expensive and/or complex mobile phases. Imatinib, 
a tyrosine-kinase inhibitor utilized in various cancer treatments, was quantified in human plasma 
using both ultra-high performance liquid chromatographic-MS/MS and FIA-MS/MS methods.125 
Both methods produced comparable results across concentrations measured within cancer 
patients, as shown by a bland-altman plot (Figure 1.5), however, the FIA method achieved its 
results in less than one quarter of the time of ultra-performance liquid chromatography and one 
quarter of the cost.125 In addition, additives were simplified as for the analysis of imatinib in 
human plasma; LC-MS/MS analysis utilized a 4 mM ammonium formate buffer system at pH 
3.2, which is time consuming to produce in comparison to the addition of 0.1% formic acid to the 
methanol mobile phase used in the FIA method.125  
 Finally, the application of FIA techniques to lab on a chip technology has the potential to 
further simplify pharmaceutical analysis because it integrates several laboratory functions onto a 
miniaturized chip.126 The benefits of lab on a chip technology are a reduction in consumables, 
use of individual ESI tips resulting in no sample carryover and the incorporation of sample 
preparation techniques into the chip. Application of this technology to the quantification of 
verapamil and norverapamil in human plasma demonstrated that concentrations lower than 2.5 
ng/mL can be detected and quantified; results that are comparable to LC-LR-MS/MS.127, 128 The 
elimination of sample carryover has the potential to increase the dynamic range of any 
bioanalytical assay, especially at the lower limit of quantification, and use relatively inexpensive 
lab on chip technology and minimal solvent flows.126, 128 In addition, an enhancement in the limit 
of quantification following the removal of proteins through precipitation suggests that this 
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technology can be coupled to a traditional sample clean-up procedure in order to achieve 
superior limits of detection. The viability of such technology shows the potential for both FIA 
lab on chip technology MS and FIA-MS to detect and quantify ions without the requirement of 
chromatographic separation; reduce bioanalysis expenditures while maintaining the sensitivity 
and linearity of conventional chromatographic techniques. 
1.7.2 Matrix assisted laser desorption ionization 
 MALDI-MS is not commonly associated with the analysis of small molecules or 
quantification. However, advances in both MALDI-MS technology, sample preparation 
techniques and matrices has allowed for quantitative data to be rapidly attained for small 
molecules.129 The high frequency of the laser pulse utilized during MALDI and the acquisition 
rate of mass spectrometry allows for rapid sample analysis. In addition to its rapid time of 
analysis, MALDI-MS is being utilized for the quantification of small molecules due to reduced 
sample carry over, ability to tolerate salts and propensity to form singly charged molecules.129-132 
In addition, the stability profile of analytes can be extended by some matrices whose deposition 
provides a protective mechanism that maintains long term analyte stability.133 Through the 
minimization of degradation and oxidation, samples may be qualitatively and/or quantitatively 
re-analyzed in the future.133 Such MALDI specific characteristics can be beneficial to the 
pharmaceutical industry, resulting in both improvements in data produced and economical gains. 
However, the future application of MALDI-MS for the quantification of small molecules will 
benefit from further improvements in instrumentation and available matrices, leading to 
enhanced ionization, ion analysis, and reduction in background noise.129 
1.7.2.1 Small molecule analysis using matrix assisted laser desorption ionization 
 Analysis of low molecular weight analytes requires better matrices and/or enhanced 
delayed extraction ion analysis to reduce the background noise associated with MALDI. The 
introduction of new matrices as well as alterations to existing matrices is an ongoing process 
with synthetic and purification processes being altered to reduce contaminant levels. In addition, 
the evaluation of novel matrices strives to not only improve ionization but minimize low 
molecular weight interference.134, 135 This can be achieved through the use of matrices that have 
higher molecular weights and do not contribute to background noise in the low mass region. For 
example, nanomaterial matrices have been applied to the analysis of small molecules by 
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MALDI-MS, providing a matrix that ionizes analytes and minimizes background noise by 
reducing analyte fragmentation.134 The deposition of silane matrix on the analyzed MALDI 
surface was achieved through the use of N-(3-trimethoxysilylpropyl)diethylenetriamine and 
octadecyltricholorosilane, producing homogenous deposition.134 Laser desorption analysis of 
analytes deposited on the silane surface resulted in a drastic reduction in non-analyte peaks, 
simplifying analysis of the small drug molecule acrivastine and angiotensin I.134 Similarly, 
exploration of non-traditional small molecule matrices has resulted in a reduction in spectral 
noise. The combination of 3-hydroxycoumarin and 6-aza-2-thiothymine as a MALDI matrix 
resulted in the ionization and identification of the drug donepezil in brain tissue with minimal 
matrix interference.135 The continued exploration of novel MALDI matrices may result in the 
expanded use of MALDI for the quantification of low molecular weight drug analytes.  
  The demand by health professionals to rapidly attain information related to the 
absorption, distribution, metabolism, and excretion (ADME) properties of a pharmaceutical is 
one area in which MALDI has a benefit over traditional mass spectrometry methods. MALDI's 
rapid acquisition of data provides near instantaneous therapeutic drug monitoring that may 
benefit clinical patient care through an improvement in assessing patients' dosage regimen. The 
ability to monitor the drugs allows for the creation of a dosage regimen that balances toxicity and 
efficacy, while MALDI analysis allows for the rapid quantification of multiple analytes, 
producing near real time feedback. The benefit of instantaneous feedback is particularly 
important for patients undergoing treatment with toxic drugs, such as those afflicted with Human 
immunodeficiency virus (HIV).136 Quantification of the HIV drugs lamivudine, lopinavir, and 
ritonavir by MALDI-HR-MS concur with results provided by LC-MS/MS analysis, though 
MALDI-HR-MS results were attained significantly faster.137 The quantitative range of the 
method was viable for a linear range of at least 100x for each analyte, providing accurate and 
precise measurements with less than 10% relative standard deviation (RSD).137 In addition, the 
LOD attained by a prototype MALDI-LR-MS/MS was 10 fold less than that obtained for LC-
LR-MS/MS.137  
1.7.2.2 MALDI-MS Sample preparation  
 The ability of MALDI-MS to tolerate salts simplifies sample preparation, further 
reducing the analysis time, particularly when compared to LC-MS. No sample preparation is 
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needed to perform drug quantification within tissue samples, as matrix deposition on the tissue 
surface is the sole procedure performed.131, 138 For example, the simultaneous imaging and 
quantification of olanzapine in liver tissue by MALDI-HR-MS achieved quantitative levels 
comparable to LC-LR-MS/MS, but with 100 µm imaging resolution on the tissue surface.139 The 
ability of MALDI-MS to both spatially and rapidly quantify a drug molecule provides a 
significant advantage over other MS methods and makes MALDI an important tool for assessing 
drug localization. For example, analysis of olanzapine within liver tissue sections using MALDI-
HR-MS provided relative quantification data that correlated with LC-LR-MS/MS of individual 
tissue segments with an accuracy of 14% (Figure 1.6).139 Through the addition of an internal  
standard, MALDI-MS is able to quantify both drug and metabolite analytes within the treated 
tissue while also enhancing their stability during storage.133 
 The removal of complex sample preparation allows for automated sample processing. 
The quantification of cyclosporin in whole blood was performed by MALDI-HR-MS following 
an automated and rapid liquid/liquid extraction.138  The LOD and accuracy for cyclosporin 
Figure 1.6 A linear relationship is observed between the amount of olanzapine in a single 
tissue section of rat liver as measured by LC-LR-MS/MS and the integrated MALDI-HR-
MS response in an adjacent tissue section. Used with permission from reference 139. 
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achieved by MALDI-HR-MS was superior to immunoassay methods; the conventionally 
accepted method for monitoring cyclosporin.138 Selectivity was also enhanced, in comparison to 
immunoassay, as superior analyte specificity was attained by MALDI-HR-MS, differentiating 
between the drug molecule and its metabolites to reduce both false positive and false negative 
results.138  
1.7.2.3 Quantitative imaging capabilities of matrix assisted laser desorption ionization 
 MALDI-MS surface analysis provides both quantitative and analyte localization 
information that is not accessible by chromatographic techniques. Assignment of an analyte to a 
specific tissue region is beneficial for pharmaceutical discovery and development because it 
provides better ADME  analysis. However, it does require excision of the tissue of interest from 
the specimen/patient. MALDI-MS imaging is able to achieve micrometer resolution, providing a 
highly precise representation of analyte distribution.140, 141 In the study of erlotinib within a rat 
animal model, MALDI-HR-MS enabled the profiling of erlotinib in liver, spleen, and muscle 
samples.141 The quantitative data showed that erlotinib was present at concentration of 5.73 ng 
per mg of liver tissue, which is beneficial for the treatment of liver cancer.141  The data correlated 
with the LC-LR-MS/MS results after taking into account recovery.141 The close association 
between LC-MS and MALDI-MS quantitative data highlights the benefits of MALDI-MS 
analysis, including speed, minimal sample carryover, tolerance for salts and application in 
imaging.141 The main drawback of MALDI-MS analysis is the requirement of a matrix, which 
introduces a required sample preparation step and the potential for interference.140 
1.7.3 Ambient environment desorption ionization techniques 
 Analysis of pharmaceuticals by DI mass spectrometry techniques within an ambient 
environment does not require sample preparation or the addition of matrix, thereby removing 
limitations associated with other ionization techniques.142 The techniques of DESI and DART 
ionization are two of the most widely utilized ambient environment desorption techniques. 
Although both desorb analytes from a surface, DESI utilizes the principles of ESI to achieve 
ionization while DART utilizes the principles of atmospheric-pressure chemical ionization.142-144 
The location of the sample and the mechanism of desorption utilized by these ionization 
techniques minimizes sample carry-over and offers the possibility of using these techniques to 
determine the localization a molecule on a flat surface; including sectioned tissue samples.82, 144 
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In addition, the elimination or minimization of sample preparation provides considerable benefits 
over conventional quantitative and imaging techniques. Some DI methods, however, have 
utilized simple sample preparation methods to improve the limit(s) of detection; achieving limits 
comparable to chromatographic-MS methods.142, 144 Although several ambient environment DI 
techniques exist, this section will focus on the application of DESI, a widely used ambient 
ionization technique.  
DESI's close relation to ESI results in both ionization methods producing identical 
protonated/deprotonated ionic species.82 This was demonstrated by the analysis of 21 different 
pharmaceutical formulations by DESI-MS, where the ions behaved in an identical manner to the 
ions produced by ESI.145 The similarities between DESI and ESI ionization mechanisms allows 
for DESI analysis to take advantage of MS and MS/MS spectra libraries produced by ESI; 
beneficial for both qualitative and quantitative analysis.145 Correlating DESI data to previously 
developed spectral libraries simplifies data analysis, demonstrating that DESI data can be both 
rapidly acquired and evaluated.  
DESI-MS, like MALDI-MS, is rapid in nature due to the absence of chromatographic 
separation and the high rate of data acquisition provided by mass spectrometry. Data acquisition 
can be less than ten seconds per sample, confirming the identity of an analyte by both MS and 
MS/MS analysis.145 For the quantification of propranolol, a small molecule that acts as a β-
blocker, DESI-LR-MS/MS analysis utilized a scan time of less than 10 seconds, per sample, and 
provided a 10 nM LOD and a dynamic linear range extending to 100 µM.146 In addition, 
validation parameters demonstrated that DESI-LR-MS/MS can be successfully employed for 
high-throughput quantitative analysis.146 These DI techniques, however, provide time saving 
benefits over other mass spectrometric ionization techniques because they do not require the 
sample to be maintained under high vacuum and only require (simple) sample preparation.147  
The removal of sample preparation has three distinct benefits; reducing analysis time, 
decreasing sample contamination, and minimizing variables associated with sample introduction. 
DESI has been applied to the quantification of low-molecular weight analytes within biological 
fluids, achieving ng/mL LOD, without utilizing any sample preparation. The use of isotope 
labeled internal standards resulted in USFDA validation parameters being satisfied. The widest 
application of ambient DI analysis without sample preparation is the analysis of pills and 
capsules, where they are directly placed on the sample stage and analyzed, providing 
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instantaneous feedback on the pharmaceuticals composition.82, 145, 148, 149 The rapid analysis 
provides the ability to analyze more samples, a feature that is particularly important for the 
detection of counterfeit drugs.  
In a similar manner to MALDI, ambient environment DI techniques can be used for 
quantitative spatial imaging. The qualitative and quantitative two dimensional spatial distribution 
of an analyte is valuable information for drug discovery and development process because it 
correlates information about metabolism and cellular localization.82 Although the absolute 
quantification of an analyte requires the addition of an internal standard, the additional sample 
preparation step, when performed properly, maintains the sample integrity.150 Clozapine 
quantification by DESI-HR-MS within rat coronal brain sections showed the localization of 
clozapine within the lateral ventricles 45 minutes after dosing with concentrations varying 
between 0.2 to 1.2 ng in individual brain sections.150 LC-LR-MS/MS analysis confirmed the 
results obtained by DESI-HR-MS, however, the amount of time required to perform LC-MS/MS 
analysis of individual sections was longer.150 The ability of DESI-MS to deliver information on 
an analytes concentration and spatial distribution makes it a very valuable high-throughput 
method for MS analysis.150  
1.7.4 Ion analysis 
 The quantitative capabilities of mass spectrometry do not rely solely upon analyte 
ionization, but the complementary nature of ionization and the ion separation methodologies 
(i.e., mass analyzers). The fast ion analysis required by high-throughput quantitative methods is 
possible due to the advances in the rate of analysis provided by mass analyzers. Both high and 
low resolution mass analyzers are able to achieve scan rates that produces the number of scans 
required for USFDA method validations. The benefit of MS/MS analysis is the specificity it 
achieves by monitoring the transition of a precursor ion to its product ion(s).151 HR-MS has the 
ability to achieve high spectral resolution, allowing for a m/z value to be correlated with potential 
molecular formulae, providing an additional level of specificity and allowing for analyte 
identification.151, 152  
1.7.5  Single stage mass spectrometry quantification using high resolution instruments 
 Advances in the field of mass spectrometry have produced dramatic improvements in the 
resolution of mass spectrometers.153 The rapid acquisition of quantitative data with high mass 
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accuracy is often attained through the use of either an orbitrap or time of flight (TOF) mass 
analyzers, both are capable of producing quantitative data without comprising resolution. The 
association of HR-MS peaks to molecular formulae  facilitates the identification of precursor 
molecules and their metabolites.69 For example, the application of qualitative-quantitative 
workflows on orbitrap instruments resulted in both the quantification of drug molecules with 
LLOQ comparable to those achieved on QQQ-MS/MS instruments in addition to providing 
molecular formula assignment of metabolites.154  
 The use of HR-MS for quantitative analysis requires that the rate of data acquisition be 
optimized in order to achieve the requirements of the quantification process.153 For example, on 
an orbitrap instrument an increase in the monitored m/z range results in the acquisition time 
being lengthened or the resolution and resolving power of the instrument being decreased. A 
potential result is that an increase in the acquisition time will negatively influence the number of 
data points collected while a reduction in peak resolution will reduce the accuracy of the 
measured m/z values, both having a deleterious effect on quantitative data. Therefore, validation 
of a HR-MS quantification method, like LR-MS(/MS), requires optimal and reproducible 
chromatographic or chromatographic-like peak shape, and a minimum of 10 data acquisition 
points across the peaks needed to properly define the eluting components.155 
 The ability of FC to generate optimal peak shape through the use of short columns or 
guard columns allows HR-MS to achieve a minimum of 10 data points across a chromatographic 
peak. The reproducible peak shape achieved by FC-HR-MS enhances the accuracy and precision 
of HR-MS methods, which can provide quantitative data within an 18 second period of analysis. 
156 For example, five tricyclic amines, utilized as physiotropic pharmaceuticals, were quantified 
within fortified human plasma by a FC-HR-MS.156 The TOF mass analyzer’s high resolution 
capabilities provided mass accuracy values less than 10 parts per million (PPM), using two point 
internal calibrations, and satisfied all the requirements of USFDA method validation; with an 
LOD between 1 and 2 ng/mL.156 Although four of the five tricyclic amines achieved quantitative 
results comparable to LC-HR-MS, the quantification of desipramine by FC-HR-MS achieved a 
limit of quantification 5x lower than LC-HR-MS.156, 157  
 The ability of HR mass analyzers to provide quantitative data within a very short elution 
window is also applicable to FIA-HR-MS, where applications that utilize multiple autosamplers 
are able to achieve analysis of eight individual samples in the short period of forty-five 
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seconds.158   A limitation of high throughput methods, however, is that they are susceptible to ion 
suppression due to an increase in matrix effects from co-eluting molecules.78 This can result in a 
higher limit of quantification and unsatisfactory linear range, precision and accuracy. However, 
with changes in sample preparation and/or analyte detection, it is possible for the quantitative 
outcomes of FIA-HR-MS to be similar to LC-HR-MS because of the specificity it provides.78 To 
minimize interference produced by the matrix, an optimization of the resolution and resolving 
power of HR-MS instruments is required, allowing for the separation and identification of 
isobaric ions. For example, the analysis of a drug mixture of 17 analytes (including isobaric 
analytes that differed by 8.8 to 23.5 mDa) by a TOF-MS, demonstrated the ability of FIA-HR-
MS to resolve and identify isobaric ions (Figure 1.7).159   
The application of HR-MS to the quantification of pharmaceutical excipients within a 
formulation, has allowed for an assessment of quality control and assurance. PEG is a widely 
utilized excipient and as a result numerous methods have been evaluated for its quantification.160-
163 FIA-HR-MS allowed the concurrent resolution and quantification of different PEG oligomer 
fractions.164 The limits of quantification are superior to those achieved by conventional 
quantification methods for PEG without chromatographic separation. 164 PEG can be 
differentiated from other non-PEG components using HR-MS analysis by selectively monitoring 
the ions that match the m/z of each PEG oligomer.164 The Specificity of HR-MS allowed for the 
quantification of PEG oligomer within urine matrices; a matrix that is much more complex than 
a pharmaceutical formulation.165  
 The HR-MS data acquired across a specific mass range not only allows for the 
quantitative analysis of analytes but also for mining of the spectra for metabolites, degradation 
products, and contaminants.100 For example, triclosan metabolites that had undergone 
combinations of sulfonation, hydroxylation, and glucuronidation were identified using HR-
MS.166 The inference of each biotransformation relies upon the exact mass measurements 
provided by HR-MS, allowing for the determination of the analytes' molecular formula; 
however, it does not provide information on the analytes' molecular structures. 
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1.7.6 Multistage mass spectrometric quantification using low resolution instruments 
 MS
n
 provides structural information by fragmenting precursor ions into their unique 
product ions, thus resulting in a distinctive spectral fingerprint for quantitative125, 167, 168 and 
qualitative analysis.169-171 The consistent production of unique MS
n
 spectra provides a means to 
correlate molecular authenticity to quantitative analysis of active drugs, excipients, and 
metabolites as well as allowing for structural elucidation.172 MS/MS, the simplest MS
n
 
experiment,  enable the differentiation of closely related analytes by monitoring specific 
Figure 1.7 Total ion chromatogram and extracted ion chromatograms of the five tricyclic 
amines, doxepin (1), desipramine (2), imipramine (3), amitriptyline (4) and trimipramine (5) in 
human plasma extract obtained from their FC-MS elution on a SB-C18 column (15 × 2.1 mm 
i.d.). Adapted and used with permission from reference 159. 
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fragment ions of precursor ions.173 Analytes that are both structurally related and unrelated can 
be detected and quantified as well as structurally confirmed via MRM analysis.173 The ability of 
MS/MS to minimize interferences from isobaric molecules, molecules that share nominal 
molecular masses, through MS/MS analysis is a significant benefit over single stage MS.174 An 
MS/MS method has been developed to quantify creatine levels within blood to diagnose patients 
that suffer from primary creatine disorders.175 The quantification of creatine is difficult because it 
shares the nominal mass of 131 with leucine and isoleucine, that can also be present in blood 
samples.175 The application of MS/MS allowed for creatine to be differentiated from leucine and 
isoleucine, with no inference being observed within blood samples spiked with μM 
concentrations of leucine and isoleucine; demonstrating the robust nature of MS/MS detection.175 
Discriminating between each analyte is accomplished using their unique fragment ions.175 In 
addition, the butyl ester metabolites of creatine, leucine and isoleucine, which share the nominal 
mass of 187, were detected and differentiated from one another using MS/MS.175  
 The robust nature of MS/MS produces valid results that display continuity over an 
extended period of time. An evaluation of MS/MS reproducibility showed that the performance 
of a single instrument was consistent over a four year period despite contamination, 
maintenance, and increased usage.176 In addition, MS/MS spectra were reproducible and 
consistent between both identical instruments and instruments supplied by different vendors.176 
The consistency is valid for both the analyte's fragment ions and the intensity of those fragment 
ions when instruments were correctly tuned and standardized.176 Such results indicate the 
specificity provided by MS/MS is universal, allowing for the compilation of reference libraries 
for compound searches.  
1.7.7 Quantification using High-field asymmetric waveform ion mobility spectrometry  
 One disadvantage of MS is that isomeric ions cannot be separated using single stage HR-
MS, while MS/MS is not always able to differentiate them.177 The inability of mass spectrometry 
to resolve such ions leads to ambiguity in the interpretation of MS or MS/MS data. For example, 
differentiation of the isomers leucine and isoleucine within full scan MS is not possible and will 
lead to the uncertain assessment of each diasteroisomer's fragment ions.177 Chromatographic 
separation aims to alleviate such issues, however, this may not be possible for closely related 
molecules, including diastereoisomers. The application of ion mobility techniques, which operate 
29 
 
at atmospheric pressure, allows not only the differentiation of ions but also facilitates their 
identification based on their respective ion mobilities (a function of size and charge) and m/z 
values when coupled to MS.177  Ion mobility spectrometry separates ions based on changes in ion 
mobility between low and high electric fields by applying a high voltage asymmetric waveform 
between two electrodes. 178 The benefits of FAIMS over traditional separation methods is its 
ability to rapidly, at atmospheric pressure, separate, focus, and/or trap ions.179  
 The separation of ions within a FAIMS instrument relies upon the application of a high 
voltage waveform between two metal plates.179 The applied high voltage waveform causes ion 
dependent changes in mobility that can be offset by a direct current offset voltage; referred to as 
the compensation voltage. At a given compensation voltage, some ions will drift toward and 
impact one of the metal plates, resulting in their neutralization, while other ions are focused 
between the two plates because the compensation voltage offsets the difference in mobility. This 
results in those ions not migrating toward either plate.179 Those ions that are focused between the 
plates can be transmitted or ejected from the FAIMS device.179 A FAIMS instrument can also 
ramp its electric field strength to separate co-eluting analytes prior to their analysis, reducing the 
spectral interference observed during MS.180  
Appling FAIMS prior to MS analysis allows for the separation of ions into individual 
packets of ions, by setting a constant compensation voltage, thereby reducing the spectral 
interference observed during MS.180 For example, the quantification of norverapamil in the 
presence of verapamil within urine samples resulted in mass spectrometry interferences that 
negatively affected the LLOQ (Figure 1.8).181 However, the use of FAIMS resulted in spectra 
and chromatographs that presented less interference, producing chromatographic peaks that were 
easier to integrate (Figure 1.8).181 Similarly, over-estimation of the concentration of the amine-
drug candidate occurs because the amine drug candidate and its N-oxide metabolite co-eluted 
during MS-analysis.182 The use of FAIMS allowed for the efficient separation of the N-oxide 
metabolite and more accurate quantification of both drug and metabolites (Figure 1.8). 182 
In addition, FAIMS' ability to separate co-eluting analytes has led to its application in FIA-
FAIMS-MS as it could reduce interferences that are present during conventional FIA-MS 
analysis. For example, the quantification of morphine and codeine within human urine by ESI-
FAIMS-MS provided a linear dynamic range extending over two orders of magnitude with a 
LOD of 60 ng/mL and 20 ng/mL, respectively.183 These results were achieved without the 
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addition of any internal standard or sample preparation, demonstrating the ability of FAIMS to 
minimize background interference.183 Regardless of which mode of analysis is used, FAIMS can 
assist in the quantification of small molecule analytes by mass spectrometry through a reduction 
in interfering ions entering the mass spectrometer and by providing the added property of ion 
mobility for differentiating analytes from one another. 180 
1.8 Perspectives on the application of high-throughput mass spectrometry to the 
quantitative analysis of small molecules 
 The recent advancements in high-throughput MS analysis allowed for the procurement of 
data that is, in many cases, comparable if not better than conventional quantification methods.  
 
  
Figure 1.8 Representative chromatographs obtained by LC-LR-MS/MS and LC-FIAMS-
MS/MS for an amine compound at 25 ng/mL and a mixture of the amine compound and its 
metabolite at 25 and 2500 ng/mL, respectively. For LC-LR-MS/MS, the metabolite adds to 
the peak area of the drug resulting in an erroneously high concentration determination. 
During LC-FAIMS-MS/MS, however, the presence of the metabolite does not affect the peak 
area of the drug. Adapted from reference 182 with permission. 
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Application of these methods to the quantification of small drug molecules within an array of 
matrices, from solutions to tissue slices, has demonstrated the versatility of MS. Through the 
implementation of such technology, the pharmaceutical industry has realized the benefit of high-
throughput MS, namely a reduction in analysis time, reduction of operating costs, and decrease 
in sample contamination. 
 Realizing the advantages of high-throughput methods, the pharmaceutical industry is 
beginning to transition away from solely utilizing conventional quantification techniques. The 
ability of high-throughput MS methods to achieve quantitative results in a shorter period of time 
than LC is their primary advantage. This has a twofold benefit, first allowing for faster decision 
making based on the results and second it provides important cost savings. The enhanced 
economy can be attributed to a shorter analysis as well as a reduction and/or simplification in the 
sample preparation. As a result, the chance of sample contamination and degradation is 
decreased, thereby improving data quality.  
The aptitude of all of high-throughput MS-based methodologies is their ability to rapidly 
analyze samples; balancing data volume with system performance to achieve the desired level of 
quantification. Data acquired by high-throughput mass spectrometric analysis provides the 
advantage of traditional quantification techniques, but some methods have the added benefit of 
spatial imaging and data mining. Spatial imaging and data mining provide quantitative results 
that more conclusively explain the fate of molecules though the further understanding of cellular 
deposition and metabolism. In addition, the data produced by high-throughput MS has the ability 
to enhance pharmaceutical research by providing additional information on analyte’s cellular 
fate. The incorporation of high throughput MS techniques in the pharmaceutical industry will 
continue to expand as they provide confirmatory and complementary data in a rapid and sensitive 
fashion.  
1.9 Purpose of research 
1.9.1 Perspectives on the need to quantify diquaternary ammonium gemini surfactants 
 Non-viral gene therapy agents, such as diquaternary ammonium gemini surfactants, 
ensure cellular delivery of genetic material and its subsequent expression. They facilitate 
transfection through the formation of a lipoplex around the genetic material that protects it from 
degradation, assists with cellular uptake, and allows for its subcellular release. There are 
32 
 
numerous studies demonstrating the effective use of diquaternary ammonium gemini surfactants 
for both in vivo and in vitro applications.
48, 54
 However, to my knowledge, no post transfection 
quantitative evaluation of diquaternary ammonium gemini surfactants has been undertaken. The 
need for post transfection evaluation of diquaternary ammonium gemini surfactants' cellular fate 
stems from their intended use for gene delivery applications, which is heavily regulated. An 
understanding of the post transfection concentration of gemini surfactants is required because 
they are new molecular entities governed by the statutes similar to new drug entities; requiring 
an understanding of their quality, efficacy, and safety.  
1.9.2 Perspectives on the need to develop mass spectrometric methods for the 
quantification of diquaternary ammonium gemini surfactants 
 MS was chosen for the quantification of diquaternary ammonium gemini surfactants 
because their structure lacks both a chromophore and fluorophore. Instead, diquaternary 
ammonium gemini surfactants contain two quaternary ammonium functional groups; each of 
which possess a permanent positive charge that is ideal for MS analysis. In addition, MS/MS is a 
very sensitive method that provides a high level of specificity and selectivity by monitoring for 
specific precursor ion  fragment ion transitions. The selection and detection of the specific 
transition is reliant upon both the method of ionization and the mass analyzer(s).  
 Validating and comparing several MS-based methods for the quantification of gemini 
surfactants was undertaken for two reasons. First, the application of quantitative MS or MS/MS 
methods to the post-transfection evaluation of G16-3 will allow for an assessment of its cellular 
concentration so that cellular uptake and degradation can be monitored. Second, it is the first 
comparative study, to my knowledge, of five different MS quantification methods: LC-LR-
MS/MS, FC-HR-MS, FC-LR-MS/MS, MALDI-HR-MS, and DESI-LR-MS/MS. These five 
methods will be compared to one another based upon preparation time, run time, limit of 
quantification, linearity, accuracy, precision, sample complexity, and cost. Understanding the 
advantages and disadvantages of each method for the quantification of G16-3 within murine 
epidermal keratinocyte cells (PAM212) will allow for selection of the optimal method. In 
addition, this study will provide a valuable comparison of these MS-based methods that can be 
applied to the development of quantitative methods for other small molecules. The comparison 
of each validated quantification method to one another provides support for choosing the most 
advantageous method for quantification within PAM212 cell lysate. Validation of each 
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quantitative MS-based method complied with the USFDA's criteria for bioanalytical method 
validation; including recovery, specificity, sensitivity, accuracy, precision and stability. The 
purpose of performing a method validation is to demonstrate the reliability of using the method 
for the measurement of analyte concentrations within the biological matrix. 
1.9.3 Rationale for research 
 In order to develop diquaternary ammonium gemini surfactants as carriers for gene 
delivery, an evaluation of their safety, including an understanding of their post transfection fate, 
is required. An assessment of diquaternary ammonium gemini surfactants' safety requires 
analytical methods that specifically, selectively, and sensitively identify and/or quantify these 
analytes. The choice of MS for this task stems from the nature of the diquaternary ammonium 
gemini surfactants, containing two permanent cationic entities within their structure.  In addition, 
MS is specific and selective, and allows for the differentiation of molecules based upon their 
unique MS/MS fragmentation behavior. Each MS-based method will be evaluated based on its 
own analytical merits to identify and differentiate diquaternary ammonium gemini surfactant, 
allowing for their quantitative analysis. 
 The mass spectrometry behavior of these diquaternary ammonium gemini surfactants has 
not been previously elucidated. Therefore, an understanding of their MS, MS/MS, and quasi MS
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behavior will confirm their molecular structure and will ensure the selection of the most specific 
and selective m/z signatures during MS(/MS) analysis, allowing for the identification of these 
analytes within, theoretically, any biological sample. Second, the development of several MS-
based quantification methods will ensure that the most efficient, sensitive, and selective method 
is applied to the evaluation of diquaternary ammonium gemini surfactants. In addition, the ease 
of method development, efficacy of each method as well as the inherent advantages and 
disadvantages of each method will be evaluated.. 
1.9.4 Hypotheses 
1.9.4.1 Structural confirmation and identification of diquaternary ammonium gemini 
surfactants by MS/MS analysis 
Hypothesis: The structural similarities between diquaternary ammonium gemini 
surfactants result in their analogous dissociation, in both fragment structure and pathway 
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sequence, allowing for the establishment of a universal fragmentation pattern for all 29 
evaluated molecules. 
 The MS/MS dissociation behavior and structural confirmation of each diquaternary 
ammonium gemini surfactant has been assessed using both a QQQ-MS and quadrupole time of 
flight mass spectrometer (Q-ToF-MS). High resolution full scan mass spectrometric analysis and 
MS/MS were applied. HR-MS (i.e., Q-ToF-MS) provided information about the molecular 
composition of the analyte, while the fragmentation pattern of each surfactant confirmed the 
proposed structure. Quasi MS
3
 analysis, using a QQQ-MS, was employed because of the lack of 
available trapping instruments that could perform MS
n
 analysis. Quasi MS
3
 analysis confirmed 
the fragmentation pathways by tracing the origin of each product ion. In addition, the MS 
analysis will assist in the identification of suitable fragment ions for multiple reaction monitoring 
(MRM) MS/MS quantitative analysis. 
 Two specific goals are achieved for each diquaternary ammonium gemini surfactant: 
 Confirmation of the molecular structures of the gemini surfactants' using MS, 
MS/MS, and quasi MS
3
 analysis 
 Establishment of a universal MS/MS fingerprint 
1.9.4.2 Development and validation of five mass spectrometry methods for the 
quantification of diquaternary ammonium gemini surfactant G16-3 within PAM212 
cell lysate 
Hypothesis: LC-LR-MS/MS analysis is the most effective quantitative method for the 
quantification of G16-3 within PAM212 cellular lysate achieving the lowest lower limit 
of quantification (LLOQ).  
 LC-LR-MS/MS is highly utilized by the pharmaceutical industry for the quantification of 
small molecules; including metabolites and degradation products.69, 70, 99 The prevalence of LC-
MS/MS is a result of the ability of mass spectrometry to act as a highly selective and specific 
method of detection by identifying ionizable analyte(s). Similarly, LC is able to selectively 
separate an analyte(s) from molecules that may interfere with its detection. The lengthy time of 
analysis, however, is a prominent disadvantage of LC and led us to compare quantitative LC-
MS/MS analysis to other high throughput mass spectrometric methods. Five different MS-based 
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quantification methods for G16-3 were developed, evaluated, and validated.  G16-3 was chosen 
as a model compound because of the high transfection efficiency as previously demonstrated.56, 57 
Two specific goals will be achieved during the development/evaluation/validation of each 
quantitative method: 
 The development, evaluation, and/or validation of G16-3 quantification method 
for the following methods: 
 LC-LR-MS/MS (validated) 
 FC-LR-MS/MS (validated) 
 FC-HR-MS (validated) 
 MALDI-HR-MS (validated) 
 DESI-LR-MS/MS (validated) 
 FC-FAIMS-LR-MS/MS) (evaluated) 
 A comparison of the five validated MS methods to determine the competitive 
advantages and disadvantages of each method.   
1.9.4.3 Assessing post-transfection concentration of G16-3 within PAM212 cell lysate 
Hypothesis: The concentration of gemini surfactant, G16-3, within PAM212 cellular 
lysate, displays an increase in concentration during incubation with the transfection 
solution and will decline in concentration from the maximal value after removal of the 
transfection solution due to transformation within the PAM212 cells.  
 Gene transfection into mammalian cells has been demonstrated using gemini surfactants 
that include alkyl spacers,56, 57 amino substituted spacers,184 and amino acid185 substituted spacers. 
Previous work, however, did not track the post-transfection cellular concentration of gemini 
surfactants.56, 57 Previously reported transfection studies focused on the toxicity and transfection 
efficacy. 56, 57 The developed mass spectrometry quantification methods, however, allow for 
insight into the cellular concentrations of gemini surfactants post-transfection. All validated mass 
spectrometry quantification methods will be used to measure the total amount of intact G16-3 
within cellular lysate post-transfection time points, allowing for an assessment of the change in 
G16-3 concentration over time. 
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The following specific goal will be achieved for the G16-3 gemini surfactant: 
 Application of the mass spectrometry quantification methods to the assessment of 
the post-transfection concentration of G16-3 within PAM212 cellular lysate 
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 The application of mass spectrometry to answering qualitative and quantitative research 
questions is a result of its specificity, selectivity, and sensitivity. Mass spectrometry is a 
powerful analytical tool that can be utilized for assessing the molecular composition of an 
analyte using high resolution single stage MS as well as MS/MS analysis. The development of 
MS/MS fingerprints will allow for the rapid screening of biological and environmental samples 
to determine the presence or absence of particular compounds within the tested samples. 
Using ESI quadrupole time-of-flight (Qq-ToF) hybrid MS/MS, the molecular 
composition and structure of 10 novel diquaternary ammonium gemini surfactants was 
elucidated, including the establishment of their MS/MS fingerprints. The gemini surfactants 
tested belong to two different structural families, namely, G12-s and G18:1-s where ‘s’ 
corresponds to the spacer length. High resolution, single stage MS analysis showed that mass 
accuracy was less than 5 PPM for all compounds, confirming their molecular composition. In 
addition, similarities and differences in the fragmentation patterns within and between each 
gemini surfactant family were identified, allowing for the identification of individual gemini 
surfactant moieties. A comparison of each gemini surfactant’s MS/MS fragmentation pattern 
demonstrated the presence of fragment ions shared by all gemini surfactants as well as ions 
which are unique to specific gemini surfactants and/or gemini surfactant families. 
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Introduction 
Nanoparticles have garnered attention for their possible use in non-viral gene delivery 
systems to treat both genetically based and infectious diseases.
1-7
 This is due to their relatively 
low cost of preparation,
8
 ability to target specific tissues, capability to encapsulate and carry 
large amounts of genetic material,
9
 and increased safety when compared to viral vectors.
10
 One 
particular group of nanoparticles that have gained attention for their ability to deliver genetic 
material into cells are gemini surfactants.  
Gemini surfactants are constructed by covalently binding the hydrophobic tail regions, 
(t), directly to or near the polar head group of both termini of a spacer molecule, (s),  to produce 
a tail-spacer-tail structure, (t-s-t); these structures are given identifier names comprised of G, for 
gemini surfactant, carbon tail length – carbon spacer length, (Gt-s) (Figure 2.1).11  The chemical 
variation in both the spacer and tail regions allows for the production of a wide variety of gemini 
surfactants. The efficiency of each compound to form a compact and stabilized morphology 
around unprotected DNA
12
 depends upon its ability to self-assemble which in turn depends upon 
its CMC values,
13
 how closely its hydrophobic groups can pack together,
14, 15
 and the efficiency 
with which the positively charged nitrogen interacts with the DNA phosphate groups.
15, 16
 
Stabilization and compaction of DNA-gemini surfactant complexes is driven by entropy and 
results from the electrostatic interactions between the polyanionic DNA backbone and the 
dicationic gemini surfactants as well as the hydrophobic interactions between the gemini 
surfactants’ two apolar hydrocarbon tails.17 
           The two Gt-s gemini surfactant nanoparticle families used in this study are comprised of 
N,N-bis(dimethyl‘alkyl’)-α,ω-‘alkane’diammonium dibromide ([C12H[(2•12)+1]] N
+
(CH3)2 (CH2)s 
N
+
(CH3)2 [C12H[(2•12)+1]] • 2Br
–
) (Figure 2.2A) and N,N-bis(dimethyl‘alk-σ-ene’)-α,ω- 
‘alkane’diammonium dibromide ([C18H[(2•18)-1]] N
+
(CH3)2 (CH2)s N
+
(CH3)2 [C18H[(2•18)-1]] • 2Br
–
) 
(Figure 2.2B) salts. Gemini surfactants belong to the self-assembling, lipid-based nanoparticle 
drug delivery systems.
18, 19
 They have been used as nanomaterials for nearly two decades
20
 and 
are well-characterized.
21, 22
 For example, analysis of the size distribution of many diquaternary 
ammonium gemini surfactants was performed by either non negative least squares algorithmic 
(NNLS) analysis (measurement of the light scattered by particles in solution illuminated by a 
laser beam (γ= 1731)), zeta potential, or atomic force microscopy with size distribution being 
assessed to be between 100 and 200 ±10 nm.
23, 24
 In addition, these polycationic molecules have 
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been successfully employed for both in vitro and in vivo gene delivery applications.
13, 22- 25
 For 
example, topical transfection of the IFNγ gene into mouse epidermis using the G12-3 and G16-3 
gemini surfactants produced a 250% to 450% increase in levels of IFNγ in the epidermis 
compared to unprotected IFNγ genes.9, 23, 24  
Mass spectrometry (MS) is a powerful analytical tool that has been used for both 
qualitative and quantitative applications.
26- 29 
Single stage MS and MS/MS can be utilized for 
structural determination and MS/MS fingerprint identification.
30
  For example, using ESI, the 
MS/MS analysis of 18 novel cholesteryl neoglycolipids, used in liposomes-based gene delivery, 
resulted in the formation of specific common fingerprint fragments regardless of the nature of the 
sugar moiety or the spacer group that link the carbohydrate portion to the lipid cholesteryl 
moiety.
31
 In addition, the unknown molecular structure of lipid A, isolated from the A. 
salmonicida lipopolysaccharide, was established by single stage MS and MS/MS analysis using 
ESI ionization and Qq-ToF-MS/MS techniques.
32, 33
 Similarly, the fragmentation routes of 
morphine antagonists were precisely determined using ESI-Qq-ToF MS/MS.
32
 
Figure 2.1 The general structure of a gemini surfactant A) that contains a spacer group that is 
linked directly to the ionic (polar) head groups and B) that contains a spacer group that is 
linked to the hydrophobic tail group near the ionic (polar) head groups.  
Spacer Group (s) Hydrophobic Tail Groups (t)Ionic (Polar) Head Groups
Ionic (Polar) Head Groups Spacer Group (s) Hydrophobic Tail Groups (t)
A 
B 
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MS/MS fingerprints and will allow for the rapid screening of biological materials and 
environmental samples to determine the absence or presence of particular compounds within the 
tested samples. In addition, MS/MS data can be used to develop MS-based quantification 
methods. 
This paper describes the findings regarding the elucidation of the exact molecular 
structure for the G12-s and G18:1-s families of gemini surfactants as well as the identification of 
the fingerprint product ions for all 10 gemini surfactants analyzed and their fragmentation pattern 
using MS/MS.  The analysis of an additional 25 gemini surfactants belonging to 3 different 
structural gemini families are currently being investigated.   
CH3CH2N
+
CH2N
+
CH2CH3
CH3
CH3
CH3
CH3
S11 11
Ionic (polar) head groups
Hydrophobic tail groups (t)
Spacer (s)
CHCH2N
+
CH2N
+
CH2CH
CH3
CH3
CH3
CH3
CH CH2 CH3CHCH2CH3
S 8
Ionic (polar) head groups
Spacer (s)
787
A
B
Hydrophobic tail groups (t)
Figure 2.2 The general structure of the gemini surfactants A) G12-s N,N-
bis(dimethyldodecyl)-1,‘s’-“alkan”diammonium with the “alkan” and ‘s’ referring to the 
carbon composition of the spacer region, s, and B) G18:1-s N,N –bis(dimethylheptadec-9-
ene)-1,‘s’-“alkan”diammonium with the “alkan” and ‘s’ referring to the carbon composition 
of the spacer region 
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Experimental 
 The Gt-s gemini surfactant nanoparticles analyzed were obtained from Dr. Ronald E. 
Verrall’s research group in the Department of Chemistry at the University of Saskatchewan.26 
The compounds are from the G12-s and G18:1-s families (Figure 2.2) and include:  
 G12-2 or N,N-bis(dimethyldodecyl)-1,2-ethanediammonium dibromide 
 G12-4 or N,N-bis(dimethyldodecyl)-1,4-butanediammonium dibromide 
 G12-6 or N,N-bis(dimethyldodecyl)-1,6-hexanediammonium dibromide 
 G12-8 or N,N-bis(dimethyldodecyl)-1,8-octanediammonium dibromide 
 G12-10 or N,N-bis(dimethyldodecyl)-1,10-decanediammonium dibromide 
 G12-12 or N,N-bis(dimethyldodecyl)-1,12-dodecanediammonium dibromide 
 G12-16 or N,N-bis(dimethyldodecyl)-1,16-hexadecanediammonium dibromide 
 G18:1-2 or N,N-bis(dimethyloctadec-9-ene)-1,2-ethanediammonium dibromide 
 G18:1-3 or N,N-bis(dimethyloctadec-9-ene)-1,3-propanediammonium dibromide 
 G18:1-6 or N,N-bis(dimethyloctadec-9-ene)-1,6-hexanediammonium dibromide  
Gemini surfactant solutions were prepared to a concentration of 3 mM in methanol and water 
(50:50 v:v) containing 0.1 % Trifluoroacetic acid (99% purity) and stored at  
-20º C. Each sample was further diluted 4000x and 5000x at the time of analysis using the same 
mixed solvent. 
To minimize associated errors in mass measurements, internal calibration was employed 
during analysis using an Applied Biosystems, API QSTAR XL QqToF-MS/MS.  We opted for 
using doubly charged calibrants since the tested gemini surfactants are doubly charged species. 
Therefore, we used both [Glu
1
]-Fibrinopeptide B, Human (amino acid sequence 
EGVNDNEEGFFSAR, [M+2H]
2+
 m/z 785.8421, C66H95N19O26, BaChem Bioscience Inc., King 
of Prussia, PA, USA) and N,N-bis(dimethyldodecyl)-1,2-ethanediammonium dibromide ([M]
2+
 
m/z 234.2685).  The later compound was chosen because its m/z value fell within the m/z range 
of the tested compounds.  Its molecular structure was previously confirmed by elemental 
analysis, NMR, and purity evaluation.
34, 35
  
The instrument was operated in the positive ion mode with the following parameters: 
declustering potential of 100.0 V and focusing potential of 290.0 V. The collision gas used 
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during MS/MS experiments was argon and many MS/MS experiments were performed for each 
compound with the collision energy (CE) values varying between 15-100 eV.  CE was optimized 
in order to generate product ions while ensuring that the molecular ion remained abundant. 
Sample aliquots, between 100 μL and 500 μL, were infused into the mass spectrometer with an 
integrated Harvard Syringe Pump at a rate of 10 μL/min using the Turbo Ionspray source; 5.5 kV 
at a temperature between 80º and 100º C. 
A Micromass Quattro II quadrupole-hexapole-quadrupole mass spectrometer (QHQ-MS) 
was used to confirm the fragmentation pattern. The instrument was operated in the positive ion 
mode with the following parameters: infusion rate of 10 uL/min, source temperature of 140º C, 
HV lens voltate of 0.71 kV and capillary voltage of 3.50 V. The cone voltage was set at 70 V to 
induce in source fragmentation of the compounds. The collision gas used during MS/MS 
experiments was argon and the CE was set between 15 and 50 eV in order to generate product 
ions while ensuring that the precursor ion remained abundant. 
Results and Discussion 
Single Stage QqToF MS and QqToF MS/MS Analysis: 
The results from the single stage QqToF MS analysis are assessed by comparing the 
observed m/z values with the calculated m/z values, producing mass accuracies
36
 less than 5 PPM 
for all gemini surfactants using internal calibration (Table 2.1). This confirms the projected 
molecular composition of each gemini surfactant, which includes the presence of two nitrogen 
atoms in all compounds.
9, 12, 23, 37, 38
  
The variation in spacer lengths within both the G12-s and G18:1-s gemini surfactant 
families produces distinctive product ions within each MS/MS spectra (Figure 2.3A and 2.4A). 
These product ions, although specific for each gemini surfactant, follow a similar fragmentation 
pattern for each family which is seen by the incremental increases in the gemini surfactant’s 
MS/MS product ion’s m/z values that are equal to the increase in its molecular ion [M]2+ m/z 
values  (Table 2.2 and 2.3). The unique spectra and patterns produced by both G12-16 (Figure 
2.3A & 2.3B), representative of the G12-s family, and G18:1-6 (Figure 2.4A & 2.4B), 
representative of the G18:1-s family, are discussed below.  These two compounds produced the 
most complex spectra for their respective families. 
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QqToF MS/MS Analysis of G12-15 and the G12-s Gemini Surfactant Nanoparticle Family 
In all G12-s gemini surfactant nanoparticles, the unique fragmentation pattern starts with 
the formation of a singly and/or doubly charged product ion(s) that results from the loss of the 
twelve carbon tail moiety. In G12-16, this creates the singly charged species [M - C12H25]
+
 of m/z 
481.55 (2) and/or the doubly charged product ion [M - C12H24]
2+ 
of m/z 241.28 (2’) (Table 2.2 
and Figure 2.3A & 2.3B).  The loss of the hydrocarbon tail in G12-16 occurs by two mechanism 
and is dependent upon the product ion(s) formed; singly or doubly charged. The elimination of a 
neutral CH2=CH (CH2)9-CH3 (dodec-1-ene), due to a proton transfer to the nitrogen atom, 
produces the doubly charged ion observed at m/z 241.28 while the heterolytic cleavage of the N-
C bond forms the singly charged ion, m/z 481.55.  The second elimination product (m/z 481.55) 
should, in theory, produce a complementary ion of the tail the region with a theoretical m/z 
169.19.  However, this ion was not observed during MS/MS of the precursor ions using either 
QqToF-MS or QHQ-MS analysis under various experimental conditions, regardless of the  
Compound Name Molecular Formula Calculated Observed Mass Accuracy 
(Gt-s) (M) (m/z ) (m/z ) (PPM)
G12-2 C30H66N2 227.2607 227.2604 1.32
G12-4 C32H70N2 241.2769 241.2764 2.07
G12-6 C34H74N2 255.2910 255.2920 3.92
G12-8 C36H78N2 269.3084 269.3077 2.60
G12-10 C38H82N2 283.3230 283.3233 1.06
G12-12 C40H86N2 297.3393 297.3390 1.01
G12-16 C44H94N2 326.3691 326.3703 3.68
G18:1-2 C42H86N2 309.3393 309.3390 0.97
G18:1-3 C43H88N2 316.3458 316.3468 3.16
G18:1-6 C46H94N2 337.3704 337.3703 0.30
Table 2.1 Mass accuracies of compounds using the calculated and observed mass to charge ratio 
(m/z ) values
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Table 2.2A Fragment identification and corresponding m/z value for each gemini surfactant 
compound in the G12-s family
Compound G12-2 G12-4 G12-6 G12-8
Molecular Formula (M) (C30H66N2) (C32H70N2) (C34H74N2) (C36H78N2)
Spacer Region (s) (C2H4) (C4H8) (C6H12) (C8H16)
Collision Energy (eV) 16 25 25 30
Product Ions (m/z ) (m/z ) (m/z ) (m/z ) #
[ M ]
2+ 227.26 241.28 255.30 269.31 1
[ M - C12H25 ]
+ 285.32 313.39 341.41 369.42 2
[ M - C12H25 - C12H24 ]
+ 201.12 3
[ M - C12H25 - C12H24 - H2 ]
+ 199.22 4
[ M - C12H25 - C12H24 - H2 - C2H5N]
+ 72.08 100.11 128.15 156.17 5
[ M - C12H25 - C12H24 - H2 - C2H5N - CH2 ]
+ 6
[ M - C12H24 ]
2+ 143.17 157.19 171.20 185.22 2'
[ M - C12H24 - C12H24 ]
+ 87.11 101.12 3'
[ M - C12H24 - C12H24 - C2H8N]
+ 72.08 100.11 128.15 156.17 4'
[ M - C12H24 - C12H24 - ('s'+C2H6N)]
+ 46.06 46.06 46.06 46.06 5'
[ M - C14H32N ]
+ 2''
[ M - C14H32N - (CH2)S-2CH=CH2]
+ 214.09 214.09 214.10 214.24 3''
[ M - C14H32N - (CH2)S-2CH=CH2 - H2]
+ 212.24 212.24 4''
[ M - C22H48N2 - 's' ]
+ 85.10 85.10 85.10 85.10 2'''
[ M - C23H50N2 - 's' ]
+ 71.09 71.09 71.09 71.09 3'''
[ M - C24H52N2 - 's' ]
+ 57.07 57.07 57.07 57.07 4'''
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Table 2.2B Fragment identification and corresponding m/z value for each gemini 
surfactant compound in the G12-s family
Compound G12-10 G12-12 G12-16
Molecular Formula (M) (C38H82N2) (C40H86N2) (C44H94N2)
Spacer Region (s) (C10H20) (C12H24) (C16H32)
Collision Energy (eV) 30 30 35
Product Ions (m/z ) (m/z ) (m/z ) #
[ M ]
2+ 283.32 297.35 325.37 1
[ M - C12H25 ]
+ 397.45 425.49 481.55 2
[ M - C12H25 - C12H24 ]
+ 229.26 257.30 313.36 3
[ M - C12H25 - C12H24 - H2 ]
+ 227.25 255.29 311.34 4
[ M - C12H25 - C12H24 - H2 - C2H5N]
+ 184.20 212.32 268.30 5
[ M - C12H25 - C12H24 - H2 - C2H5N - CH2 ]
+ 254.29 6
[ M - C12H24 ]
2+ 199.23 213.25 241.28 2'
[ M - C12H24 - C12H24 ]
+ 115.14 129.16 157.19 3'
[ M - C12H24 - C12H24 - C2H8N]
+ 184.20 212.32 268.30 4'
[ M - C12H24 - C12H24 - ('s'+C2H6N)]
+ 46.06 46.06 46.06 5'
[ M - C14H32N ]
+ 380.44 436.49 2''
[ M - C14H32N - (CH2)S-2CH=CH2]
+ 214.26 214.25 214.26 3''
[ M - C14H32N - (CH2)S-2CH=CH2 - H2]
+ 212.24 212.24 212.24 4''
[ M - C22H48N2 - 's' ]
+ 85.10 85.10 85.10 2'''
[ M - C23H50N2 - 's' ]
+ 71.09 71.09 71.09 3'''
[ M - C24H52N2 - 's' ]
+ 57.07 57.07 57.07 4'''
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Table 2.3 Fragment identification and corresponding m/z value for each gemini 
surfactant compound in the G18:1-s family 
Compound G18:1-2 G18:1-3 G18:1-6
Molecular Formula (M) (C42H86N2)(C43H88N2)(C46H94N2)
Spacer Region (s) (C2H4) (C3H6) (C6H12)
Collision Energy (eV) 20 25 31
Product Ions (m/z ) (m/z ) (m/z ) #
[ M ] 
2+ 309.34 316.35 337.38 1
[ M - C18H35 ] 
+ 367.41 381.43 423.48 2
[ M - C18H35 - C18H34 - (CH3)2NH] 
+ 72.08 86.10 128.15 3
[ M - C18H34 ] 
2+ 191.35 212.25 2'
[ M - C18H34 - C18H34 ] 
2+ 87.11 3'
[ M - C18H34 - C18H34 - ('s'+(CH3)2N] 
+ 46.06 46.06 46.06 4'
[ M - C30H63N2 - S] 
+ 97.10 97.10 97.11 2''
[ M - C31H65N2 - S ] 
+ 83.09 83.09 83.09 3''
[ M - C32H67N2 - S ] 
+ 69.08 69.08 69.08 4''
[ M - C33H69N2 - S ] 
+ 55.06 55.06 55.06 5''
[ M - C33H67N2 - S ] 
+ 57.07 57.07 57.07 2'''
 
collision energy.  It is possible that the ion expected at m/z 169.19 was instantly formed and 
neutralized via proton transfer from other species within the collision cell.  As discussed below 
and shown in Table 2.2, only short aliphatic radical ions were observed at m/z 85.10 (2’’’), 71.09 
(3’’’), and 57.07 (4’’’) (Figure 2.3A & 2.3B), which supports the notion that longer singly 
charged alkyl chains were neutralized.  
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Following the same mechanism described in the previous section, the loss of the second 
twelve carbon tail produces a doubly charged product ion [M - C12H24 - C12H24]
2+
, at m/z 157.19 
(3’), and the singly charged ion [M - C12H25 - C12H24]
2+
,at m/z 313.36 (3), from m/z 481.55 and 
241.28 (Table 2.2 and Figure 2.3A & 2.3B). The origin of the fragment ions was confirmed via 
MS/MS analysis using QHQ instrument.  QHQ, contrary to QqToF, is able to generate strong “in 
source” fragmentation and hence this allowed us to authenticate the proposed fragmentation 
pathways and the order in which ions are formed (Table 2.4). An additional aminium ion that is 
produced by the loss of two hydrogen atoms from the singly charged ion, [M - C12H25 - C12H24]
2+
 
(3), results in the formation of a double bond between the terminal carbon of the spacer and the 
nitrogen;
 
 [M - C12H24 - C12H25 - H2]
2+
at m/z 311.34 (4) (Table 2.2 and Figure 2.3A & 2.3B).  The 
loss of a neutral CH2=N-CH3 (N-methylidenemethanamine) from the singly charged, m/z 311.34 
(4) produces the product ion of [M - C12H25 - C12H24 - H2 - C2H5N]
+ 
at m/z 268.3 (5) and 
subsequent elimination of a CH2 yields the ion, [M - C12H25 - C12H24 - H2 - C2H5N - CH2]
+
, at 
m/z 254.29 (6) (Table 2.2 & 2.4 and Figure 2.3A & 2.3B). The product ions represented by [M - 
C12H25 - C12H24 - H2 - C2H5N]
+ 
(5) (Figure 2.3B) are observed in all G12-s gemini surfactants 
nanoparticles presented in table 2.2. 
On the other hand, the product ion observed at m/z 157.19 (3’) is also cleaved at the 
terminal N-C bond releasing two complementary ions observed at m/z 268.3, [M – C12H24 – 
C12H24 – C2H8N]
+
 , (4’) and m/z 46.19, N-methylmethanaminium, (5’). Based upon the 
diagnostic fragments produced by the ions at m/z 311.34 (4) and 157.19 (3’) (Table 2.4), it can 
be concluded that two structural isomers exist for the ion observed at m/z 268.3 (Figure 2.3A & 
2.3B).  In a similar mechanism, another pair of complementary diagnostic product ions were 
produced from the cleavage of the N-C bond within the molecular ion and observed at m/z 
436.49 (2’’) and 214.26 (3’’) (Table 2.2 and Figure 2.3A & 2.3B).  Additional non-diagnostic 
product ions were observed at m/z 422.47, m/z 380.43, m/z 366.41, m/z 352.37, and m/z 338.34 
in G12-16 (Figure 2.3A & .3B). These minor non-diagnostic ions results from the loss of (CH2)n 
and originated from different sources (m/z 481.55, 241.28, 436.49) as confirmed by QHQ 
analysis.   
Additional non-diagnostic ions are expected and result from the tail region of the G12-s 
gemini surfactants as a result of their identical nature. Identical fragments seen in all analyzed 
G12-s gemini surfactants are singly charged small product ions, namely, N,N-dimethyldodecan-
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1-aminium (3’’), hex-1-ylium (2’’’)  pent-1-ylium (3’’’), and but-1-ylium (4’’’) (Table 2.2 and 
Figure 2.3A & 2.3B). It should be noted that these small fragment ions can be generated from all 
ions which contain the gemini surfactant tail region; for illustrative purposes, we opted to present 
these ions being generated from the molecular ion (Figure 2.3B) 
MS/MS Ions of G12-
16
241.28
481.55
157.19
268, 46
313.36
311, 268, 254
311.00
268
268.30
254
436.49 422, 352, 338, 214, 212
MS/MS Ions of G18:1-
6
212.25
128, 87, 46
423.48
Diagnostic MS/MS Ions Produced
128
366, 352, 338, 313, 311, 268, 254, 214, 
212, 157, 46
422, 380, 366, 338, 313, 311, 268, 254, 
214, 212,
Table 2.4 Tandem mass spectrometric analysis using an HQH
instrument. The formation of diagnostic ions during MS/MS
analysis confirmed the fragmentation pathway for each gemini
surfactant structural family.
Diagnostic MS/MS Ions Produced
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B) QqToF MS/MS Analysis of G18:1-s Gemini Surfactant Nanoparticle Family 
 The fragmentation pattern of the G18:1-s family of gemini surfactant nanoparticles 
follows a similar fragmentation pattern to the G12-s family and produces singly and/or doubly 
charged product ion(s) due to the loss of a tail moiety. In G18:1-6, these product ions are 
observed as [M-C18H35]
2+
 at m/z 423.48 (2) and [M-C18H34]
2+
 at m/z 212.25 (2’) (Table 2.3 and 
Figure 2.4A & 2.4B). The subsequent loss of the second tail moiety from m/z 212.25, [M-
C18H34]
2+
, results in the formation of a doubly charged ion [M-C18H34- C18H34]
+
 at m/z 87.11 (3’) 
(Table 2.3 and Figure 2.4A & 2.4B). This doubly charged ion is only observed in G18:1-6. On 
the other hand, the loss of both tail regions, one bound to a single dimethyl-amino, is observed in 
all G18:1-s gemini surfactant. In G18:1-6, this is observed as,[M-C18H35 - C20H41N]
+
 at m/z 
128.15 (3) and is concluded to have been formed from [M-C18H35]
+
 (2) due to the loss of a 
neutral CH3(CH2)7CH=CH(CH2)8N(CH3)2 and from [M-C18H34]
+
 (2’) from the loss of a neutral 
CH3(CH2)7CH=CH(CH2)6CH=CH2 and the corresponding singly charged ion m/z 46.06, N-
methylmethanaminium (Table 2.3 & 2.4 and Figure 2.4A & 2.4B). In fact, the doubly charged 
ion observed at m/z 87.11 (3’) is a very minor product ion (Figure 2.4A) and therefore it is very 
likely that its formation is transient and it is relatively unstable due to the close proximity of the 
positive charges in both G18:1-2 and G18:1-3.   
Since all G18:1-s gemini surfactants contain identical tail regions it is expect that there 
will be shared fragments within this gemini surfactant family. The presence of a double bond in 
the tail regions of the G18:1-s gemini surfactants results in a double bond also being present in 
their product ions, producing alk-1-en-1-ylium fragments: hept-1-en-1-ylium (2’’), m/z 97.11, 
hex-1-en-1-ylium (3’’), m/z 83.09, pent-1-en-1-ylium (4’’), m/z 69.08, and but-1-en-1-ylium 
(5’’), m/z 55.06 (Table 2.3 and Figure 2.4A & 2.4B).  Similar to the G12-s family, an additional 
identical fragment seen in all analyzed G18:1-s gemini surfactants: a singly charged but-1-ylium 
at m/z 57.07 (2’’’)  (Table 2.3 and Figure 2.4A & 2.4B). 
Increased fragmentation complexity is observed, in Tables 2.2 and 2.3, as the spacer 
region length is increased from two to sixteen or two to six carbons in length; with G12-16 and 
G18:1-6 generating the most complex fragmentation patterns of their respective families (Figure 
2.3A, 2.3B, 2.4A & 2.4B). However, these spectra possess the fragments that are present in the 
spectra of other gemini surfactants and therefore they are representative of the G12-s and G18:1-
s gemini surfactant families of nanoparticles, respectively. Within these distinct spectra there is, 
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however, one identical product ion shared by all ten compounds, but-1-ylium at m/z 57.07 
(Tables 2.2 & 2.3), and several ions among the ten compounds which are structurally conserved; 
for example, the loss of a single tail fragment, 2 and 2’ (Tables 2.2 & 2.3 and Figure 2.3A, 2.3B, 
2.4A & 2.4B)  
Conclusion 
The molecular composition of each G12-s and G18:1-s gemini surfactant was supported 
by QqToF-MS analysis. The assessment of the fragmentation pattern for each gemini surfactant 
was done by QqToF-MS/MS and demonstrated that the gemini surfactants share fragmentation 
patterns that are specific to their respective gemini surfactant families. Currently, a study of other 
gemini surfactant families is taking place with the intent of identifying two to three product ions 
for each gemini surfactant that have unique m/z values and will be utilized in multiple reaction 
monitoring. MRM utilizes both the precursor ion and select diagnostic product ions produced for 
the quantification of the compound. In addition both the precursor-to-product ion transition and 
retention times of each compound will allow for their exact identification. By identifying both 
the similarities and differences between each gemini surfactant product ions, the differing 
product ions are candidates for use during LC-MS/MS quantification of them and their 
metabolites in biological samples.  By quantifying both the gemini surfactants and their 
metabolites an evaluation of their toxicity, bioavailability and half-life during the course of 
transfection can be undertaken. Currently, the LC method required to separate the gemini 
surfactants is being designed in order to quantify individual gemini surfactants in media mixture.  
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CHAPTER 3 
TANDEM MASS SPECTROMETRY ANALYSIS OF NOVEL DIQUATERNARY 
AMMONIUM GEMINI SURFACTANTS AND THEIR BROMIDE ADDUCTS IN 
ELECTROSPRAY-POSITIVE ION MODE IONIZATION 
 
Joshua Buse, Ildiko Badea, Ronald E. Verrall, Anas El-Aneed 
Published in Journal of Mass Spectrometry 46 (2011), p 1060-1070 
 
The identification of MS/MS fingerprints for a bioactive molecule is important for the 
development of qualitative and quantitative analytical methods. Chapter 2 outlined the 
fragmentation behavior of 10 novel diquaternary ammonium gemini surfactants with alkyl spacer 
moieties. These gemini surfactants had a conserved fragmentation pattern regardless of the 
length of the spacer region and provided preliminary data on the fragmentation of simplistic 
diquaternary ammonium gemini surfactants and their ionization behavior within ESI-MS 
instruments. In this study, single stage MS and MS/MS analysis of 29 gemini surfactant moieties 
was undertaken to understand the gas phase and CID behavior of gemini surfactants with various 
structural features.  
Structural elucidation and characterization of 29 novel diquaternary ammonium gemini 
surfactant molecules was achieved using a QqToF-MS/MS and a QhQ-MS. The tested 
compounds were categorized into four distinct structural families based upon the composition of 
the spacer region: alkyl chains, secondary and tertiary amines, hydroxyl functional groups as 
well as ether linkers. MS, MS/MS, and quasi MS
3
 analysis of both the gemini surfactants and 
their bromide adducts allowed for the confirmation of each gemini surfactant’s molecular 
composition and structure through the identification of common and unique product ions as well 
as their origin. 
High resolution, single stage MS analysis showed that mass accuracy was less than 5 
PPM for all gemini surfactants and 10 PPM for all gemini surfactant bromide adducts; 
confirming their molecular composition. Identification of similarities in the gemini surfactants’ 
fragmentation behavior resulted in the production of a universal fragmentation pathway, while 
differences were identified as unique product ions that are indicative of specific structural 
elements.   Furthermore, evidence for the association of a gemini surfactant with bromine 
counter ion was confirmed during MS analysis of tested gemini surfactants regardless of their 
chemical composition. Previously, evidence for bromine and gemini surfactant association was 
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only observed with compounds bearing short alkyl spacer regions. MS/MS analysis of the 
bromine adducts was also confirmatory to the molecular structure.  
The universal fragmentation pathway has proven beneficial in the qualitative and 
quantitative analysis of these 29 gemini surfactants by multiple-reaction monitoring methods 
(CHAPTER 4) because it identifies product ions with unique m/z values, ensuring the specificity 
of the analysis.  
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Introduction 
 Drug delivery has been facilitated by various cationic polymers and lipids,
1, 2
 such as 
diquaternary ammonium gemini surfactant lipoplexes.
3
 Gemini surfactants are classified as 
compounds which contain two polar head regions, each covalently bound to a hydrophobic tail 
region (t), separated by a spacer (s); producing a tail-spacer-tail configuration (t-s-t) (Figure 
3.1).
4
 These structures are given identifier names comprised of G, for gemini surfactant, t for tail 
region composition and length as well as s for spacer region composition and length: (Gt-s). 
Numerous functional groups can be incorporated within the spacer region to reduce toxicity and 
enhance therapeutic outcomes. In this study, four major groups of gemini surfactants were 
evaluated; the classification of which was dependent on the chemistry of the spacer region: alkyl 
chains (designated as s corresponding to the length of alkyl chain - Figure 3.1A), secondary and 
tertiary amines (designated as sN where s corresponds to length of alkyl chains - Figure 3.1B), 
hydroxyl functional groups (designated as 4(OH)n where n corresponds to the number of 
hydroxyl functional groups - Figure 3.1C) as well as ether linkers ((designated as EOs where s is 
the number of ethoxy moieties - Figure 3.1D). 
The formation of cationic liposomal nanostructures occurs spontaneously when a lipid 
mixture, including cationic diquaternary ammonium gemini surfactants, are introduced into 
solution with genetic material.
5-7
 The electrostatic interactions of the cationic head region with 
the anionic backbone of the genetic material and the hydrophobic packing of the negative charge 
results in the internalization of genetic material within the lipoplex.
8
 Those gemini surfactants 
that are symmetrical in nature, specifically the presence of symmetry between the tail regions, 
were found to have superior interactions with deoxyribonucleic acid, leading to enhanced 
transfection efficiency, in comparison to asymmetrical gemini surfactants.
9
 In addition, the 
spacer length, valence, head group size, tail length, and molecular architecture of gemini 
surfactants play a critical role in their interaction with genetic material.
9
 An increase in the length 
of the hydrocarbon tail regions was found to increase the transfection efficacy facilitated by 
gemini surfactants due to their ability to adopt a variety of polymorphic structures.
11-13 
Conversely, modifications in the spacer region were undertaken to ensure optimal spacing of 
those regions within the molecule involved in interactions with the genetic material.
14 
Furthermore, the inclusion of ethylene oxide, hydroxyl, and amine substituent's within the spacer 
region sought to increase the number of points of interaction between the gemini surfactant and 
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Figure 3.1 Diquaternary ammonium gemini surfactants evaluated in this study are comprised of 
two tail regions (saturated [A
1
] or unsaturated [A
2
] alkyl chains) connected to one another 
through a spacer region. The compounds are categorized based upon the composition of the 
spacer region: (A
1
 & A
2
) alkyl chain with no substituent's (B) alkyl chain that include secondary 
and tertiary amine(s) functional group(s) (C) alkyl chain that includes hydroxyl functional 
group(s) (D) alkyl chain that contains ether linker(s). The variation in the tail and spacer region 
can induce difference in the gemini surfactants properties. 
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the DNA leading to enhanced transfection efficiency through an increase in structure-activity and 
binding efficiency;
14, 15
 the gemini surfactant G12-3NH displayed a 9 fold increase in 
transfection efficiency in comparison to the compound G12-3.
10 
Gemini surfactants are well-characterized for their use as gene delivery agents.
16-18
 The 
size distribution of many diquaternary ammonium gemini surfactant-based nanoparticles is 
between 100 and 200 ±10 nm. The nano-scale size distribution of gemini surfactant complexes 
and their polycationic nature allows for their use for both in vitro and in vivo gene delivery 
applications.
3, 17, 19 For example, topical transfection of the IFNγ gene using nanoparticles 
containing G16-3 into mouse epidermis produced superior results compared to the unprotected 
IFNγ gene.17 Similarly, DNA transfection into human fibroblast cells was found to be enhanced 
by gemini surfactants in comparison to commercially available cationic lipids.
20
  
MS is routinely used for qualitative and quantitative applications.
21-25 
Single stage MS 
and MS/MS can be utilized for structural determination and MS/MS fingerprint identification.
26-
28
 The identification of MS/MS fingerprints for a bioactive molecule is important for 
identification and quantification  purposes within biological or environmental samples.
29, 30
 
Glycosyl isoflavonoids, for example, can be selectively identified through the fragmentation of 
the O-glycosidic bond as well as the subsequent loss of methyl functional groups and hydrogen 
atoms.
31
 The spectra produced and corresponding relative m/z intensities of each glycosyl 
isoflavonoids following multi-stage MS analysis are indicative of the their structures and can be 
utilized in the future for their identification in crude plant extracts.
31
 Similarly in our recent 
communication, 10 novel diquaternary ammonium gemini surfactants with alkyl spacer moieties 
(Figure 3.1A
1
 and 3.1A
2
) were analyzed by ESI-MS/MS.
26
 These gemini surfactants had a 
conserved fragmentation pattern regardless of the length of the spacer region.
26
 The information 
acquired during MS and MS/MS experiments provided preliminary data on the fragmentation of 
simplistic diquaternary ammonium gemini surfactants and their ionization behavior in ESI-MS 
instruments. 
 
In this work, the molecular structure of twenty-nine gemini surfactants, with varying 
spacer complexity, and their MS/MS fingerprint/fragmentation pathways were elucidated using 
single stage MS, MS/MS, and quasi MS
3 
experiments. The experimental data provided the basis 
for the proposed universal fragmentation pathway. The complexity of the fragmentation pattern, 
however, increased proportionally with the molecular weight as well as the complexity of the 
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spacer region. In addition, the MS and MS/MS analysis of gemini surfactant bromide adducts 
demonstrated that ion pair formation can occur within the gas phase between bromide and 
gemini surfactants of varying composition. 
Experimental 
Materials 
All twenty-nine Gt-s gemini surfactants, categorized into four families based upon the 
spacer composition, were synthesized by Dr. Ronald E. Verrall's research group in the 
Department of Chemistry at the University of Saskatchewan based upon previously reported 
methods of synthesis.
32-34
 Variations in the gemini surfactant’s chemical structure included: tail 
region length and saturation (Figure 3.1A
1
 & 3.1A
2
), length of non-substituted alkyl spacers 
(Figure 3.1A
1
 & 3.1A
2
), inclusion in the spacer of secondary and tertiary amines (Figure 3.1B), 
of hydroxyl functional groups (Figure 5.1C) or of ether linkers (Figure 3.1D). The association of 
bromide counterions with all gemini surfactants analyzed is due to the action of bromide as a 
counterion in the starting material utilized during chemical synthesis.
34
 Following the synthesis 
of each gemini surfactant, the purity of each compound was determined from surface tension 
measurements and the chemical structures of each gemini surfactants was confirmed by 
1
H NMR 
in CDCl3.
34 
Sample Preparation 
All gemini surfactants solutions were individually prepared to a concentration of 3 mM in 
methanol-water (50:50 v:v) and stored at -20 °C prior to analysis. For MS, MS/MS, and quasi 
MS
3
 analysis, each sample was further diluted 1000 to 5000x at the time of analysis, to achieve 
optimal ion counts, using methanol-water (50:50 v:v) with 0.1% formic acid. Methanol (LC 
grade purity, Caledon, Georgetown, ON, Canada), formic acid (98% GR ACS purity, EMD 
Chemicals Inc., Merck KGaA, Darmstadt, Germany) and Milli-Q organic-free water (Millipore, 
Bedford, MA, USA) were used as solvents. MS and MS/MS analysis of gemini surfactant 
bromide adducts, required a 100x to 1000x dilution at time of analysis using methanol. 
Single Stage MS Analysis 
An Applied Biosystems, API QSTAR XL MS/MS QqToF-MS/MS was used for MS and 
MS/MS analysis. The instrument was operated in the positive ion mode with the following 
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parameters: declustering potential between 20.0 and 50.0 V, declustering potential 2 of 100.0 V 
and focusing potential of 290.0 V. Sample aliquots were infused into the mass spectrometer by 
an integrated Harvard Syringe pump, through a Turbo Ionspray Source; 5.5 kV at a temperature 
of 80 °C. Two-point internal calibration was performed for all gemini surfactants. The internal 
calibrants were chosen because their m/z values fall within the m/z range of the tested 
compounds. Internal calibration was performed for the MS analysis of all twenty-nine 
diquaternary ammonium gemini surfactants using two doubly-charged calibration standards: 
[Glu1]-Fibrinopeptide B Human (amino acid sequence EGVNDNEEGFFSAR, [M+2H]2+ m/z 
785.8421, C66H95N19O26, BaChem Bioscience Inc. [King of Prussia, PA, USA]) and N,N-
bis(dimethyldodecyl)-1,2-ethanediammonium dibromide (G12-3 - [M]2+ m/z 234.2685). The 
molecular structure of G12-3 was previously confirmed by NMR while purity was confirmed by 
elemental and surface tension measurements.
35
 
Analyses of the gemini surfactant's bromide adduct were performed in an identical 
manner to the above experiment, using an Applied Biosystems, API QSTAR XL QqToF-
MS/MS. MS analysis of eight diquaternary ammonium gemini surfactant bromine adducts 
utilized two external calibrants: the cesium ion (molecular weight  = 132.9055) from cesium 
iodide (CsI) and the iPD1 peptide (amino-acid sequence ALILTLVS ([M]); molecular weight = 
828.5315; C39H72N8O11; Bachem Bioscience Inc., King of Prussia, PA, USA). 
Low-Energy Collision Induced  Dissociation MS/MS Analysis 
All parameters applied during MS analysis were maintained for CID-MS/MS analysis of 
each compound using the API QSTAR XL system. For CID-MS/MS, nitrogen collision gas was 
infused into the collision cell and the CE was optimized for each compound between 15 and 50 
eV to ensure the formation of product ions while maintaining the precursor ion in abundance.   
Quasi MS
3 
Analysis 
A Micromass Quattro II QhQ-MS was utilized during quasi MS
3
 analysis to establish the 
gemini surfactants' fragmentation pattern. The instrument was operated in the positive ion mode 
with an infusion rate of 25 µL/min, source temperature of 140º C, HV lens voltage of 0.71 kV 
and capillary voltage of 3.50 V. The cone voltage was set at 70 V to induce in source 
fragmentation of the compounds prior to entering the first quadrupole. The collision gas used 
during MS/MS experiments was argon and the CE was set between 15 and 50 eV in order to 
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generate product ions while ensuring that the precursor ion remained abundant. The Micromass 
Quattro II was superior in terms of inducing insource fragmentation in comparison to the 
Applied Biosystems, API QSTAR XL QqToF mass spectrometer and was therefore chosen to 
perform quasi MS
3
 analysis. 
Results and Discussion 
Previously structural analysis of the diquaternary ammonium gemini surfactants by 
1
H 
NMR in CDCl3 resulted in the identification of each gemini surfactants structure.
34
 The MS, 
MS/MS, and quasi MS
3
 outlined here provided data on each gemini surfactant’s structure that 
correlated with previous 
1
H NMR results. In addition, the establishment of the universal 
fragmentation template has resulted in the identification of gemini surfactants within complex 
matrices and allow for confirmation of the chemical structures of newly synthesized gemini 
surfactants’, including the presence of a bromide counter ion.    
Single Stage Mass Spectrometric Analysis of Gemini Surfactants and Corresponding 
Bromide Adducts 
Single stage QqToF MS analysis resulted in the formation of the doubly charged ion of 
all tested gemini surfactants with mass accuracies of less than 5 PPM (Table 3.1A). As such, the 
theoretical molecular formula of each gemini surfactant, including the presence of the correct 
number of nitrogen atoms, was confirmed. The precision and accuracy of these measurements 
were enhanced through the use of two doubly charged internal calibrants. 
The identification of several gemini surfactant bromide adducts confirmed the presence 
of bromide within the purified samples as well as its action as a counter ion. The detection of the 
gemini surfactant bromide adduct ions required a greater concentration than the doubly charged 
gemini surfactants and produced mass accuracy values less than 10 PPM (Table 3.1B). In 
addition to utilizing mass accuracy data to confirm the presence of a single bromide, the isotopic 
distribution of bromide was employed to confirm its presence within the singly charged ion 
(Figure 3.2). 
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Gemini Surfactant Theoretical Observed Mass Accuracy
Gt-s m/z m/z PPM
G12-2 227.261 227.260 -1.540
G12-3 334.269 334.268 -0.598
G12-4 241.276 241.277 2.072
G12-6 255.292 255.291 -3.917
G12-7 262.300 262.299 -2.669
G12-8 269.308 269.308 2.599
G12-10 283.323 283.323 -1.059
G12-12 297.339 297.339 1.009
G12-16 325.370 325.369 -3.688
G16-3 290.331 290.330 -3.100
G16-6 311.355 311.354 -2.730
G16-7 318.363 318.361 -4.712
G18-3 318.363 318.363 0.314
G18-7 346.394 346.394 0.577
G18:1-2 309.339 309.339 0.970
G18:1-3 316.347 316.345 -4.742
G18:1-6 337.370 337.369 -3.853
G12-EO1 249.274 249.273 -4.613
G12-EO2 271.287 271.286 -2.765
G12-EO3 293.300 293.299 -2.216
G12-4(OH) 249.274 249.274 -1.003
G12-4(OH)2 257.271 257.270 -4.276
G12-2N 255.790 255.789 -2.150
G12-3N 269.805 269.806 3.521
G12-2N2 284.319 284.318 -1.057
G12-3NH 262.798 262.797 -1.522
G16-3NH 318.860 318.860 -0.627
G18-3NH 346.891 346.893 3.171
G18:1-3NH 344.876 344.875 -3.335
Table 3.1A Mass Accuracy of Gemini surfactants and Gemini Surfactant Bromine 
Adducts
Gemini Surfactants
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Gemini Surfactant Theoretical Observed Mass Accuracy
Gt-s m/z m/z PPM
G12-16 729.660 729.653 -9.045
G16-3 659.581 659.580 -2.123
G18:1-6 753.660 753.659 -0.133
G12-EO3 665.519 665.520 0.751
G12-4(OH)2 593.462 593.459 -4.718
G12-3N 618.530 618.531 2.587
G16-3NH 730.655 730.649 -7.527
G18-3NH 772.702 772.707 6.600
Table 3.1B Mass Accuracy of Gemini surfactants and Gemini Surfactant Bromine 
Adducts
Gemini Surfactant Bromine Adducts
  
Figure 3.2 The m/z isotopic distribution for both the G12-4(OH)2 gemini surfactant and 
corresponding bromide adduct clearly depicts the two positive charges found on the gemini 
surfactant ion and the formation of gemini surfactant bromide adduct ion; respectively. 
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The degree of ion pair formation between a gemini surfactant and a bromide counter ion 
in the gas phase was observed in a wide range of gemini surfactants (Table 3.1). This finding 
contradicts Blomberg et al.’s report of gemini surfactants in the liquid phase which indicated that 
bromide ion pair formation occurred only for gemini surfactants containing short spacer region; 
verified by surface force measurements.
36
 Analysis of the decay length of the repulsive double-
layer force at concentration below the CMC showed the gemini surfactants to be mainly 
dissociated from one another, however, increasing the concentration resulted in an increase in 
ion pair formation.
36
 In addition, such association was observed with gemini surfactants with 
short alkyl spacer regions.
36
 The difference in the degree of ion pair formation between the gas 
and liquid phases is not unexpected as the dielectric constant is much lower in the gas phase in 
comparison to the liquid phase.
37, 38
 The present results, therefore, confirm the propensity of the 
gemini surfactant cation to form an ion pair with its counter ion under favorable conditions.  
Universal MS/MS Fragmentation  
Structural identification of each gemini surfactant was established through both CID-
MS/MS and quasi MS
3
 analysis utilizing a QqToF-MS/MS and QhQ-MS/MS; respectively. 
Quasi MS
3
 involves fragmentation of ions within the ionization source, in-source fragmentation, 
followed by MS/MS of selected product ions.
21, 39
   It has been successfully utilized to 
authenticate the fragmentation pattern of different bioactive compounds and garner further 
structural information on precursor and product ions.
21, 39, 40
 For example, Sioud and coworkers 
evaluated the fragmentation behaviour of commercial biotin reagents using MS/MS and 
confirmed the proposed fragmentation pathways using quasi MS
3
.
 40
 Therefore, both MS/MS and 
quasi MS
3
 data  provided structural information about each compound (APPENDIX A) while 
quasi MS
3
 analysis rationalized the fragmentation route(s).   
Analysis and comparison of the CID-MS/MS and quasi MS
3
 behavior for all doubly 
charged gemini surfactant ions, [M]
2+
, resulted in the establishment of a universal MS/MS 
fragmentation pathway (Figure 3.3A) which was observed during the analysis of all twenty-nine 
gemini surfactants (Table 3.2). While Figure 3.3A illustrates the universal fragmentation pattern,  
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[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
227.26 285.32 72.08 143.17 72.08 214.09 85.1 → 57.07
234.28 299.35 131.16 86.1 150.18 86.1 85.1 → 57.07
241.28 313.39 100.11 157.19 100.11 214.09 85.1 → 57.07
255.3 341.41 128.15 171.2 87.11 128.15 214.1 212.24 85.1 → 57.07
262.31 355.42 187.22 142.16 178.21 94.11 142.16 296.34 214.1 212.24 85.1 → 57.07
269.31 369.42 201.12 199.22 156.18 185.22 101.12 156.18 310.35 214.25 212.24 85.1 → 57.07
283.32 397.45 229.26 227.25 184.2 199.23 115.14 184.2 352.4 214.26 212.24 85.1 → 57.07
297.35 425.49 257.3 255.29 212.24 212.24 129.16 212.24 380.44 214.25 212.24 85.1 → 57.07
325.37 481.55 313.36 311.34 268.3 241.28 157.19 268.3 436.49 214.26 212.24 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
290.34 355.41 131.15 86.1 178.21 86.1 85.1 → 57.07
311.41 379.34 173.42 128.19 199.21 87.03 128.19 270.33 85.1 → 57.07
318.39 411.34 187.36 144.57 206.25 94.03 144.57 352.43 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
318.38 383.45 131.16 86.1 192.23 86.1 85.1 → 57.07
346.41 439.51 187.22 142.17 220.26 94.12 142.17 380.44 297.97 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
309.34 367.41 72.08 72.08 97.1→55.06
316.35 381.43 86.1 191.35 86.1 97.1→55.06
337.38 423.48 128.15 212.25 211.24 128.15 97.1→55.06G18:1-6
Table 3.2 Product ions identified following CID-MS/MS analysis of each precursor ion 
extracted from the Gemini Surfactant Ion. Unique product ions are 1a, 2a & 3a.
G12-s Gemini Surfactants (m/z)
G12-2
G12-4
G12-10
G12-16
G12-3
G12-6
G12-7
G12-12
G18:1-2
G18:1-3
G16-3
G12-8
G16-s Gemini Surfactants (m/z)
G18:1-s Gemini Surfactants (m/z)
G18-s Gemini Surfactants (m/z)
G16-6
G18-7
G16-7
G18-3
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[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
249.28 329.37 161.21 116.11 165.19 116.11 85.1 → 57.07
271.3 373.39 205.2 160.14 187.2 103.11 160.14 314.32 85.1 → 57.07
293.31 417.42 249.23 204.16 209.22 125.12 204.16 346.35 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
249.29 329.35 116.11 165.19 116.11 85.1 → 57.07
257.28 345.23 132.11 173.19 132.11 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
255.8 129.14 171.71 129.14 149.17 214.26 212.25 212.25
269.72 185.72 284.32 214.26 212.25 212.25
262.82 188.23 143.17 178.72 143.17 271.32 214.27 212.25 212.25
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
284.33 423.48 129.15 212.25 129.15 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
318.87 412.47 188.22 143.17 206.74 143.17 327.38 270.32 85.1 → 57.07
[M]2+ 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5
346.89 188.21 143.15 220.74 143.15 397.45 297.96 85.1 → 57.07
G12-sN Gemini Surfactants (m/z)
Table 3.2 continued 
G12-4(OH)s Gemini Surfactants (m/z)
G12-EOs Gemini Surfactants (m/z)
G12-EO1
G12-EO3
G12-4(OH)
G12-EO2
G12-4(OH)2
G18-3NH
G12-3NH
G16-sN Gemini Surfactants (m/z)
G16-3NH
G18-sN Gemini Surfactants (m/z)
G12-2N2
G12-sN Gemini Surfactants (m/z)
G12-2N
G12-3N
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regardless of the exact molecular structure of the tested compound, the MS/MS spectra of G12-
16 will be used in the following sections for illustrative purposes (Figure 3.3B, 3.3C, and 3.3D). 
Unique product ions formed from the precursor ion are classified into three distinct 
fragmentation pathways that involve either heterolytic or homolytic cleavage of the C-N bonds 
of the quaternary aminium ion. Two fragmentation pathways arise from the removal of the alkyl 
tail region producing either a singly charged ion containing aminium and amine functional 
groups through heterolytic cleavage (Figure 3.3A - struc. 1a) or a doubly charged diaminium ion 
through homolytic cleavage (Figure 3.3A - struc. 2a). The third fragmentation pathway results in 
the production of two complementary ions, a singly charged alkenyl-N,N-dimethylalkanaminium 
ion (Figure 3.3A - struc. 3a) and a dimethylalkanaminium ion (Figure 3.3A - struc. 3b).   
 Fragmentation pathway 1: As indicated earlier, G16-12 is used as an illustrative 
example. Doubly charged precursor ion extracted from G16-12 m/z 325.37 is cleaved at the C-N 
bond between the quaternary aminium and the first carbon within the tail region producing  a 
singly charged product ion 1a, m/z 481.55, bearing aminium and amine functional groups 
(Figures 3.3A & 3.3B). The loss of the second alkyl tail region as a neutral molecule produced 
the successive singly charged aminium product ion 1b, m/z 313.36 (Figures 3.3A & 3.3B). The 
subsequent loss of H2 produced a singly charged product ion 1c, m/z 311.34, containing a double 
bond within the spacer region (Figures 3.3A & 3.3B). Finally, the dissociation of 
methylidenemethanamine, yielded the singly charged aminium product ion 1d, observed at m/z 
268.30 (Figures 3.3A & 3.3B). 
 Fragmentation pathway 2: The second fragmentation pathway starts with the homolytic 
cleavage of the C-N bond between the quaternary aminium and the first carbon within the tail 
region producing the doubly charged product ion 2a; observed at m/z 241.28 in the case of G16-
12 (Figures 3.3A & 3.3C). The loss of the second, uncharged alkyl tail region through homolytic 
cleavage from the doubly charged product ion 2a produces the second diaminium product ion 
2b, m/z 157.19 (Figures 3.3A & 3.3C). The diaminium product ion 2b produced a singly charged 
aminium product ion 2c, m/z 268.30 (Figures 3.3A & 3.3C), through the loss of complementary 
methylmethanaminium; observed when scanning below 50 Da at m/z 46.07.
26
 
 Quasi MS
3
 analysis revealed an interrelation between product ions within pathways 1 and 
2. First, the singly charged aminium product ion 1b (Figure 3.3A) was also generated from the 
doubly charged product ion 2a (Figure 3.3A) as a result of cleavage of the alkyl tail region. 
101 
 
Second, the cleavage of methylmethamine from the singly charged species 1b (Figure 3.3A) 
resulted in the production of the singly charged aminium species 2c (Figure 3.3A). In addition, 
structures 1d and 2c (Figure 3.3A) are isobaric structural isomers varying only in the location of 
the double bond; the formation of which was confirmed via MS
3
 analysis of ions 1b, 1c, and 2b. 
Furthermore, ions which precede 2c within the fragmentation pathway may be either singly (1b) 
or doubly (2b) charged in nature (Figure 3.3A). 
 Fragmentation pathway 3: The third fragmentation pathway occurs as a result of 
cleavage of the C-N bond between the quaternary aminium and the neighboring carbon within 
the spacer region, producing two complementary ions confirmed via quasi MS
3
: alkenyl-N,N-
dimethylalkanaminium ion 3a, m/z 436.49, and dimethylalkanaminium ion 3b, m/z 214.26 
(Figures 3.3A & 3.3D). Subsequent loss of H2 from dimethylalkanaminium ion 3b (Figures 3.3A 
& 3.3D) produced a dimethylalkenaminium ion 3c, m/z 212.24 (Figures 3.3A & 3.3D). Further 
fragmentation of the spacer or tail regions in alkenyl-N,N-dimethylalkanaminium ions (Figures 
3.3A & 3.3D - Struc. 3a)  resulted from loss of methylium (Figure 3.3D insert). The nature of 
this fragmentation was confirmed by the sequential loss of CH2 during quasi MS
3
 analysis and 
was solely observed in gemini surfactants that contained ten or more linear carbon atoms within 
their spacer region (Figure 3.3D - Struc. 3a & insert). Due to such fragmentation, ion 3a is not 
suitable for LC-MS/MS ion identification during multiple reaction monitoring, because of the 
observed sequential loss of CH2. For example, the 3a ions of both G12-12 and G12-10 were 
observed in the MS/MS spectra of G12-16.  
In addition to the three major fragmentation pathways, non-diagnostic ions are observed 
in the low m/z range and result from fragmentation of the alkyl tail region of gemini surfactants. 
The product ions observed differed solely based on the saturation of the tail region. Those gemini 
surfactants with a single unsaturation produced hept-1-en-1-ylium, hex-1-en-1-ylium, pent-1-en-
1-ylium, and but-1-en-1-ylium ions (Figure 3.3A - Struc. 4) while those with saturated tail 
regions produced hex-1-ylium, pent-1-ylium, and but-1-ylium ions (Figure 3.3A - Struc. 5). 
These ions were observed in the quasi MS
3
 analysis of any species bearing a tail region, hence it 
was suitable to illustrate the precursor ion as the source in Figure 3.3A. 
 In summary, the three ion types found to be unique during gemini surfactant MS/MS 
analysis were produced from 1) the loss of a singly charged tail region (Figure 3.3A - Struc. 1a), 
2) the loss of a neutral tail region (Figure 3.3A - Struc. 2a) or 3) the loss of a 
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dimethylalkanaminium ion (Figure 3.3A - Struc. 3a). At least one unique product ion is observed 
in the MS/MS analysis of all tested gemini surfactants, while two or more unique product ions 
being observed in the MS/MS analysis of 27 of 29 gemini surfactants (Table 3.2). In addition, 
increased MS/MS data complexity is observed for gemini surfactants with a greater number of 
atoms within their spacer region (Table 3.2). It is speculated that the increased complexity is a 
result of decreased repulsion between the quaternary ammonium functional groups resulting in 
the formation of stabilized product ions.  
Unique Fragmentation Observed in the MS/MS Analysis of Gemini Surfactants 
 Unique fragmentation was observed during the MS/MS analysis of the Gt-EOs (Figure 
3.4) as well as Gt-sN and Gt-sNH (Figure 3.5) gemini surfactant families in addition to the 
universal fragmentation pattern aforementioned.  The unique product ions that result from Gt-
EOs gemini surfactants were concluded to be formed from the product ion 2a (Figure 3.3A). For 
example, the fragmentation of the product ion 2a of G12-EO3, m/z 209.22, at two different ether 
bond locations within the spacer region produced two singly charged product ions. Specifically 
cleavage between the oxygen and neighboring carbon nearest to the quaternary amine produced 
an ion observed at m/z 242.35 (Figure 3.4 – Frag. 2), while cleavage between the oxygen and 
neighboring carbon nearest to the tertiary amine produced an ion observed at m/z 346.35 (Figure 
3.4 - Frag. 3). The later ion at m/z 346.35 yielded the formation of an ion at m/z of 178.37 
(Figure 3.4 – Frag. 4), which occurs in an identical manner to that observed for the production of 
the doubly charged product ion, m/z 209.22 through the loss of a neutral tail region (Figure 3.4 – 
Frag. 1). 
The origin and structural elucidation of these unique product ions were confirmed by 
quasi MS
3
 analysis. The product ion observed at m/z 209.22 is produced solely from m/z 293.32 
following the transfer of a proton to the tertiary nitrogen and the elimination of a neutral 
dodecene molecule (Figure 3.4 – Frag 1). Subsequent fragmentation of the m/z 209.22 ion 
produces the product ions with m/z 242.35 (Figure 3.4 – Frag 2) and m/z 346.35 (Figure 3.4 – 
Frag. 3). However, the manner of the fragmentation is different because of differences in the 
electronegativity between the nitrogen atoms within the product ion.
41
 In the case of product ion 
at m/z 346.35, the tertiary ammonium would have a greater electronegativity and this may 
influence the formation of a double bond between the two terminal carbons within the 
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A 
Figure 3.4 Unique fragment ions produced by Gt-EOs gemini surfactants as represented by 
the G12-EO3 gemini surfactant  
Figure 3.4A Corresponding MS/MS spectra for m/z 293  209 demonstrating the sequential 
fragmentation pattern. 
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G16 MSMS 209.41 cone 55 Temp 140 Capillary 3.5 Collision 20
20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360
m/z0
100
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MAY 5 - G16 MSMS 209   24 (0.847) Sm (Mn, 2x0.75); Cm (6:26) Daughters of 209ES+ 
1.21e6x272.13
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Frag. 3 
B 
G16 MSMS 346.40 cone 55 Temp 140 Capillary 3.5 Collision 35
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Figure 3.4B Corresponding quasi MS
3
 spectra for m/z 209  346 (C) demonstrating the 
sequential fragmentation pattern.  
Figure 3.4C Corresponding quasi MS
3
 spectra for m/z 346  178 demonstrating the sequential 
fragmentation pattern.  
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complementary ion observed at m/z 72.12 (Figure 3.4 – Frag. 3).41 Conversely, the reduced 
electronegativity of the quaternary ammonium ion may result in a reduction in attraction which it 
has for electrons,
41
 allowing for the terminal carbon to be saturated within the ion of m/z 242.35 
(Figure 3.4 – Frag. 2) and production of the complementary ion at m/z 176.16.  
 Another structural family that produced unique ions are gemini surfactants bearing a 
secondary and tertiary amine within their spacer region. These compounds produced product 
ions which resulted from the loss of any uncharged alkyl amine (Figure 3.5 - Frag. 1); and 
cleavage between the amine of the spacer region and its neighboring carbon atom (Figure 3.5 - 
Frag. 2). G12-3NH, for example, produced both product ions during quasi MS
3
 analysis of ion 
m/z 143.18, resulting in m/z 98.08 (Figure 3.5 - Frag. 1), due to loss of the terminal amine, and 
m/z 86.31 (Figure 3.5 - Frag. 2), due to cleavage of the spacer amine; such fragmentation was 
observed solely in product ions that had terminal tertiary ammonium atoms due to the loss of the 
tail region.  
Figure 3.5 Unique fragment ions produced by Gt-sN and Gt-sNH gemini surfactants and the 
corresponding quasi MS
3
 spectrum. 
G23 MS3 143.2 cone 60 Temp 140 collision 13
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160
m/z0
100
%
JAN 17 11 - G23 MS3 143 1 (0.059) Daughters of 143ES+ 
1.38e698.08
86.31
86.18
85.99
70.06
58.17
143.18
142.99
143.63
Frag. 1 
Frag. 2 
106 
 
 
Tandem Mass Spectrometric and Quasi MS
3
 analysis of Gemini Surfactant Bromide 
Adducts 
 Structural confirmation of several gemini surfactants was further supported by the MS 
and MS/MS analysis of their bromide adducts. The mass accuracy and isotopic data corroborated 
the projected molecular formula of 8 selected gemini surfactants from each family analyzed 
(Figure 3.1) and the formation of a bromide ion pair. The 8 gemini surfactants chosen covered all 
four families of gemini surfactants (Figure 3.1) and included variation in the size and 
composition of both the spacer and tail regions. The benefit of the MS/MS analysis of the gemini 
surfactant's bromide adducts is the ability to correlate the product ions to the gemini surfactants 
structure. Both the [M + Br
79
]
+
 and [M + Br
81
]
+
 molecular ions were analyzed by MS/MS to 
identify product ions which contain bromide adducts.  
 Five dominant product ions were observed following the fragmentation of 8 gemini 
surfactant bromide adducts with three of five producing distinct m/z for each gemini surfactant; 
G16-3 is used as an illustrative example. The first product observed resulted from the 
dissociation of the bromide ion from the gemini surfactant producing the doubly charged gemini 
surfactant observed at m/z 290.34 (Figure 3.6 - Struc. 1); distinct for all gemini surfactants 
analyzed. The dissociation of the bromide ion with the a methylium group heterolytically cleaved 
from a quaternary aminium resulted in a singly charged product ion m/z 565.66 (Figure 3.6 - 
Struc. 2). Similarly, dissociation of the bromide ion with an alkyl tail moiety due to heterolytic 
cleavage produced  a singly charged ion bearing aminium and amine functional groups with a 
single tail region, m/z 355.41 (Figure 3.6 - Struc. 3). The ion observed at m/z 310.35 was 
produced via heterolytic cleavage of the precursor ion's dimethyl"alkan"aminium tail region, 
giving rise to a singly charged product ion comprised of a spacer attached to a tail region via a 
dimethyl aminium group (Figure 3.6 - Struc. 4). Finally, cleavage of the tail region as 
dimethyl"alkan"aminium can produce a doubly charged product ion comprised of a cationic 
spacer attached to a tail region via a dimethyl aminium group; one cationic charge is offset by a 
bromide counter ion, m/z 390.28 (Figure 3.6 - Struc. 5). The presence of each general structure 
in the MS/MS spectrum of 8 gemini surfactants is visually displayed in Table 3.3. 
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[M+Br]
+ 1 2 3 4 5
729.64 325.37 635.72 481.55 436.48 517.41
659.58 290.34 565.66 355.41 310.35 390.28
753.67 337.38 659.72 423.47 364.39 458.34
665.52 293.3 571.58 417.41 452.28
593.45 257.27 300.29
618.53 524.59 370.41 311.35 405.28
730.65 636.72 426.48 367.4 461.35
772.69 678.76 440.5 381.45 375.37
Gemini Surfactant Bromine Adducts
Table 3.3 - Fragment ions identified in the MS/MS analysis of several 
bromine adduct gemini surfactant ions.
G18-3NH
G12-3N
G12-16
G18:1-6
G16-3NH
G16-3
G12-EO3
G12-(OH)2
 
 
Additional fragmentation of the gemini surfactant bromide adducts is observed in both 
the Gt-sN and Gt-sNH families, including the formation of a tail region attached to an ionized 
tertiary amine. In addition, cleavage of the carbon-nitrogen bond of the secondary/tertiary amine 
located within the spacer region also produced unique product ions that could be utilized for 
MS/MS identification of such gemini surfactants. The uniqueness of each structure will allow for 
the identification of gemini surfactant bromide adducts within various medium, including 
formulations and cell cultures. 
Conclusion 
Confirmation of the projected molecular formula of 29 novel gemini surfactants was 
achieved by MS analysis of both the doubly charged ions and bromide adducts on a Qq-ToF 
mass spectrometer using two point internal calibration and external calibration, respectively. The 
observed m/z value for each doubly charged, gemini surfactant differed from the theoretical 
value by less than 5 PPM, while the singly charged, bromide adduct gemini surfactant ions 
differed by less than 10 PPM. Confirming the molecular formula and the molecular structure of 
each gemini surfactant required MS/MS and quasi MS
3
 analysis on QqToF and QhQ mass 
spectrometers; respectively. The product ions produced during MS/MS and quasi MS
3
 analysis 
of gemini surfactants and their bromide adducts confirmed their proposed molecular structures 
and fragmentation pathways. This allowed for the development of a universal fragmentation 
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pathway (Figure 3.3A). The universal fragmentation pathway will be beneficial in future 
quantitative and qualitative analysis of these 29 gemini surfactants by multiple-reaction 
monitoring methods because it identifies product ions with unique m/z values, ensuring the 
specificity of the analysis.  
Quantitation of G16-3, for example, has been achieved within a tissue culture matrix at 
concentrations up to 3 μM by LC-MS/MS (data will be reported in a future manuscript) using the 
MS/MS fingerprint reported within this paper. Similarly, the quantitation of G12-3NH within 
COS-7 African Green monkey kidney fibroblast cells, has been achieved following gene 
transfection using a formulation containing a 111 μM of G12-3NH (data will be reported in a 
future manuscript). In addition, the universal fragmentation pattern was utilized to predict the 
dissociation behavior of novel amino acid-substituted gemini surfactants (data will be published 
upon completion of analysis). The overall fragmentation observed followed the universal 
fragmentation pathway (Figure 3A) with novel fragmentation being associated with the amino 
acids/dipeptide conjugated to the spacer region. From our experience, the use of the universal 
fragmentation pathway in the identification of the product ions shortened the time required for 
MS/MS analysis of novel diquaternary ammonium gemini surfactants. 
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CHAPTER 4 
A GENERAL LC-MS/MS METHOD FOR THE QUANTITATIVE DETERMINATION OF 
DIQUATERNARY AMMONIUM GEMINI SURFACTANT DRUG DELIVERY AGENTS IN 
PAM212 CELLULAR LYSATE 
 
Joshua Buse, Ildiko Badea
, 
Ronald E. Verrall, Anas El-Aneed 
Published in the Journal of Chromatography A 1294 (2013), p 98-105 
 
The continued development of efficient and safe gene delivery agents will benefit directly 
from an understanding of their cellular fate upon transfection. The development of a simple and 
rapid LC-LR-MS/MS method for their quantification is, therefore, required. Previous work 
(CHAPTER 2 & 3) on the low-energy CID-MS/MS behavior of twenty-nine gemini surfactant 
analytes was instrumental in the selection of diagnostic MRM transitions used during LC-
MS/MS analysis. 
A LC-MS/MS method is reported that is specific for the quantification of twenty-nine 
individual diquaternary ammonium gemini surfactant molecules and was validated for G16-3 
within PAM212 cell lysate according to USFDA bioanalytical method validation guidelines. The 
ten minute chromatographic separation procedure utilized an Agilent Zorbax CN column (100 x 
2.1 mm with 3 micron particles) with LC-MS grade water and acetonitrile, both containing 0.3% 
(vol:vol) formic acid and 1 mM triethylamine. Extraction of the gemini surfactant from PAM212 
keratinocyte cell lysate was performed using octanol and 10 μL aliquots were injected onto the 
column.  
The standard curve was linear from 0.30 μg/mL to 220 μg/mL (r2 ≥ 0.999) for G16-3 and 
precision and accuracy were within USFDA specified limits. G16-3 analyte was assessed as 
stable during storage in the auto-injector, bench-top, freeze-thaw cycling, and long-term (60 
days) storage at -20 °C. Cellular uptake and fate of G16-3, during both the incubation and post 
incubation periods was monitored for 55 hours. The absence of a change in concentration after 
the removal of the transfection solution at the 5 hour mark indicates the absence of metabolic 
activity that would degrade G16-3 within PAM212 cells.
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Introduction 
Gemini surfactants (Gt-s) are compounds comprised of two hydrophobic tail regions (t) 
covalently bound to individual polar head groups that are linked chemically to one another by a 
spacer region (s).
1
 The potential for numerous structural modifications, e.g., variations in the 
chemical nature and structure of the hydrophobic tails, head groups, and spacer, has resulted in 
the synthesis of an array of structurally unique gemini surfactants which fulfill specific roles in 
soil remediation,
2
 agrichemical spreading,
3
 anti-foaming agents,
4
 as well as pharmaceutical 
formulations.
5
 The benefits of the gemini surfactants in comparison to monovalent surfactants 
include enhanced surface active properties and a lower CMC.
6, 7
 These characteristics permit the 
use of a lower molar concentration of gemini surfactant(s) to achieve the desired outcome(s) in 
comparison to conventional surfactants. For example, the remediation of 2-napthanol 
contaminated soil by diquaternary ammonium gemini surfactants was superior to conventional 
quaternary ammonium surfactants.
2
  
Prominent use of gemini surfactants has also occurred in pharmaceutical formulations, 
particularly gene delivery. For example, modification of the gemini surfactants’ structures, 
including variations in the spacer and tail substituent's, were found to achieve the desired 
compaction and protection of DNA.
8, 9
 The benefit of using a diquaternary ammonium gemini 
surfactant is that the electrostatic interaction between the cationic ammonium head groups and 
the genetic material’s anionic backbone compacts the DNA to form a lipoplex.10 The 
formulations utilized for gene delivery are typically heterogeneous mixtures of a single 
diquaternary ammonium gemini surfactant, helper lipid, most commonly DOPE, and genetic 
material.
5, 11
 At present, diquaternary ammonium gemini surfactants can achieve a rate of 
transfection, as assessed by expression of the transfected gene, which is comparable or superior 
to commercial transfection systems. In cellular models, gene expression was comparable to that 
achieved with, commercially available, Lipofectamine plus™.9 Similarly, gene delivery in 
animal models using gemini surfactants was found to be more effective in comparison to 
unprotected DNA as well as a cationic lipid: cholesteryl 3β-(N-[dimethylaminoethyl]carbamate) 
delivery system; respectively.
5
 Additional research has further supported the efficacy of gemini 
surfactants for the intracellular delivery of genetic material.
12-15
 However, the gene delivery 
efficacy of the diquaternary ammonium gemini surfactants is offset by an absence of detailed 
information about their fate; e.g., biological stability, action following transfection. The benefits 
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of determining their post-transfection fate include an enhanced understanding of the rate of 
gemini nanoparticle uptake, the occurrence of cellular interactions, the formation of toxic 
metabolites. This can be attributed to the absence of suitable analytical methods to detect, 
differentiate, and quantify diquaternary ammonium gemini surfactants within biological 
matrices. 
 Therefore, prior to an investigation of the fate of gemini surfactants in mammalian cells, 
a validated quantification method is required. Mass spectrometry (MS) detection was chosen for 
the quantification of gemini surfactants because of the absence of a chromophore or fluorophore 
on the diquaternary ammonium gemini surfactants and the presence of two permanently charged 
diquaternary ammonium groups, making it specifically detectable by MS. Previous work on the 
low-energy CID-MS/MS behavior of twenty-nine gemini surfactant analytes was instrumental in 
the selection of diagnostic MRM transitions used during LC-MS/MS analysis.
16, 17
 An 
understanding of the fragmentation behavior of each gemini surfactant was needed to confirm 
the molecular structure and understand the behavior of the tested compounds after undergoing 
ESI and CID-MS/MS analysis within a mass spectrometer. Such MS/MS knowledge lays the 
foundation for developing a MRM quantification method. Analyte separation by liquid 
chromatography, prior to MRM analysis, has been demonstrated to be critical, in many 
situations, to minimize the influence of co-eluting analytes within the matrix;
18
 hence, allowing 
for the identification and quantification of the gemini surfactants.  
 Although high performance liquid chromatographic quantification methods are available 
for some ionic
19
 and nonionic
20
 gemini surfactants, the existence of significant structural 
differences prevent such methods from being directly applied to the gemini surfactants utilized 
for gene delivery. Our development of an LC-MS/MS method allows for confirmation of the 
specific diquaternary ammonium gemini surfactants through the monitoring of their specific 
retention times and precursor/product ion transitions.
21, 22
 The validated method presented in this 
manuscript can be utilized for the quantification of 29 diquaternary ammonium gemini 
surfactants (Table 4.1), including those which contain an alkyl spacer region (Figure 4.1A),  
secondary and tertiary amine(s) (Figure 4.1B), polyethyoxylated (Figure 6.1C) or hydroxyl 
(Figure 4.1D) substituted alkyl chains. MRM transitions were specifically chosen to take 
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Table 4.1 LC-MS/MS analysis of 29 diquaternary ammonium gemini surfactants 
 
Reference 
ID 
Spacer Region Tail Region 
Retention 
Time 
MRM 
Transitions 
Monitored 
Gt-s Name 
Molecular 
Formula 
Name 
Molecular 
Formula 
Minutes m/z  m/z 
G12-2 Ethyl C2H4 Dodecyl C12H25 4.77 227  285 
G12-3 Propyl C3H6 Dodecyl C12H25 4.81 234  299 
G12-4 Butyl C4H8 Dodecyl C12H25 4.83 241  313 
G12-6 Hexyl C6H12 Dodecyl C12H25 4.94 255  341 
G12-7 Heptyl C7H16 Dodecyl C12H25 5.02 262  355 
G12-8 Octyl C8H16 Dodecyl C12H25 5.19 269 369 
G12-10 Decyl C10H20 Dodecyl C12H25 5.34 283  397 
G12-12 Dodecyl C12H24 Dodecyl C12H25 5.55 297  425 
G12-16 Hexadecyl C16H32 Dodecyl C12H25 5.8 325  481 
      
 
G16-3 Propyl C3H6 Hexadecyl C16H33 5.03 290  355 
G16-6 Hexyl C6H12 Hexadecyl C16H33 5.76 311  379 
G16-7 Heptyl C7H16 Hexadecyl C16H33 5.82 318  411 
      
 
G18-3 Propyl C3H6 Octadecyl C18H37 6.02 318  383 
G18-7 Heptyl C7H16 Octadecyl C18H37 6.43 346  439 
      
 
G18:1-2 Ethyl C2H4 
Octadec-9-
ene 
C18H35 5.65 309  367 
G18:1-3 Propyl C3H6 
Octadec-9-
ene 
C18H35 5.87 316  381 
G18:1-6 Hexyl C6H12 
Octadec-9-
ene 
C18H35 6.14 337  423 
      
 
G12-2N 
N-ethyl-N-
methylethana
mine 
C5H11N Dodecyl C12H25 4.37 256  172 
G12-3N 
N-propyl-N-
methylpropana
mine 
C7H15N Dodecyl C12H25 4.7 270  186 
G12-3NH 
N-
propylpropana
mine 
C6H13N Dodecyl C12H25 4.57 263  179 
G12-2N2 
N,N'-diethyl-
n,N'-
dimethyleetha
ne-1,2-diamine 
C8H18N2 Dodecyl C12H25 4.78 284  423 
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Table 6.1 Continued 
       
Reference 
ID 
Spacer Region Tail Region 
Retention 
Time 
MRM 
Transitions 
Monitored 
Gt-s Name 
Molecular 
Formula 
Name 
Molecular 
Formula 
Minutes m/z  m/z 
G16-3NH 
N-
propylpropan
amine 
C6H13N Hexadecyl C16H33 5.52 319  412 
      
 
G18-3NH 
N-
propylpropan
amine 
C6H13N Octadecyl C18H37 5.99 347  221 
G18:1-3NH 
N-
propylpropan
amine 
C6H13N Octadecyl C18H35 5.65 345  220 
      
 
G12-4OH Butane-2-diol C4H6O Dodecyl C12H25 3.99 249  165 
G12-4OH2 
Butane-2,3-
diol 
C4H6O2 Dodecyl C12H25 4.28 257  345 
      
 
G12-EO1 
1,1'-
oxydiethane 
C4H8O Dodecyl C12H25 4.88 249  165 
G12-EO2 
1,2-
diethyoxyleth
ane 
C6H12O2 Dodecyl C12H25 4.96 271  187 
G12-EO3 
1-ethoxy-2-
(2-
ethoxyethoxy)
ethane 
C8H16O3 Dodecyl C12H25 4.88 293 209 
 
advantage of the doubly charged nature of the gemini surfactants, which gave product ions with a 
m/z value greater than the precursor ion. The validated MRM analytical method for gemini 
surfactant G16-3 utilized two product ions, the first was chosen for its unique nature, whereas the 
other for its superior ionization intensity. We applied the quantification method to effectively 
measure the cellular uptake of the G16-3 gemini surfactants in PAM212 keratinocyte cell lysate, 
contributing to an understanding of the post transfection fate of the gemini surfactants. 
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Experiments 
Chemicals 
The diquaternary ammonium gemini surfactants used in this study were synthesized by 
Dr. Ronald E. Verrall's research group in the Department of Chemistry, University of 
Saskatchewan, using previously reported procedures.
9, 23
 1-Octanol (99%) was purchased from 
Figure 4.1 The general structure of first and second generation quaternary ammonium gemini 
surfactants as categorized based upon their spacer composition; Alkyl chain (A), 2 & 3 amine 
(‘R’ can be a hydrogen or methyl substituent)  (B), polyethoxylated (C), and hydroxyl (D) 
substituted alkyl chains. 
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Acros Organics (Geel, Belgium). Mass spectrometry-grade water and acetonitrile were 
purchased from Fisher Scientific (Ottawa, ON, Canada). Formic acid and triethylamine (TEA) 
were purchased from EMD (Gibbstown, NJ, USA). PAM212 cells were grown in MEM 
modified medium obtained from ATCC (Manassa, VA, USA). Media supplements of Fetal 
Bovine Serum Albumin and Antibiotic were obtained from Sigma Aldrich (St. Louis, MO, 
USA). DOPE was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). 
Instrumentation 
The high performance liquid chromatography (HPLC) MS/MS system consisted of an 
Agilent series 1100 quaternary pump with an online degasser and auto sampler (Agilent 
Technologies, Mississauga, ON, Canada) coupled to an AB Sciex API 4000 QTRAP mass 
spectrometer (AB Sciex, Concord, ON, Canada).  HPLC separation of the analytes was achieved 
by using an Agilent Eclipse CN column (100 x 2.1 mm with 3 micron particles) with an Agilent 
Eclipse CN column guard (12.5 x 2.1 mm with 5 micron particles) (Agilent Technologies, 
Mississauga, ON, Canada). The mass spectrometry grade water and acetonitrile mobile phases 
both contained 0.3% (% vol) formic acid and 1 mM triethylamine (Figure 4.2). Sample aliquots 
of 10 μL were injected onto the column and eluted using a gradient flow of 400 μL/min (Figure 
4.2). Sample carryover in the autosampler was negated by the injection of double blank 
following injection of the highest standard curve concentration. No carryover was detected. The 
column was maintained at room temperature during the run and subsequently washed with water 
followed by acetonitrile after every use. 
The ABSciex QTRAP 4000 mass spectrometry utilized a curtain gas pressure of 30 psi as 
well as GS1 and GS2 parameters set at 40 psi.  The ionspray voltage was set at 5500 V and the 
temperature of the ESI source interface was maintained at 600 °C. The mass spectrometer 
utilized MRM to identify and/or quantify each gemini surfactant analyte. Assessing the 
chromatographic retention time of each gemini surfactant required that 10 μL of a homogenous 
50 μg/mL solution be injected onto the column with specific transitions being monitored for each 
analyte (Table 4.2).  
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Deculstering 
Potential
Collision 
Energy
Collision Cell 
Exit Potential
[M]
2+
 →  [M-X]
+ 
m/z → m/z eV eV eV
[M]
2+  → [M-C16H33]
+ m/z  290 → 355 40 21 10
[M]
2+  → [M-C33H70N2]
+ m/z 290 → 86 40 35 6
[M]
2+  → [M-C16D33]
+ m/z 323 → 388 35 25 10
Transition
Table 4.2 ABSCIEX QTRAP 4000 MRM instrument parameters
 
Quantification of G16-3 was achieved through use of the transitions [M]
2+
  to [M-
C16H33]
+
 (m/z 290  355) and [M]2+  to [M-C33H70N2]
+
 (m/z 290  86) (Figure 4.3) at the 
instrument conditions defined in Table 4.2; peak areas were summed through use of Analyst 
Figure 4.2 Gradient chromatographic conditions utilized for the elution of diquaternary 
ammonium gemini surfactants for MS/MS detection and quantification 
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Software. The internal standard utilized a transition from [M]
2+
  to [M-C16D33]
+
 (m/z 323  388) 
(Figure 4.3) at the instrument conditions defined in Table 4.2.  
Preparation of Standard Solutions 
 Accurately weighed gemini surfactant analyte were dissolved in minimal essential media 
(MEM) modified media to prepare 10 mM stock solutions. Stock solutions of the internal 
standard G16D66-3 were produced by dissolving an accurately weighed amount of analyte in 
octanol to produce a 200 μM concentration. Stock solutions were prepared weekly and were 
serially diluted with MEM modified media immediately before use. All analyte solutions were 
stored under darkness at -20 °C. 
Sample preparation 
 PAM212 murine keratinocytes (kindly provided by Dr. S. Yuspa, National Cancer 
Institute, Bethesda, MD, USA), which did not undergo transfection, were seeded on Falcon 75 
cm
2
 tissue culture flasks (BD, Mississauga, ON) with MEM media at a density of 
1 × 10
4
 cells/mL.
5
 To ensure complete lysis of the PAM212 cells, they were directly transferred 
immediately after harvesting to -80 °C, followed by six freeze/thaw cycles and sonication at 25 
kHz for one hour prior to analysis. The analyzed solutions were comprised of 200 μL of the cell 
lysate of 1.0 x10
6
 PAM212 cells, to which 200 μL of a 40mM G16D66-3  in octanol were added. 
Prior to injection, the samples were vortexed for 30 seconds to ensure partitioning of the 
diquaternary ammonium gemini surfactant into the organic phase. Separation of the aqueous and 
Figure 4.3 The product ions of the analyte (G16-3) and internal standard (G16D66-3) that were 
monitored during LC-MS/MS analysis  
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organic phases was allowed to occur at room temperature using pulse centrifugation and the 
organic phase, containing G16-3, was extracted for analysis.  
Method validation  
Full method validation for G16-3 was performed in accordance with USFDA guidance. 
Specificity was evaluated by analysis of six different passages of PAM 212 cells to detect any 
potential interference with co-eluting endogenous substances. Linearity was determined across 
the linear range of 0.30 to 220 μg/mL by plotting the ratio of the summed peak areas associated 
with G16-3 and the peak area associated with G16D66-3. A linear least square analysis was 
conducted with 1/χ as weighting factor, and the slope, intercept and coefficient of determination 
(r
2
) were determined to establish linearity. The LOD was defined as the lowest detectable 
concentration with a signal to noise ratio of 3. The lowest limit of quantification was defined at 
the lowest concentration that gives precision and accuracy within ±20% of the nominal value.  
The intra- and inter-day precision and accuracy of the method was established through 
the analysis of six replicates of samples at four different concentrations (LLOQ, lower 
quantification concentration [LQC], middle quantification concentration [MQC], and high 
quantification concentration [HQC]) on three different days. Single assay runs were accepted 
only when the relative standard deviation (RSD) was found to be less than ±15% at 
concentrations other than the LLOQ, which allowed ±20%. The criterion for accuracy was set at 
±15% of the nominal concentration of the QC samples and ±20% for LLOQ. In no case did more 
than one third of the QC samples violate these criteria. Studies involving freeze–thaw stability, 
bench-top stability, and long-term stability were undertaken at LQC, MQC, and HQC. Freeze–
thaw stability was tested after three freeze–thaw cycles spaced at least twenty-four hours apart 
with sample storage at −20 ± 5 °C between sample thawing. Twenty-four hour stability of G16-3 
in PAM212 cell lysate under bench-top conditions was established. Predicted concentrations 
were calculated using newly prepared calibration standards. Samples were stored at −20 ± 5 °C 
for 30 and 60 days prior to analysis of long-term stability. Samples were considered stable when 
the criteria for precision and accuracy were met.  
Preparation of the G16-3 Gemini Surfactant/DOPE Gene Delivery system 
Transfection experiments utilized a pGT·IFN-GFP plasmid.
24
 Transfection formulations 
of plasmid/gemini surfactant/DOPE (PGL) particles were prepared as previously described.
24
 A 
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1:10 charge ratio of plasmid:gemini surfactant facilitated transfection and DOPE was utilized as 
a colipid at a 1:100 (wt:wt) ratio of plasmid:DOPE. 
Transfection of PAM212 cells using Gemini Surfactant G16-3 and DOPE 
PAM212 murine keratinocytes were seeded on Falcon 6-well tissue culture plates (BD, 
Mississauga, ON) with MEM media at a density of 3 × 10
5
 cells/well 24 hours prior to 
transfection. Transfection experiments were carried out using 100 ng plasmid DNA/well. Cells 
were harvested at prescribed periods of time using trypsin to lift the cells and stored in 200 μL of 
unsupplemented MEM media prior to analysis by LC-MS/MS. The reported results are the 
average of two individual transfection assays of triplicate wells. 
Results 
  The simplicity of the sample preparation methodology as well as the selectivity and 
sensitivity of the LC-MS/MS technique indicates that this approach is suitable for the 
measurement of the cellular concentration of gemini surfactants. The benefits of LC separation, 
included the mitigation of analyte carryover and assignment of a retention time to each analyte, 
resulted in its choice over flow injection analysis-tandem mass spectrometry for quantitative 
analysis of gemini surfactants. Analysis of the gemini surfactants by FIA-MS/MS, involving the 
direct injection of samples into the mass spectrometer, resulted in sample carryover and 
therefore, was not suitable for quantitative analysis of gemini surfactants. In addition, 
chromatographic separation provided analyte selectivity based upon each analytes specific 
retention time (Table 4.1), while MRM analysis provided structural specificity for each gemini 
surfactants based upon the precursor/product ion transitions monitored. By combining LC and 
MS/MS, highly specific and selective quantification of gemini surfactants can be achieved as 
demonstrated by G16-3. In addition, the LC-MS/MS method allowed for an evaluation of the 
rate of cellular uptake of the nanoparticles and the level of metabolism/excretion of the 
analyte(s).  
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Figure 4.4 An increase of gemini surfactants’ tail length results in an increase in the 
corresponding retention time (RT). This is demonstrated by G12-7 (RT = 5.02), 
G16-7 (RT = 5.81) and G18-7 (RT = 6.43) 
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Although, the current method validation was completed for a single gemini surfactant, 
G16-3, it may be applied to other diquaternary ammonium gemini surfactants. The retention 
times of each of the twenty-nine bisquaternary ammonium gemini surfactants analyzed by LC- 
MS/MS were within 3.99 and 6.42 minutes of the ten minute chromatographic run (Table 4.1). In 
addition, the elution behavior of the gemini surfactants was predictable: longer spacer and tail 
regions took a greater length of time to elute in comparison to their shorter counterparts. For 
example, as the alkyl tail region of gemini surfactants, containing a hexadecyl spacer region, 
increase from an dodecyl to octadecyl the elution time increased from 5.01 minutes to 
6.43minutes (Figure 4.4).  The MS/MS provided a high level of specificity for all gemini 
surfactants based upon the specific MRM transitions monitored (Table 4.1), producing no 
observable carry-over from one run to the next. 
Based upon the previous success of G16-3 for the transfection of genetic material,
5
 it was 
chosen as a model compound for which a LC-MS/MS method would need to be validated in 
order to monitor its post transfection fate. For example, topical application of the IFNγ gene into 
mouse epidermis using the gemini surfactant G16-3 produced a 450% increase in levels of IFNγ 
in the epidermis compared to unprotected IFNγ genes.5, 11, 13  Diquaternary ammonium gemini 
surfactants possessing a shorter spacer also showed a lower toxicity than those gemini 
surfactants with longer spacer or those containing secondary amines.
25
  
LC-MS/MS Method Validation for the Analysis of G16-3 in PAM212 Cells  
 Specificity for G16-3 and G16D66-3 was established using mass spectrometry analysis, 
by monitoring the transitions of [M]
2+
 (m/z 290) to both [M-C16H33]
+
 (m/z 355) and [M-
C33H70N2]
+
 (m/z 86) and the transitions of [M]
2+
 (m/z 323) to [M-C16D33]
+
  (m/z 388); 
respectively (Figure 4.3). No interference was observed for  the analyte’s and internal standard’s 
transitions within the PAM212 cell lysate (Figure 4.5A). The transitions specificity was observed 
while monitoring blank PAM212 cell lysate within MEM media for both G16D66-3 (Figure 
4.5B) and G16-3 (Figure 4.5C & D). 
Recovery  
 The concentration of analyte recovery was consistent within the lower, middle, and upper 
limit of quantification. The mean±SD recoveries of G16-3 in PAM212 cells were 71.3±4.7,  
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Analysis Day Accuracy Precision
(#) % %RSD
LLQC 1 0.273 ± 0.023 90.6 7.9
0.300 μg/mL 2 0.295 ± 0.051 98 7.1
3 0.278 ± 0.024 92.6 9.1
LQC 1 3.37 ± 0.13 90.9 3.4
3.71 μg/mL 2 3.38 ± 0.19 91.2 5.1
3 3.34 ± 0.22 88.4 6.3
MQC 1 39.87 ± 1.64 107.7 4.6
37.1 μg/mL 2 40.75 ± 0.99 110 2.89
3 38.4 ± 2.41 103.6 6.4
HQC 1 161.17 ± 3.71 87.1 1.9
185 μg/mL 2 168 ± 8.7 90.7 4.7
3 175.16 ± 5.5 94.5 3
Observed Concentration
(mean±SD, µg/mL)
Quality Control
Table 4.3 Intra-day assay of precision and accuracy for G16-3 using LC-MSMS in PAM212 
cell lysate
70.1±5.9, and 68.2±3.3% at lower, middle, and upper limit of quantitation: respectively. 
Similarly, recovery of the internal standard G16D66-3 was assessed to be 69.7±5.3%. 
Method Validation  
 The validation results for diquaternary ammonium gemini surfactant G16-3 within 
PAM212 cell lysate satisfied the requirements specified by the USFDA for analytical method 
validations. Additional method validations on the remaining twenty-eight diquaternary 
ammonium gemini surfactants were not carried out at this time. 
The LOD was based upon a signal to noise ratio of 3:1, leading to an assessment of 0.180 
μg/mL for LOD. The LLOQ was based upon a reproducibility of 20% accuracy, leading to an 
assessment of  0.300 μg/mL for LLOQ (Figure 4.5C). The linearity of the method had an r2 value 
of ≥0.999 for the range of 0.30-220.00 μg/mL. The reproducibility of the calibration curve was 
consistent on all occasions. 
The accuracy of the validated method varied between 89.3 and 109.5 for all evaluated 
calibration curve concentrations (data not shown). The intra- and inter-day accuracy of the 
method was established in replicates of six at the LLOQ, LQC, MQC, and HQC concentrations 
(Tables 4.3 & 4. 4). The 
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Concentration Accuracy Precision
(μg/mL) % %RSD
LLQC 0.3 0.282 ± 0.032 93.7 8
LQC 3.71 3.36 ± 0.18 90.2 4.9
MQC 37.1 39.67 ± 1.68 107.1 4.6
HQC 185 168.11 ± 5.97 90.8 3.2
Observed Concentration 
(mean±SD, µg/mL)
Quality Control
Table 4.4 Inter-day assay of precision and accuracy for G16-3 using LC-MSMS in PAM212 
cell lysate
Accuracy Precision
% %RSD
LQC 0 hour 3.55 ± 0.62 95.8 2.2
3.71 μg/mL 24 hours RT 3.62 ± 0.5 97 14.5
F/T - 3rd Cycle 3.81 ± 0.46 102.7 12.5
LT - 60 day 4 ± 0.19 108.3 4.72
MQC 0 hour 35.9 ± 1.9 96.9 5.2
37.1 μg/mL 24 hours RT 38.8 ± 1.21 104.7 3.5
F/T - 3rd Cycle 35.67 ± 2.65 96.2 7.2
LT - 60 day 37.5 ± 2.8 97.6 5.6
HQC 0 hour 181.33 ± 2.5 98.9 1.4
185 μg/mL 24 hours RT 190.33 ± 4.16 102.96 10.4
F/T - 3rd Cycle 190.33 ± 3.24 103 1.73
LT - 60 day 184 ± 1.84 99.4 10.3
Observed Concentration
Quality Control Analysis Type
(mean±SD, µg/mL)
Table 4.5 Stability assays of precision and accuracy for G16-3 using LC-MSMS in PAM212 
cell lysate
 
intra-day accuracy was assessed between 87.1 and 107.7% while inter-day accuracy was between 
90.2 and 107.1%.  Intra-day precision was assessed between 1.9 and  9.1 % relative standard 
deviation while inter-day precision was between 3.2 and 8.0 % relative standard deviation.  
Gemini surfactants were stable when stored at room temperature for short periods of time 
and at -20°C for extended lengths of time. Both twenty-four hour bench top (~22 °C) stability 
studies and freeze/thaw (-80 °C <> 22 °C) stability studies, spaced twenty-four hours apart, 
produced suitable accuracy and precision at the LQC, MQC, and HQC concentrations. The 
calculated accuracy and precision values for LQC, MQC, and HQC were between 108.3 and  
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95.8% as with 1.4 and 14.5% relative standard deviation,  respectively (Table 4.5). Such values 
were within the acceptable parameters when performed in triplicate (Table 4.5). 
Quantification of Diquaternary Ammonium Gemini Surfactant G16-3 in PAM212 Cell 
Lysate Transfected with a G16-3 Gemini Surfactant/DOPE Gene Delivery System 
The validated quantification method was applied to diquaternary ammonium gemini 
surfactant G16-3 extracted from PAM212 cells transfected with a G16-3 gemini 
surfactant/DOPE gene delivery system. All quality control tests met the set criteria during the 
analysis. The sensitivity and specificity of the assay were found to be adequate for accurately 
assessment of the uptake of G16-3 and monitor its post-transfection cellular concentration.  
Linear uptake of the G16-3 gemini surfactant following addition of the transfection solution was 
observed during the zero to five hour period (Figure 4.6). 
Figure 4.6 Mean G16-3 concentration ± SD post transfection within the PAM212 cell lysate. 
An increase in G16-3 concentration was observed during incubation with the transfection 
solution (Δ), while the cellular concentration of G16-3 was maintained after the transfection 
solution was removed (); solution was removed at 5 hours (orange dotted line) 
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No significant change in the concentration of G16-3 gemini surfactant within PAM212 
cells was observed (220.1±16.0 ng/well) over the five to fifty-three hour period following 
removal of the transfection solution. This suggests the absence of any metabolism/excretion 
mechanisms within PAM212 cells that would diminish the cellular concentration of the G16-3 
gemini surfactant.  
Discussion 
LC-MS/MS has been deemed the gold standard for the quantification of small molecules 
by the pharmaceutical industry because of the selectivity and specificity that it provides.
26, 27
 LC 
provided analyte selectivity based upon the measured retention time while mitigating analyte 
carryover through use of gradient elution conditions,
28
 results which could not be achieve 
through use of FIA-MS/MS alone. Use of MRM analysis allows for all 29 gemini surfactants to 
be distinguished from one another, achieving analyte selectivity without the need for baseline 
separation. In addition, the use of liquid:liquid extraction and liquid chromatography[29]  prior 
to MRM detection allowed for a LOD to be achieved through removal of interfering molecules.  
Use of a cyano column, instead of other columns tested during method development (i.e., 
C18, C4, and phenyl stationary phases), for liquid chromatographic separation was based upon 
its ability to achieve selective and reproducible separation of structurally-related gemini 
surfactants. The selectivity and reproducibility achieved by the cyano stationary phase was 
superior to a C18 stationary phases which was unable to elute the gemini surfactants as well as a 
C4 or a phenyl stationary phase which exhibited poor elution behavior and sporadic selectivity 
(APPENDIX B). In addition, the reproducibility of peak shape was achieved through the 
inclusion of 1 mM TEA within both mobile phases which resulted in a large reduction in the 
observation of peak tailing.
30
 The inclusion of TEA and 0.3 % formic acid as mobile phase 
organic modifiers resulted in each gemini surfactant displaying a specific retention time based 
upon its structural properties. Increases in the retention time of gemini surfactants as the size of 
the tail and/or spacer region increases incrementally demonstrate that the cyano column is 
selective in its separation (Table 4.1). In addition, the ability to easily couple LC and mass 
spectrometry through an ESI interface allows for the analysis of every surfactant molecule. The 
need to minimize matrix effects attributed to the PAM212 cell lysate samples and sample 
carryover resulted in the choice of liquid:liquid extraction and LC for sample preparation and 
analyte separation. Use of octanol, toluene, and hexane for liquid: liquid extraction resulted in 
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the gemini surfactants 
partitioning out of the PAM212 cell lysate into the octanol phase (APPENDIX C). The structural 
complementarities between the hydrophobic tail regions and polar head regions of octanol and 
the gemini surfactants facilitated their interaction.  
Quantification of surfactants by UV absorption or fluorescence detection has previously 
been reported.
31
 However, due to the absence of a chromophore and flourophore on the 29 tested 
gemini surfactants, analysis by these detection methods was not amenable to our analytes of 
Figure 4.7 Gemini surfactants G16-7 and G18-3 have identical molecular formulae and m/z 
values. Differentiation between both analytes can be achieved based upon the unique MRM 
transitions for both analytes (G16-7 = 318 m/z  411 m/z and G18-3 = 318 m/z  383 m/z) 
as well as the different retention times (G16-7 = 5.81 and G18-3 = 6.02) 
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interest.
17, 18
 The presence of two quaternary ammonium moieties, both of which possess a 
permanent positive charge, makes bisquaternary ammonium gemini surfactants ideal for mass 
spectrometric detection. The use of MS/MS allowed for the differentiation of all 29 gemini 
surfactants, including those with identical m/z values. For example, G16-7 and G18-3, both with 
a molecular formula C43H92N2 and m/z of 318, are differentiated by both liquid chromatography, 
with retention times of 5.81 and 6.02 (Figure 4.7), and mass spectrometry, based upon the 
fragment ions of m/z 411 and 383 (Table 4.1); respectively.
16, 17
 The use of both retention time 
and MRM analysis provides analyte specificity which can be correlated to individual gemini 
surfactant structures.
21
 In addition, the selectivity of MRM analysis provides the ability to 
distinguish and quantify structurally similar analytes without it the need to achieve their baseline 
separation, an inherent advantage of MS/MS.
32, 33
 Analysis of the fragmentation pathways was 
confirmed the unique identities of each gemini surfactant through MRM analysis; monitored 
MRM transitions were unique for each gemini surfactants (Table 6.1).
16, 17
  
Validation of the quantitative method was performed for a single gemini surfactant, G16-
3, within PAM212 cell lysate based upon FDA guidelines. The cell culture media and PAM212 
cell lysate presented no interference with the selected MRM transitions and minimal carryover 
was detected (Figure 4.5A). The limit of quantification was suitable for monitoring the post 
transfection cellular uptake of the nanoparticles. We believe that in addition to monitoring 
cellular uptake, our method can serve as a starting point to quantify gemini surfactants for other 
applications, including pharmacokinetic studies and quality control purposes.  
Quantification of Gemini surfactant G16-3 post transfection demonstrates the cellular 
uptake of the G16-3 gemini surfactant/DOPE gene delivery systems. This post-transfection 
uptake over the five hour incubation period results in a G16-3 concentration of 220.1±16.0 
ng/well being observed. The absence of a change in concentration after the removal of the 
transfection solution at the 5 hour mark indicates the absence of metabolic activity that would 
degrade G16-3. Future studies include testing other gemini surfactants and monitoring their 
subcellular localization. The goal is to link cellular fate to the observed variations in toxicity.
5, 9
 
Completion of this work will assist in producing a gemini surfactant which have a higher 
efficacy and lower toxicity. 
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Conclusion 
 The expanding interest in utilizing non-viral gene delivery agents as treatment options 
requires their continued evaluation for delivery efficacy and cellular fate. Gemini surfactants 
have been previously assessed for delivery efficacy and cellular toxicity, however, no previous 
study has been performed to track the cellular concentration of gemini surfactants, including 
cellular uptake and post-transfection fate. The LC-MS/MS technique provides a highly suitable 
method of cellular quantification of gemini surfactants that lack a chromophore or fluorophore 
within the structure In addition, the specificity provided by MS/MS detection allows for the 
quantification of multiple analytes during each acquisition and took advantage of previous 
studies that discussed the fragmentation behavior of the gemini surfactants.
16, 17
 Therefore this 
method is suitable for an evaluation of the cellular uptake and excretion of gemini as well as 
analysis of both simple and complex nano-sized gene delivery systems. Currently, the developed 
method is being evaluated for the quantification of gemini surfactants and drugs which they can 
encapsulate, as well as being applied to the sub-cellular quantification of the gemini surfactant, 
G16-3, within PAM212 cells. 
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CHAPTER 5 
COMPARATIVE ASSESSMENT OF FIVE QUANTITATIVE HIGH-THROUGHPUT MASS 
SPECTROMETRY-BASED METHODS 
 
Joshua Buse, Randy W. Purves, Ronald E. Verrall, Ildiko Badea, Haixia Zhang, Christopher C. 
Mulligan, Kerry M. Peru, Jonathan Bailey, John V. Headley, Anas El-Aneed  
Liquid chromatography-high resolution-tandem mass spectrometry (LC-LR-MS/MS) is 
considered the gold standard for the quantification of small molecules due to its specificity and 
sensitivity. However, the length of time required for sample analysis and method development as 
well as the amount of solvent required for sample analysis makes LC-LR-MS/MS inefficient for 
the quantification of a low number of analytes. We compared four alternative, high-throughput 
mass spectrometry (MS) quantitative methods, namely fast liquid chromatography-low 
resolution-tandem mass spectrometry (FC-LR-MS/MS), fast liquid chromatography-high 
resolution-mass spectrometry, desorption electrospray ionization-low resolution-tandem mass 
spectrometry and matrix assisted laser desorption ionization-high resolution-mass spectrometry 
(MALDI-HR-MS), to a previously developed LC-LR-MS/MS for the quantification of a drug 
delivery agent (G16-3) within PAM212 cellular lysate. In comparison to LC-LR-MS/MS, each 
high-throughput MS method utilized less consumables to provide quantitative data in a shorter 
period of time. In addition, FC-LR-MS/MS achieved a superior lower limit of quantification in 
comparison to LC-LR-MS/MS, while MALDI-HR-MS and LC-LR-MS/MS provided increased 
linear dynamic ranges. Comparing all five quantitative MS methods demonstrated that: (i) the 
time of analysis for high-throughput MS methods is at least one quarter of that required for LC-
LR-MS/MS; (ii) the time required for the method development of high-throughput MS methods 
is reduced; and (iii) the results of the validated methods are comparable to those of LC-LR-
MS/MS. These results demonstrate that the four high-throughput MS methods are faster, more 
efficient, and less expensive than a conventional LC-LR-MS/MS method for the quantification 
of a single analyte within a biological sample.  
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Introduction 
The approval of new biological drugs has been continually growing, with 
biopharmaceuticals accounting for one third of approved new products since 2004,
1
 including 
eleven products in 2012.
2
 The processes associated with the approval of a biopharmaceutical 
strive to ensure that novel and innovative formulations possess superior properties; including 
enhance stability and cellular targeting.
3-6
  For example, gene-based biopharmaceuticals 
generally require a delivery vector, which can effectively transport the genetic material into the 
target cell where it is subsequently transcribed into mRNA, producing the desired protein(s) and 
restoring normal cellular function.
5, 6
 The viability of such therapy relies heavily upon the 
delivery vector's capacity to protect, target, and/or deliver the gene-based therapeutic. Cationic 
lipids are one class of delivery vectors that have facilitated the encapsulation and compaction of 
genetic material into non-immunogenic lipoplexes; protecting the genetic cargo from degradation 
and ensuring efficient delivery.
7, 8
  Delivery of the genetic cargo and its subsequent expression 
has been achieved by numerous cationic lipoplex systems; however, the cellular and sub-cellular 
fates of lipoplex components are substantially understudied. 
Diquaternary ammonium gemini surfactants are one class of cationic lipid molecules that 
are being utilized for gene delivery; achieving both in vitro
9, 10
 and in vivo success.
11
 The 
structural organization of two hydrophobic tail regions (t) attached to the polar head groups, and 
separated by a spacer region (s), creates an amphiphilic compound (Gt-s) that self-assembles into 
lipoplex structures when introduced into solution with genetic material.
12
 We recently developed 
a quantitative LC-LR-MS/MS method to monitor the cellular uptake and fate of G16-3 into 
PAM212 cell lysate using its deuterated analog as an internal standard (Figure 5.1).
12
  The 
selectivity, specificity, and sensitivity of LC-LR-MS/MS
13-16
 and its recognition as the gold 
standard in the pharmaceutical industry
17-19
 influenced our decision to utilize it for the 
quantification of G16-3. The final method achieved a LOD of 405 nM with a linear range 
approaching 1000-fold.
12
  However, this method required a time of analysis of eleven minutes 
per sample, and its LOD was negatively affected by the addition of triethylamine in the elution 
buffer, which was required to reduce peak tailing. In an attempt to improve the quantitative 
results and reduce the total time of analysis, alternative high-throughput mass 
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spectrometric methods for the quantification of G16-3 were developed using fast 
chromatography (FC), desorption electrospray ionization (DESI), and matrix assisted laser 
desorption ionization (MALDI). These ionization and sample introduction techniques were 
chosen because of their rapid nature and ability to attain quantitative results comparable with 
LC-LR-MS/MS.
20-23
 
Both LR
24
 and high resolution (HR)
19
 mass analyzers coupled to alternative 
ionization/introduction methods have been applied to the quantitative analysis of pharmaceutical 
formulation components. Attaining quantitative data that satisfies the USFDA guidelines for 
bioanalytical analysis has been demonstrated for both LR and HR mass analyzers coupled to 
either LC or FC by ESI; to achieve a minimum of 10 data points across a chromatographic peak 
required for quantification.
25, 26, 27
 For example, five tricyclic amines, utilized as physiotropic 
pharmaceuticals, were quantified within fortified human plasma by FC-HR-MS.
27
 Mass accuracy 
values that confirmed the molecular composition of each analyte are provided by a high 
resolution time of flight mass analyzers, utilizing two point internal calibrations.
27
 In addition, 
each analyte satisfied all USFDA requirements for bioanalytical method validation and attained a 
LOD between 1 and 2 ng/mL.
27
  
While ESI is the prevalent ionization method for quantitative analyses because of the 
ease of coupling LC to MS, surface DI techniques (i.e., MALDI, DESI) can be effectively 
coupled to either LR or HR MS instruments for the quantitative analysis of analytes.
28-30
 Surface 
DI techniques offer the potential advantage of eliminating or minimizing sample preparation, 
providing considerable benefits over conventional LC-MS quantitative techniques.
31, 32
 Although 
rarely associated with the analysis of small molecules or quantification, advances in MALDI-MS 
technology and matrices have extended its use for the quantification of small molecules.
33
 The 
quantification of chlormequat by MALDI-MS achieved a LLOQ of 50 ng/mL by impacting each 
sample spot with 50 laser shots, requiring less than 1 second of instrument time per sample. In 
addition to its rapid analysis time, MALDI-MS offers advantages that include the elimination of 
sample carry over as well as the ability to tolerate salts.
33-36
 Similarly, DESI-MS analysis 
allowed for rapid quantitative analysis. However, unlike MALDI-MS, DESI-MS analysis does 
not require the addition of matrix to facilitate ionization. DESI-MS takes advantage of the 
specificity, selectivity, and sensitivity of the mass spectrometer to alleviate limitations associated 
with other ionization techniques.
37
 For example, the inclusion of simple sample preparation 
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protocol prior to DESI-MS analysis of anisodamine improved the LOD and enabled an LLOQ 
comparable to that of chromatographic-MS methods. 
37
  
To our knowledge, there has not been a comprehensive comparison of the technical 
abilities of various MS-based quantification methods. We have, therefore, assessed the 
quantitative ability of four high-throughput mass spectrometric methods (FC-HR-MS, FC-LR-
MS/MS, DESI-LR-MS/MS, and MALDI-HR-MS) for the quantification of G16-3 within 
PAM212 cell lysate. Each method's quantitative capabilities are compared with a recently 
developed LC-LR-MS/MS method.
12
  Based upon the comparison of these four quantitative 
high-throughput methods to the LC-LR-MS/MS
12
 method we can conclusively state that: (i) the 
analysis time for high-throughput mass spectrometric methods is less than LC-LR-MS/MS; (ii) 
the time required for method development is reduced when employing high-throughput mass 
spectrometry methods; and (iii) the results of the validated methods are comparable with those of 
LC-LR-MS/MS. This indicates that the quantification of a single cationic delivery agent by high-
throughput mass spectrometry methods are faster, more efficient, and less expensive than a 
conventional LC-LR-MS/MS method.  
Materials and Methods 
Chemicals and reagents 
 Gemini surfactant G16-3 and the internal standard, G16D66-3 (Figure 5.1), were 
synthesized as described previously.
38-40
 All methods of analysis utilized mass spectrometry 
grade water, acetonitrile, and/or methanol, purchased from Fisher Scientific (Ottawa, ON, 
Canada). Formic acid was purchase from EMD (Gibbstown, NJ, USA). Octanol (99% grade) 
was acquired from Acros Organics (New Jersey, USA). MALDI grade sinapinic acid was 
purchased from Sigma Aldrich (St. Louis, MO, USA). Minimal essential media (MEM) for 
tissue culture was obtained from ATCC (Manassa, VA, USA). Media supplements of Fetal 
Bovine Serum Albumin and antibiotic were obtained from Sigma Aldrich (St. Louis, MO, USA). 
1,2 Dioleyl-sn-glycerophosphatidylethanolamine (DOPE; Avanti Polar Lipids, Alabaster, AL, 
USA) and α-tocopherol (Spectrum, Gardena, CA, USA) were utilized for the preparation of 
transfection lipoplexes. 
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Preparation of standard solutions 
 Stock solutions of G16-3 (10 mM) were prepared by dissolving the gemini compound in 
MEM modified media.  Stock solutions of the internal standard G16D66-3, with a concentration 
of 200 μM, were made by dissolving the analyte in octanol. Stock solutions were prepared 
weekly (stored at -20 °C). Serial dilutions were performed immediately prior to use.  
Preparation of double blank and blank PAM212 cell lysate 
Untransfected PAM212 murine keratinocytes (provided with thanks by Dr. S. Yuspa, 
National Cancer Institute, Bethesda, MD, USA) were seeded on Falcon 75 cm
2
 tissue culture 
flasks (BD, Mississauga, ON) with MEM media at a density of 1 × 10
5
 cells/mL.
41
 To ensure 
complete lysis of the PAM212 cells, they were transferred immediately after harvesting to -80 
°C, followed by six freeze/thaw cycles and sonication at 25 kHz for one hour prior to analysis. 
Double blank PAM212 cell lysate was not supplemented with either G16-3 or G16D66-3, while 
blank PAM212 cell lysate was only supplemented with G16D66-3 at the internal standard 
concentration stipulated for each method. 
Sample preparation for FC-MS(/MS) 
 The analyzed solutions comprised 200 μL of the cell lysate from 1.0 x106 PAM212 cells, 
to which 200 μL of a solution of 20μM G16D66-3 in octanol or methanol were added. Samples 
were subsequently vortexed for 30 seconds to ensure partitioning of the diquaternary ammonium 
gemini surfactant into the octanol phase. Separation of the aqueous and organic phases was 
allowed to occur at room temperature using pulse centrifugation and the organic phase 
containing G16-3 and G16D66-3 was extracted for analysis. Methanol protein precipitation 
required that the samples experience a force of 2000 times gravity for five minutes with the 
supernatant being analyzed by FC-MS(/MS). 
Instrumentation methodology for FC-LR-MS/MS quantification 
 The LC-LR-MS/MS system was comprised of an Agilent series 1200 quaternary pump 
with an online degasser and auto sampler (Agilent Technologies, Mississauga, ON, Canada) 
coupled to an AB Sciex API 4000 QTRAP mass spectrometer (AB Sciex, Concord, ON, 
Canada). Aliquots of 7.5 μL were injected onto an Agilent Eclipse CN guard column (12.5 x 2.1 
mm with 5 micron particles) (Agilent Technologies, Mississauga, ON, Canada) and analytes  
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 were eluted using a gradient with mobile phases consisting of MS grade A) water and B) 
methanol; both containing 0.1% (v:v) formic acid (Appendix D Figure 1). The LC system 
(samples and guard column) was maintained at room temperature during the run and methanol 
was utilized for washing and storage of the guard column after each batch. The carry over into 
the autosampler was negated by the injection of a double blank following injection of the highest 
standard curve concentration; detected carryover was not greater than the initial double blank. 
Three MRM scan events were optimized on the AB Sciex API 4000 QTRAP instrument and 
used for quantitative analysis (Table 5.1); two for the analyte (290 m/z  355 m/z and 290 m/z 
 86 m/z) and one for the internal standard (323 m/z  388 m/z) (Figure 5.1).  
Instrumentation methodology for FC-HR-MS quantification 
 A high resolution LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, 
Mississauga, ON, Canada) was utilized for the FC-HR-MS quantification of G16-3 from 
PAM212 cell lysate. The LC system was comprised of a Thermo Scientific Accela 1250 series 
quaternary pump with an online degasser and auto sampler (Thermo Scientific, Mississauga, ON, 
Canada). The LC system was utilized in an identical manner to FC-LR-MS/MS analysis (Section 
- Instrumentation methodology for FC-LR-MS/MS quantification) with the exception of the 
sample storage unit that was maintained at 10°C during analysis. Therefore, autosampler stability 
was assessed in addition to room temperature stability. The LTQ Orbitrap Velos mass 
spectrometer was operated in the positive ion mode, covering a range from m/z 150 to 500 using 
a resolving power of 30,000. The optimization procedure resulted in a sheath gas flow of 0.6 
Table 5.1 ABSCIEX QTRAP 4000 MRM instrument parameters 
Transition 
Declustering 
Potential 
Collision 
Energy 
Collision Cell 
Exit Potential 
[M]
2+
 to  [M-X]
+
  m/z to m/z eV eV eV 
[M]
2+
  to [M-C16H33]
+
  290 to 355 40 21 10 
[M]
2+
  to [M-C33H70N2]
+
  290 to 86 40 35 6 
[M]
2+
  to [M-C16D33]
+
  323 to 388 35 25 10 
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L/min, an auxiliary gas flow of 0.9 L/min, a spray voltage of 4.5 kV and a capillary temperature 
of 320 °C being utilized. Individual m/z values for G16-3 (290.331 m/z) and G16D66-3 (323.538 
m/z) were extracted from the full spectrum scan and utilized for quantification (Appendix D 
Figure 2). 
Sample preparation for MALDI-HR-MS 
 The analyzed solutions comprised 200 μL of the cell lysate from 1.0 x106 PAM212 cells, 
to which 200 μL of a 40 μM G16D66-3 methanol solution were added. Prior to the addition of the 
matrix, the samples were vortexed for 30 seconds and centrifuged at 1500 x g for 5 minutes to 
ensure removal of the precipitated proteins from the cellular lysate solution. Aliquots of the 
solution were mixed with an acetonitrile solution containing 10 μg/μL sinapinic acid (5:1) and 
subsequently vortexed for 10 seconds. Aliquots of the final solution (1 µL) were spotted on the 
stainless steel Opti-TOF MALDI sample plate and allowed to air dry. 
Instrumentation methodology for MALDI-HR-MS quantification 
 An Applied Biosystems 4800 MALDI-TOF/TOF MS analyzer (AB Sciex, Concord, ON, 
Canada), operating in reflector positive ion mode, was utilized to analyze a mass range between 
m/z 150 and 500; the focusing mass was set at m/z 300. The neodymium-doped yttrium 
aluminum garnet 200 Hz laser was operated at a fixed laser intensity of 4200 and 500 laser shots 
were acquired for each sample. Internal calibration for MALDI-HR-MS was obtained using 
signals from the sinapinic acid matrix; including monomers and dimers as well as their 
potassium and sodium adducts. MALDI-HR-MS analysis caused instability of both the analyte 
and internal standard ions, resulting in complete fragmentation between the quaternary 
ammonium moiety and the α-carbon in the spacer region; this fragmentation was consistent and 
reproducible. Both the G16-3 (290.331 m/z  310.346 m/z and 268.299 m/z [Figure 5.2]) and 
G16D66-3 (323.538 m/z  343.554 m/z and 301.507 m/z [Appendix D Figure 3]) ions 
fragmented in an identical fashion into two fragment ions that were utilized for quantification. 
The individual G16-30 fragment ion at 310.346 m/z and the corresponding G16D66-3 ion at 
343.554 m/z were utilized for quantification, with the other complementary fragment ions used 
for confirmation of the data. The absence of sample to sample interference was verified by 
analyzing double blanks on a sample spot adjacent to the highest standard curve concentration, 
with no interference being detected. 
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Figure 5.2 Fragmentation of G16-3 (m/z 290.331), in sinapinic acid matrix, into two ions of m/z 
310.346 and m/z 268.299 during MALDI-HR-MS analysis. No precursor ion was observed at 
the expected m/z value for G16-3 ([M]2+ = m/z 290.33) 
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Sample preparation for DESI-LR-MS/MS 
 G16-3 was extracted from 200 μL of the cell lysate from 1.0 x106 PAM212 cells by 
adding 200 μL of an octanol solution containing 50μM G16D66-3 and vortexing each sample for 
30 seconds to ensure partitioning of the diquaternary ammonium gemini surfactant into the 
organic phase. Separation of the aqueous and organic phases was allowed to occur at room 
temperature using pulse centrifugation and 1 µL of the organic phase was spotted on a Prosolia’s 
66 teflon well hydrophobic array (Omni Slides™, 26x76 mm, Indianapolis, IN, USA) and dried 
for one hour in an oven set at 60 °C. 
Instrumentation methodology for DESI-LR-MS/MS quantification 
 The DESI-LR-MS/MS system was comprised of a Prosolia OmniSpray™ one 
dimensional automated sample stage coupled to a Thermo Scientific LCQ Fleet Ion Trap MS
 
(Thermo Scientific, San Jose, CA, USA). Analysis of G16-3 utilized the 66 well Omni Slides™ 
mentioned above, with a total of 18 hydrophobic spotting regions being used per slide; 9 were 
located on both leading edges of the slide.  Spotting of 1.5 μL of the extracted octanol sample 
solution utilized less than 50% of the total surface area of each hydrophobic spotting region (i.e., 
individual teflon well) and enhanced ionization was observed when the spot was positioned on 
the hydrophobic spotting region located adjacent to the leading edge of the slide. The slide was 
maintained at atmospheric conditions during the run. Each spotting region was analyzed by 
oscillating ±0.5 mm over the centre of the spot 14 times during the 0.73 minutes time of analysis. 
Carry over was negated by monitoring the blank glass region between each spot for 0.10 minutes 
by oscillating ±0.05 mm from the centre of these regions 6 times following analysis of each 
sample. No carry over was detected. Three MRM scan events were optimized on the LCQ Fleet 
Ion Trap MS
n
 instrument and utilized for quantitative analysis (Table 5.2); two for the analyte 
(m/z 290  m/z 355 and m/z 290  m/z 86) and one for the internal standard (m/z 323  m/z 
388) (Figure 5.1). 
Method validation 
 The quantitative assay for G16-3 underwent full method validation in accordance with 
USFDA guidelines. Six different passages of PAM 212 cells were evaluated to detect any 
potential interference with co-eluting endogenous substances. The linearity of each method was  
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determined by plotting the peak area ratio of analyte to internal standard versus the analyte 
concentration of seven or eight calibration standards. A linear least square analysis was 
conducted without use of a weighting factor, and the slope, intercept and coefficient of 
determination (r
2
) were used to establish linearity. The lowest limit of quantification was defined 
at the lowest concentration that gives precision and accuracy within ±20% of the nominal value. 
 The intra- and inter-day precision as well as accuracy of the method was established by 
analysis of six replicates of samples at four different concentrations (LLOQ, LQC, MQC, and 
HQC) on three different days. Single assay runs were accepted only when the relative standard 
deviation (RSD) was found to be less than ±15% at all other concentrations, except at LLOQ 
which allowed ±20%. The criteria for accuracy was set at ±15% of the nominal concentration of 
the QC samples, except at LLOQ where it was set at ±20%. In no case did more than one third of 
the QC samples violate these criteria. 
 Stability studies involving freeze–thaw stability, bench-top stability, autosampler 
stability, and long-term stability were undertaken at LQC, MQC, and HQC as per USFDA 
guidelines. Samples were considered stable when the criteria for precision and accuracy were 
met. 
Preparation of the G16-3 gemini surfactant/DOPE gene delivery system 
A pGT·IFN-GFP plasmid was used as a model for DNA transfection experiments.
10
 
Transfection formulations of PGL particles were prepared as previously described.
10
 A 1:10 
Table 5.2 Thermo Scientific LCQ Fleet Ion Trap MRM instrument parameters 
Transition 
Ion Spray 
Voltage 
Capillary  
Voltage 
Collision 
Energy 
[M]
2+
 to  [M-X]
+
  m/z to m/z kV V eV 
[M]
2+
 to [M-C16H33]
+
  290 to 355 4.46 24.29 35 
[M]
2+
  to [M-C33H70N2]
+
  290 to 86 4.46 24.29 35 
[M]
2+
  → [M-C16D33]
+
  323 to 388 4.46 24.29 35 
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charge ratio of plasmid:gemini surfactant facilitated transfection and DOPE was utilized as a co-
lipid at a 1:100 (w:w) ratio of plasmid:DOPE.
10 
PAM212 transfection by gemini surfactant G16-3/DOPE gene delivery system 
 PAM212 murine keratinocytes were seeded on Falcon 6-well tissue culture plates (BD, 
Mississauga, ON) with MEM media at a density of 3 × 10
5
 cells/well 24 hours prior to 
transfection. Transfection experiments were carried out using 100 ng plasmid DNA/well. Cells 
were harvested at prescribed periods of time using trypsin to lift the cells and stored in 200 μL of 
unsupplemented MEM media prior to analysis by LC-LR-MS/MS. Transfection efficiency was 
visually monitored by green fluoresce protein expression and the reported results are the average 
of two individual transfection assays of triplicate wells. 
Results 
 The recent development and application of a LC-LR-MS/MS method for the 
quantification of gemini surfactants within PAM212 cell lysate achieved a LLOQ of 0.406 µM 
and linear range extending to 298 µM for G16-3.
12
 Unfortunately, the LC-LR-MS/MS method 
suffered from a long analysis time and ion suppression due to the addition of triethylamine used 
to minimize peak tailing. The exploration of FC-LR-MS/MS, FC-HR-MS, DESI-LR-MS/MS, 
and MALDI-HR-MS for the quantification of G16-3 was undertaken in order to understand the 
inherent benefits of each method and to compare them with our recently reported LC-LR-
MS/MS method.
12
  
Structural Specificity for G16-3 and G16D66-3 
 Differentiation of G16-3 from its internal standard, G16D66-3, was achieved through the 
presence of sixty-six deuterium atoms on the internal standard’s alkyl chains. The difference in 
the molecular composition of G16-3 and G16D66-3 imparted a mass shift of 66.4143 Da and 
allowed for their differentiation by both MS and MS/MS when using FC-LR-MS/MS, FC-HR-
MS, and DESI-LR-MS/MS methods. Initial MALDI-HR-MS quantification experiments of G16-
3 were set to utilize the ions of G16-3 and G16D66-3 in an identical manner to FC-HR-MS. 
However we speculate that the propensity of MALDI to ionize analytes through formation of 
singly charged ions may cause instability of both the analyte and internal standard ions.
36
 The 
resulting fragmentation between the quaternary ammonium and the α-carbon in the spacer region 
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resulted in the fragmentation of G16-3 (m/z 290.331) into two ions of m/z 310.346 and m/z 
268.299 (Figure 5.2) where as G16D66-3 (m/z 323.538) gave rise to fragment ions of m/z 343.554 
and m/z 301.507; these ions were utilized for quantification (Appendix D Figure 3).  
Signal Interference  
An assessment of each method’s specificity requires that the m/z values and transitions 
monitored be free of interference from both the internal standard and endogenous molecules 
during both HR-MS and LR-MS/MS analysis. An interference was observed for both G16-3 and 
the internal standard during the analysis of a double blank PAM212 cell lysate by FC (Appendix 
D Figure 4A & 5A), resulting in an increase in the LLOQ. The level of interference for both FC 
methods was greater than that observed during LC-LR-MS/MS, however, the interference 
appeared to be more substantial for FC-HR-MS analysis and negatively impacted its LLOQ. 
Conversely, this interference was not observed for G16-3 and G16D66-3 transitions during either 
DESI-LR-MS/MS or MALDI-HR-MS analyses of double blank PAM212 cell lysate (Appendix 
D Figure 6A & 7A). During the evaluation of blank samples by each method, G16D66-3 was not 
found to produce interference in the quantification of G16-3 (Appendix D Figure 4-7B). 
Lower limit of quantification 
Using FC-LR-MS/MS analysis, the LLOQ was assessed to be 0.037 μM for G16-3 
(Appendix D Figure 4C), which is 25 times more sensitive than the LLOQ of 1.0000 μM 
(Appendix D Figure 5C) achieved by FC-HR-MS. The absence of interference for both DESI-
LR-MS/MS and MALDI-HR-MS blank spectra enhanced the final LLOQ achieved by both 
methods. DESI-LR-MS/MS quantification of G16-3 within PAM212 cellular lysate allowed for 
the LLOQ to be assessed at 1.00 μM (Appendix D Figure 6C), which was attributed to the 
relatively poor sensitivity of the instrument. Conversely, MALDI-HR-MS achieved a LLOQ of 
0.400 μM (Appendix D Figure 7C), which may have been hindered by the inability to employ an 
octanol liquid:liquid extraction during sample preparation. 
Linearity  
Intra-day analysis by FC-LR-MS/MS of six replicates at the LLOQ, LQC, MQC, and 
HQC (Appendix D Figure 4C-F: respectively) allowed the determination of the accuracy 
between 95.6 and 109.6% with a relative standard deviation (RSD) of 1.5 to 18.0 (Appendix E 
156 
 
Tables 1 & 2). The linearity of the FC-LR-MS/MS method achieved a dynamic range of 1000-
fold across concentrations ranging between 0.0375 and 37.5 μM (Appendix D Figure 8) with a r2 
value of ≥0.999; the reproducibility of the calibration curve was consistent in all instances. 
 Although both the LLOQ and linear range of the FC-HR-MS method were lower than 
those observed for the FC-LR-MS/MS method, the accuracy and precision results were within 
the acceptable parameters of USFDA method validation. The reproducibility of the calibration 
curve was consistent in all cases, achieving an r
2
 value of ≥0.999 for the concentration range of 
1.00-500. μM (Appendix D Figure 9). In addition, FC-HR-MS achieved an accuracy at the 
LLOQ, LQC, MQC, and HQC concentrations (Appendix D Figure 5C-F) in the range of 89.7 to 
110.7% and RSD values between 2.3 and 13.9% (Appendix E Tables 3 & 4).  
 The detection of G16-3 by DESI-LR-MS/MS resulted in a linear range of 100-fold 
between 1.00 and 200 μM, with a r2 value of ≥0.99 (Appendix D Figure 10). Although both the 
intra- and interday accuracy and precision values of the DESI-LR-MS/MS method were lower 
than both FC-LR-MS/MS and FC-HR-MS, they were within acceptable USFDA parameters. The 
accuracy was determined to vary between 88.5% and 110.3% with RSD values ranging between 
3.6% and 18.2% (Appendix E Tables 5 & 6). MALDI-HR-MS/MS, in contrast to the DESI-LR-
MS/MS method, presented a large dynamic range from .400 to 440 μM, with an r2 value of ≥0.99 
(Appendix D Figure 11). Six replicates at the LLOQ, LQC, MQC, and HQC concentrations 
(Appendix D Figure 7) resulted in the intra- and interday accuracy varying between 85.4% and 
111.5% with RSD values of 3.5% to 18.5 % (Appendix E Tables 7 & 8). 
Short and long term stability of gemini surfactant G16-3 within PAM212 cell lysate 
 Stability studies of gemini surfactant G16-3 were undertaken during the validation of 
each quantification method. Short term stability was assessed at both room temperature 
(Appendix E Table 9) and under autosampler conditions (Appendix E Table 10). Similarly, 
freeze/thaw (-80 °C ↔ 22 °C) stability studies, using thaw periods spaced twenty-four hours 
apart, produced suitable accuracy and precision at the LQC, MQC, and HQC concentrations 
(Appendix E Table 11).  All short term stability results were within validation parameters and 
G16-3 was stable under these conditions. In addition, gemini surfactant G16-3 was stable for 
extended periods of time when stored at both -20 °C (Appendix E Table 12) and room 
temperature (Appendix D Table 13).  
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Quantification of G16-3 within PAM212 Cell Lysate 
 Each validated G16-3 quantification method was applied to PAM212 cells transfected 
with a G16-3 gemini surfactant/DOPE gene delivery system. The sensitivity and specificity of 
each assay were adequate for accurately assessing the post-transfection cellular concentration of 
G16-3. However, not all methods could reasonably monitor its cellular uptake due to their 
respective LLOQ. This resulted in MALDI-HR-MS being unable to quantify the 0.25 hour time 
point, while FC-HR-MS and DESI-LR-MS/MS were unable to quantify the sample prior to the 2 
hour time point. Regardless, linear uptake of the G16-3 gemini surfactant following addition of 
Figure 5.3 Mean G16-3 concentration post transfection within the PAM212 cell lysate for FC-LR-
MS/MS, FC-HR-MS, DESI-LR-MS/MS and MALDI-HR-MS. An increase in G16-3 
concentration was observed during incubation with the transfection solution (◊), while the cellular 
concentration of G16-3 was maintained after the transfection solution was removed (■). In 
addition, the LLOQ of each method is included as a labeled bar on the graph. 
LC-LR-
MS/MS 
FC-LR-
MS/MS 
FC-HR-MS DESI-LR-
MS/MS 
MALDI-HR-
MS 
ESI-LR-
MS/MS 
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the transfection agent was observed during the zero to five hour period (Figure 5.3) and 
correlated with LC-LR-MS/MS data.
12
 No  significant change in the concentration of G16-3 
gemini surfactant within PAM212 cells was observed (1.45 ± 0.06 μM) between 5 to 53 hours 
following removal of the transfection mixture (Figure 5.3). This suggests the absence of any 
metabolism/excretion from PAM212 cells that would diminish the cellular concentration of the 
G16-3 gemini surfactant.  
 Assessing the efficacy of each method in determining the concentration of G16-3 within 
PAM212 cell lysate was demonstrated by the consistency of measurements for each method 
(Table 5.3).
12
 The average concentration determined by each method was within the error 
measurements observed for all four methods.  
Discussion 
 The ability of MS to monitor analytes in a specific, selective and sensitive nature 
contributed to its wide acceptance for quantitative and qualitative analysis of drugs, metabolites, 
and endogenous molecules within pharmaceutical formulations and biological matrices.
42-44
 
However, unlike LC-MS analysis, FC, DESI, and MALDI do not rely upon chromatographic 
separation to achieve their LLOQ and dynamic linear range. Application of these technologies to 
the quantification of the gemini surfactant G16-3 provided quantitative measurements 
comparable to those obtained using LC-LR-MS/MS. By achieving such results, these methods 
have proven their ability to minimize or remove the need for extensive method development and 
chromatographic separation.  
Which mass spectrometric method provided the easiest process of method development? 
 Optimization of each mass spectrometry method ensures that the sample preparation, 
introduction/ionization, and detection protocols ensure optimum LLOQ, linearity, and 
reproducibility. Two sample preparation methods were utilized, one involving protein 
precipitation with methanol and another using octanol in a liquid:liquid extraction. By using an 
octanol liquid:liquid extraction both the LLOQ and linear range of the FC-LR-MS/MS method 
were improved by 10-fold compared to the methanol protein precipitation (Figure 4), leading to 
its use for DESI and FC sample preparation. The 10-fold increase in the LLOQ for 
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Table 5.3 Post transfection concentration of G16-3 within PAM212 cell lysate measured by each mass 
spectrometry quantification method  
Time 
(Hour) 
Method Utilized for Quantification 
(Average ± Standard Deviation) 
  FC-LR-MS/MS FC-HR-MS MALDI-HR-MS DESI-LR-MS/MS LC-LR-MS/MS
12 
0.25 
0.320 
Below LLOQ Below LLOQ Below LLOQ 
0.404 
± 0.019 ± 0.057 
0.5 
0.633 
Below LLOQ 
0.594 
Below LLOQ 
0.441 
± 0.003 ± 0.024 ± 0.086 
1 
0.712 
Below LLOQ 
0.715 
Below LLOQ 
0.622 
 ± 0.034 ± 0.033 ± 0.074 
2 
1.05 1.03 1.01 0.923 1.04 
± 0.08 ± 0.09 ± 0.04 ± 0.134 ±0.14 
3 
1.24 1.27 1.25 1.27 1.15 
± 0.01 ± 0.04 ± 0.05 ± 0.14 ± 0.11 
5 
1.44 1.11 1.49 1.41 1.54 
± 0.01 ± 0.92 ± 0.03 ± 0.16 ± 0.18 
6 
1.44 1.06 1.46 1.50 1.39 
± 0.16 ± 0.81 ± 0.17 ±0.15 ± 0.16 
7 
1.45 1.56 1.32 1.36 1.37 
± 0.13 ± 0.10 ± 0.15 ± 0.12 ± 0.19 
9 
1.50 1.60 1.56  1.35 1.38 
± 0.07 ± 0.04 ± 0.10 ± 0.16 ± 0.06 
13 
1.52 1.56 1.30 1.38 1.51 
± 0.05 ± 0.08 ± 0.02 ± 0.13 ± 0.07 
17 
1.50 1.50 1.43 1.37 1.56 
± 0.10 ± 0.07 ± 0.06 ± 0.15 ± 0.05 
29 
1.48 1.52 1.48 1.57 1.50 
± 0.07 ± 0.001 ± 0.04 ± 0.11 ± 0.12 
53 
1.56 1.52 1.55 1.45 1.68 
± 0.03 ± 0.08 ± 0.17 ± 0.16 ± 0.12 
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Figure 5.4 FC-LR-MS/MS chromatographs of methanol extraction (A) and octanol 
extraction (B) of G16-3 (2.7 μM) in PAM212 cell lysate 
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FC-LR-MS/MS was a result of an increase in sample recovery that provided an increase in the 
signal to noise (Figure 4) and were within 20% accuracy and precision (Appendix E Tables 1 & 
2). The octanol liquid:liquid extraction provided enhanced recovery and/or ionization of G16-3 
in comparison with methanol protein precipitation, which may be a result of the reduction of 
endogenous molecules extracted into the octanol phase.  
The octanol extraction was not utilized for MALDI sample preparation because MALDI 
requires the co-crystallization of the matrix and sample, which is difficult to achieve with octanol 
due to its low vapor pressure. Although MALDI-HR-MS was able to achieve quantification 
across a wide linear range, a result of minimal interference and resolving power of the 
instrument, the need to apply an inferior sample preparation method negatively impacted the 
LLOQ.  
 By comparing the four sample introduction/ionization methods it is clear that DESI 
required the minimal amount of method development, with only three parameters being 
manipulated: spray solvent composition, flow rate, and ionization parameters. Evaluation of 
spray solvent composition and its impact on the solubility as well as ionization of the analyte of 
interest prompted the use of a methanol spray solvent containing 0.1% formic acid instead of 
unmodified methanol. Ionization parameters for DESI were optimized by using ESI to infuse and 
ionize G16-3 while flow rate was optimized to prevent the infusion of liquid into the mass 
spectrometer. Each of the parameters was rapidly optimized in comparison with the selection of 
the suitable sinapinic acid matrix for MALDI analysis or chromatographic conditions for FC and 
LC analysis. For example, eight MALDI matrices, including matrix free, were tested prior to the 
selection of sinapinic acid. This required an additional time commitments to determine if matrix 
interference would impede detection of the analyte, assess the optimal matrix to sample ratio as 
well as determine the ideal laser intensity, number of shots, and shot pattern.  
All four methods, however, were much easier to develop than the previously developed 
LC-LR-MS/MS method,
12
 because no consideration was required to minimize peak tailing 
and/or shifting or to ensure the absence of ion suppression from endogenous compounds. The 
benefits of having a previously developed LC-LR-MS/MS method were readily observed for 
both FC methods, which used the gradient elution profile similar to those previously developed 
for LC separation of diquaternary ammonium gemini surfactants. Optimization of the LC 
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chromatographic method for FC analysis minimized carryover and abnormal peak shape, while 
the absence of triethylamine within the mobile phases resulted in an enhanced LLOQ.  
 The complexity of both MALDI and FC resulted in extensive time being devoted to the 
choice of mobile phases/conditions, matrices, and instrument conditions. Absence of a matrix 
during DESI-LR-MS/MS analysis resulted in a simplified surface DI method that eliminates the 
interference from matrix ions. Equally, the use of a spray solvent instead of chromatographic 
conditions reduces complexity, while the ability to optimize and utilize ESI conditions for G16-3 
reduce the time required for method development. The combination of DESI’s simple sample 
introduction/ionization and its ability to utilize an effective sample preparation method ensured 
that it provided suitable quantitative data. It also confirmed that the development of an assay for 
the quantification of G16-3 with PAM212 cellular lysate was most efficiently achieved by DESI-
LR-MS/MS. 
Does one method provide superior quantitative data? 
 Utilizing mass spectrometry for detection allowed the accuracy, precision, selectivity, 
and sensitivity of all four quantitative methods to be comparable with a validated LC-LR-
MS/MS method.
12
 The selectivity achieved by both HR-MS and LR-MS/MS analysis resulted in 
the specific identification of G16-3 based upon either its molecular composition or structural 
characteristics. The sole exception was MALDI-HR-MS, which induced fragmentation of both 
the analyte and internal standard. Application of each method to the quantification of G16-3 
demonstrated that the methods are reproducible and highly suitable in assessing the cellular 
concentration of G16-3. 
Quantification of G16-3 within PAM212 cell lysate was influenced by the method of 
ionization, sensitivity of the instrument as well as the accuracy and precision of each method. A 
comparison among the methods conclusively demonstrated that FC-LR-MS/MS achieved the 
lowest LLOQ at a concentration of 0.037 μM (Figure 5.5 & Table 5.4), which is 10-fold lower 
than the LLOQ achieved by the LC-LR-MS/MS method.
12
 Peak tailing associated with the FC 
elution of G16-3 was minimal and no interference with quantitative analysis was observed 
(Appendix D Figure 4). Comparing FC-LR-MS/MS to the other four quantification methods 
demonstrated that it achieved a LLOQ 10 to 25 fold better than the other three methods. 
However, the inability to couple identical mass spectrometers to each ionization method for the 
detection of G16-3 prevented a direct comparison between methods. The use of various 
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instruments and ionization configurations is a common occurrence within multi-use mass 
spectrometry laboratories, where each instrument is often utilized in a single configuration 
 
Table 5.4 Method validation parameters for each method 
  LLOQ ULOQ Linear Range 
LC-LR-MS/MS 0.406 μM 298 μM 734x 
FC-LR-MS/MS 0.0375 μM 37.5 μM 1000x 
FC-HR-MS 1.00 μM 500. μM 500x 
DESI-LR-MS/MS 1.00 μM 200 μM 200x 
MALDI-HR-MS 0.400 μM 440. μM 1000x 
 
 
 
Figure 5.5 The linear range of G16-3 quantification for all five quantitative mass spectrometric 
methods 
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Table 5.5 Sensitivity of Mass Spectrometry Instruments utilized for G16-3 quantification 
Method Instrument Reserpine Sensitivity 
LC-LR-MS/MS AB Sciex QTRAP 4000 MS/MS 200 fg on column 
FC-LR-MS/MS AB Sciex QTRAP 4000 MS/MS 200 fg on column 
FC-HR-MS Thermo Scientific Orbitrap LTQ Velos 100 fg on column 
DESI-LR-MS/MS Thermo Scientific LCQ Fleet Ion Trap 2000 fg on column 
    Neurotensin Sensitivity 
MALDI-HR-MS AB Sciex 4800 MALDI ToFToF 418 fg per 400 laser pulses 
 
to reduce setup-time, maintenance/repair costs, and instrument instability. Since the same mass 
spectrometer could not be used for all five methods, Table 5.5 provides the relative sensitivity of 
each mass spectrometer so that a fair comparison can be made. A comparison of instrument 
sensitivity between instruments resulted in FC-LR-MS/MS attaining the superior LLOQ. After 
adjusting for instrument sensitivity, the LLOQ of FC-LR-MS/MS was 2 fold lower than DESI-
LR-MS/MS, while MALDI-HR-MS was merely 5 fold larger than FC-LR-MS/MS. Further 
adjusting the LLOQ of MALDI-HR-MS to account for improved sample preparation may 
provide an improved LLOQ compared to FC-LR-MS/MS. 
In an attempt to further improve the LLOQ for FC-LR-MS/MS, FAIMS was utilized. The 
aim of using FAIMS was to utilize its selectivity to remove ions which may interfere with the 
identification of G16-3.  Selection of instrument parameters for both ESI, FAIMS, and MS/MS 
analysis was determined by instrument optimization; dispersion voltage of -5000 V, spray 
voltage of 4000V, 50% helium gas additive, compensation voltages were assessed as -48 V (m/z 
290  m/z 355) and -48 V (m/z 290  m/z 86) as well as collision energies of 5 V (m/z 290  
m/z 355) and 16 V (m/z 290  m/z 86) (Appendix F Figure 1-3). An evaluation of blank 
PAM212 (Appendix F Figure 4) and PAM212 cell lysate spiked with G16-3 (Appendix F Figure 
5-7) demonstrated that an improvement in sensitivity was not achieved through an enhancement 
of S/N by FC-FAIMS-MS/MS and thus a method validation was not performed.  
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The linearity of both FC-LR-MS/MS and MALDI-HR-MS methods were both accurate 
and precise across a range spanning over the 1000 fold linear range (Table 5.4). MALDI-HR-MS 
achieved linearity of nearly 10,000 fold based upon an r
2 
equal to 0.99, however, the LLOQ was 
negatively influenced by such a large linear range and concentrations beyond 400 μM were not 
seen as experimentally relevant to the quantification of G16-3 within cell lysate. The large linear 
range can be beneficial for other quantitative applications, such as quality control of 
pharmaceutical formulations as no dilution is needed, thereby reducing the possibility of 
measurement errors due to sample handling. A disadvantage of MALDI-HR-MS was the 
complementary fragmentation of both G16-3 (Figure 5.2) analyte and G16D66-3 (Appendix D 
Figure 3), as confirmed by their monoisotopic masses. If the fragmentation of G16-3 had been 
excessive or incomplete it would potentially inhibit the collection of quantitative data. However, 
the identification of fragment ions, the consistency of fragmentation and the identical manner by 
which it occurred in both the analyte and internal standard allowed for both fragment ions to be 
utilized for quantitative analysis.  
FC-LR-MS/MS, conversely, did not display linearity beyond the 1000x linear range of 
the method due to uneven peak tailing which negatively influenced the accuracy and precision of 
LLOQ and LCQ samples. The linearity of the FC-HR-MS method was only 500 fold due to the 
inferior LLOQ. The inclusion of concentration values beyond the HLOQ of DESI-LR-MS/MS 
negatively influencing the precision and accuracy of lower concentration samples. 
It was hypothesized that unfavorable effects may be associated with the introduction of 
an entire sample into the mass spectrometer during FC-MS(/MS) analysis. The continual 
introduction of a mixture of compounds would lead to an increase in instrument contamination, 
which would negatively influence accuracy and precision of subsequently injected samples. To 
test this hypothesis, four hundred injections of an extracted PAM212 sample with a G16-3 
concentration at the HCQ were sequentially analyzed by FC-LR-MS/MS on a QTRAP 4000 
instrument. Deviations in the response of the MS to G16-3 were compensated by the inclusion of 
the internal standard, G16D66-3, leading to sample accuracy of ±10% for nearly all 400 samples 
(Figure 5.6). Deterioration in MS stability over time was not observed, confirming the sample-to-
sample stability of the FC-LR-MS/MS method. 
By maintaining their accuracy and precision values within the accepted limits during both 
the validation process and application, each method demonstrated its reproducibility. Each 
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method confirmed the post transfection concentration of G16-3 to be 1.50 ± 0.15 μM (Figure 
5.3), a value which concurs with the results obtained by LC-LR-MS/MS.
12
 Evaluating the 
efficacy of each mass spectrometric method in the quantification of G16-3 within PAM212 cell 
lysate demonstrates that FC-LR-MS/MS is more effective than LC-LR-MS/MS as well as the 
other three methods evaluated in this work (Table 5.4). Conversely, limitations in the LLOQ 
prevented FC-HR-MS and DESI-LR-MS/MS from assessing the PAM212 cellular uptake of 
G16-3. Its achievement of the lowest LLOQ and 1000x linear range, surpassing even LC-LR-
MS/MS, provides evidence for the future application of FC-LR-MS/MS in the quantification of a 
low number of analytes for, theoretically, any bioanalytical applications (Table 5.4). 
 
 
Figure 5.6 Repeat injections of the HCQ using FC-LR-MS/MS on a QTRAP 4000 instrument 
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Is one method more conservative in time and consumable usage?  
 Time and consumable expenditures associated with instrument analysis are often 
interrelated. This is apparent for each method evaluated with the exception of MALDI-HR-MS, 
where no solvent or gas is utilized for the ionization and introduction of ions into the instrument 
(Table 5.6). Conversely, there is no correlation between time and consumable expenditure during 
sample preparation because each is dependent upon the requirements of sample volume, 
solvents, materials, and procedures (Table 5.7). Relating the consumption of each method to 
their quantitative capabilities highlights the advantages and disadvantages of each method. 
 The basis of each sample preparation method utilized by the five quantitative methods 
was indistinguishable in total consumable consumption and time expenditure (Table 5.6). The 
ability of FC to analyze the octanol phase of the liquid:liquid extraction without further sample 
preparation results in time saving of 1 hour or greater for the preparation of 100 samples. Using a 
sample size of 100 to compare time and consumable requirements of each method allows for the 
data to be normalize in order to better illustrate the advantages of each method. The additional 
time required for DESI and MALDI analysis is a result of the final step in their sample 
preparation procedure. For example, DESI analysis of G16-3 requires sample deposition and 1  
 
Table 5.6 Time and consumable expenditure related to MS analysis  
                 (100 samples) 
  Sample Analysis Solvent/Solid Amount 
LC-LR-MS/MS 
18 Hours 
17 Minutes 
332.6 mL Acetonitrile 
116 mL Water 
FC-LR-MS/MS 
3 Hours 
57 Minutes 
78.9 mL Methanol 
15.7 mL Water 
FC-HR-MS 
4 Hours 
16 Minutes 
86.9 mL Methanol 
15.7 mL Water 
DESI-LR-MS/MS 
1 Hours 
49 Minutes 
2.9 mL Methanol 
MALDI-HR-MS 
8 Minutes 
11 Seconds 
N/A 
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hour of drying time at 60 °C to ensure the octanol is evaporated from the sample deposited. 
Similarly, MALDI requires a dry sample for analysis; however, the addition of sinapinic acid to 
the sample adds a step to sample preparation, thus increasing the total sample preparation time. 
The additional time and consumables required for DESI and MALDI sample preparation are 
compensated by their rapid MS analysis time as well as minimal use or absence of solvent for 
sample introduction (Table 5.7), respectively. FC, conversely, utilizes a relatively large volume 
of solvent to introduce a sample into the instrument. In addition, FC is a slow method of analysis, 
requiring twice as much time as DESI and 30 times more time than MALDI to analyze 100 
samples, which led to at least a 5 fold greater use of solvent (Table 5.7).  However, FC-LR-
MS/MS remained superior to LC-LR-MS/MS as it required less than one fifth the total time to 
produce analytically superior data. In fact, a comparison of each method to the previously 
developed LC-LR-MS/MS method demonstrated that all four methods were at least four times 
faster and utilized less than a quarter of the total solvent consumption (Table 5.7).   
Conclusion 
 The comparison of the efficacy of several different MS quantification methods, including 
FC-LR-MS/MS, FC-HR-MS, MALDI-HR-MS, and DESI-LR-MS/MS, demonstrates their 
Table 5.7 Time and consumable expenditure related to sample preparation for each MS method 
                 (100 samples) 
  Sample Preparation Solvent/Solid Amount Final Sample 
Volume 
LC-LR-MS/MS 
3 Hours 
45 Minutes 
20 mL Octanol 10 μL 
FC-LR-MS/MS 
3 Hours 
45 Minutes 
20 mL Octanol  7.5 μL 
FC-HR-MS 
3 Hours 
45 Minutes 
20 mL Octanol  7.5 μL 
DESI-LR-MS/MS 
4 Hours 
45 Minutes 
20 mL Octanol  1 μL 
MALDI-HR-MS 
5 Hours 
10 Minutes 
20 mL Methanol 
2 mg Sinapinic Acid 
1 μL 
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potential benefits in the quantification of G16-3 compared to LC-LR-MS/MS. Expedited method 
development is achieved by every method in comparison with LC-LR-MS/MS. DESI-LR-
MS/MS was the simplest method to develop and required only the optimization of transitions and 
spray solvent. The rapid nature of each method is directly tied to the short time of analysis and 
minimal use of consumables. These savings in both time and consumable expenditure were 
evident for all methods in comparison with LC-LR-MS/MS with minimal effect on validation 
parameters. In fact, FC-LR-MS/MS provided a LLOQ of 36.9 ng/mL, 8x lower than LC-LR-
MS/MS, while MALDI-HR-MS and FC-LR-MS/MS methods were valid across a 1000x linear 
range. Each MS methods were successfully applied to the quantification of G16-3 within 
PAM212 cell lysate. The ability of all methods to quantify G16-3 within PAM212 cellular lysate 
demonstrates that the extensive time and consumable usage associated with LC-LR-MS/MS is 
not required to achieve sensitive quantitative results. This will be beneficial in the future 
development of other diquaternary ammonium gemini surfactants as well as small molecule 
drugs and excipients. 
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 General Discussion 
 Successful utilization of diquaternary ammonium gemini surfactants for the transfection 
of DNA and RNA has been intensely investigated because of their ability to form lipoplexes with 
the DNA and RNA to facilitate its protection, delivery, and intracellular release.1-4 In vitro and in 
vivo applications of diquaternary ammonium gemini surfactants have demonstrated their 
applicability to such endeavors, achieving expression levels that are greater than the unprotected 
genetic material4, 5 and comparable to commercially available cationic lipids.6-8 In fact, a 450% 
increase in the levels of IFNγ in the epidermis of mice was reported for G16-3:DOPE vectors in 
comparison to unprotected IFNγ genes within a mouse animal model.5 All previous studies, 
however, were exclusively concerned with the enhancement of the diquaternary ammonium 
gemini surfactants’ encapsulation efficiency, transfection capability as well as reducing their 
toxic effects without assessing the cause of toxicity.  
Understanding the post transfection fate, including cellular disposition and tissue 
accumulation, of diquaternary ammonium gemini surfactants is vital to designing future cationic 
lipids that are less toxic. There are no studies that provided information on the cause of toxicity 
due to the lack of analytical methods available to identify/quantify diquaternary ammonium 
gemini surfactants post transfection. Therefore, qualitative and quantitative methods are needed 
to improve the current understanding of the post transfection fate of gemini surfactants as well as 
to advance their use as gene carriers. Mass spectrometry is ideally suited to detect and quantify 
gemini surfactants due to the permanent positive charges within their molecular structure (Figure 
1.2 and 1.3). Therefore, an understanding of their ionization, gas phase and/or CID behavior is 
needed as it ensures that the developed analytical methods are specific for the analyte(s) of 
interest.  
Specificity and selectivity are provided by mass spectrometry through both ionization and 
ion separation as each analyte behaves in a unique and reproducible manner during ionization, 
single-stage MS, MS/MS, and multi-stage MS
n
 analysis. Most analytes can be differentiated 
easily from one another using MS, ensuring specificity for the analytical method. Method 
reproducibility ensures that the data is consistent across analysis of a batch of samples, between 
batches of samples and between instruments. The ability of mass spectrometry analysis to 
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achieve both specificity and reproducibility is a result of the ionization method and ion 
separation. 
Each ionization method will provide the analyte with a specific m/z value based upon the 
addition or removal of a hydrogen atom, an electron, or the formation of adducted ion. For ESI, 
the removal of either a single bromide counter ion or both bromide counterions results in the 
formation of a singly charged bromide adduct or doubly charge diquaternary ammonium gemini 
surfactant ion; respectively (Figure 3.2). Conversely, MALDI-HR-MS did not maintain the intact 
structure of the diquaternary ammonium gemini surfactant analytes, but instead cleaved each 
molecule into two individual fragment ions (Figure 5.2). Although all the ionization methods did 
not produce identical ions for each diquaternary ammonium gemini surfactant, each ionization 
method produced ions that were specific and reproducible, allowing for quantitative analysis.  
6.1.1 Mass spectrometric analysis of 29 diquaternary ammonium gemini surfactants 
MS (Table 3.1 and Figure 3.2) and MS/MS (Table 3.2 and Figure 3.3A) analysis of each 
diquaternary ammonium gemini surfactant ion allows for the confirmation of its molecular 
composition or structural feature(s). Specifically, MS identification of analytes can be performed 
using either MS/MS analysis or accurate mass measurement during single-stage MS 
experiments. LR instruments were utilized for quantitative MS/MS, while HR instruments were 
utilized for quantitative single-stage MS. The use of both MS and MS/MS for quantitative 
analysis demonstrated their capability to specifically select the precursor and/or product ion(s) of 
interest, while providing specificity by preventing other ions from reaching the detector. The 
confirmation of the molecular formula of 29 novel gemini surfactants was achieved by both HR-
MS (Table 3.1 and Figure 3.2) and LR-MS/MS, which induces unique CID fragment ions for 
each of the tested 29 gemini surfactants (Table 3.2 and Figure 3.3A).  
An AB Sciex QSTAR XL Q-ToF-HR-MS instrument was used for accurate mass 
measurements. Doubly charged ion for each of the gemini surfactant was observed as well as 
gemini surfactant bromide adducts (Table 3.1 and Figure 3.2). Mass accuracies were less than 5 
PPM for gemini surfactants while the bromide adducts had mass accuracies less than 10 PPM 
(Table 3.1). Observation of superior mass accuracies for the doubly charged diquaternary 
ammonium gemini surfactant ions is a result of internal calibration while only external 
calibration was utilized for the corresponding bromide adducts. These results confirmed the 
178 
 
molecular formula of each gemini surfactant as well as the propensity of gemini surfactant 
cations to form an ion pair with its bromide counter ion under favorable conditions. 
While the molecular composition of each gemini surfactant was solely assessed by HR-
MS, structural identification of each diquaternary ammonium gemini surfactant and bromide 
adducts were established through both CID-MS/MS and quasi MS
3
 analysis utilizing a QqToF-
HR-MS/MS and QhQ-LR-MS/MS; respectively. The MS/MS and quasi MS
3
 data provided 
structural information about each compound (Table 3.2 and Figure 3.3B-D) while quasi MS
3
 
analysis rationalized the fragmentation route(s) (Table 2.4). MS/MS and quasi MS
3
 analysis 
allowed for the identification of a universal fragmentation pathway which pertains to all 29 
gemini surfactants.  (Figure 3.3A). Three unique CID-MS/MS product ion types were identified, 
with at least one unique product ion being observed during MS/MS analysis of all 29 gemini 
surfactants analyzed. After the completion of this work, the universal fragmentation behavior 
was applied for the analysis of novel amino-acid substituted gemini surfactants.9   
6.1.2 Quantitative liquid chromatography low resolution tandem mass spectrometric 
analysis 
Development and validation of an analytical method that is suitable for the quantification 
of gemini surfactants within PAM212 cellular lysate was required to assess their post 
transfection fate. The ability of mass spectrometry to differentiate drug molecules from their 
metabolites and endogenous molecules has made mass spectrometric analysis the analytical gold 
standard for the pharmaceutical industry; specifically LC-MS/MS.10-12 Therefore, the first method 
developed and validated was an LC-LR-MS/MS method which utilized an CN stationary phase 
column a gradient of water and acetonitrile, both containing 0.3% (vol:vol) formic acid and 1 
mM triethylamine, (Figure 4.2) to separate and elute all 29 diquaternary ammonium gemini 
surfactants (Table 4.1). The ability to correlate each gemini surfactant with a LC retention time 
and a product ion with a unique MRM ensured each analyte was specifically identified (Table 
4.1). In addition, the selectivity of MRM analysis provides the ability to distinguish and quantify 
structurally similar analytes without the need to achieve their baseline separation, an inherent 
advantage of MS/MS.13, 14 The LC-LR-MS/MS quantitative method was validated for a single 
diquaternary ammonium gemini surfactant, G16-3, following USFDA guidelines for 
bioanalytical method validation. Quantification of G16-3 resulted in an LLOQ of 0.406 µM and 
the ULOQ assessed at 298.1 µM (Figure 4.5 & 5.5 and Table 5.4); producing a 744 fold linear 
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range. Unfortunately, this method suffered from ion suppression due to the addition of 
triethylamine, an LC additive used to minimize peak tailing, and a large time of analysis that 
results from chromatographic separation.  
The observed ion suppression spurred the investigation of other high-throughput mass 
spectrometric methods; including FC-LR-MS/MS, FC-HR-MS, DESI-LR-MS/MS, and MALDI-
HR-MS (Table 5.5). Applying alternative high-throughput mass spectrometric techniques 
eliminated the time required for chromatographic separation while attaining quantitative results 
comparable/superior to LC-LR-MS/MS. 
6.1.3 Alternative high-throughput mass spectrometric-based methods 
Two FC methods were developed utilizing a CN stationary phase that was 8x shorter than 
the stationary phase utilized by the LC-LR-MS/MS. This allowed for the use of a more rapid 
gradient, using water and methanol containing 0.1% formic acid, to achieve a time of analysis 
that is ~4.5 fold faster than the LC-LR-MS/MS method (Appendix D Figure 1). In addition, the 
FC-LR-MS/MS analysis of G16-3 resulted in an LLOQ of 0.037 μM for G16-3, which is 27 
times more sensitive than LLOQ of 1.0000 μM achieved by FC-HR-MS and 11 times more 
sensitive than the LLOQ of the LC-LR-MS/MS method (Figure 5.5 and Table 5.4).  
Although additional time and consumables are required for DESI and MALDI sample 
preparation, the period of analysis was substantially abbreviated for both surface sampling 
ionization techniques. DESI-LR-MS/MS utilized a methanol spray solvent containing 0.1% 
formic acid to achieve desorption of the analyte from the hydrophobic surface in less than 45 
seconds (Table 5.6), which is ~14.5 times faster than the LC-LR-MS/MS method (Table 7.4). 
MALDI-HR-MS was ~146 times faster than LC-LR-MS/MS and utilized a sinapinic acid matrix 
during its 4.3 second analysis (Table 5.6). Sinapinic acid did not interfere with the analysis 
allowing for a LLOQ of 0.400 μM to be achieved, which is comparable to the LLOQ achieved 
by LC-LR-MS/MS (Figure 5.5 and Table 5.4).  
Each alternative method provides a more rapid quantitative analysis of G16-3 within 
PAM212 cell lysate than the developed LC-LR-MS/MS (Table 5.6). In addition, two of the four 
alternative quantitative mass spectrometric methods achieved a LLOQ that was superior or 
comparable to that of the LC-LR-MS/MS (Figure 5.5 and Table 5.4). 
In addition to the rapid nature of each alternative method several other benefits were 
realized. Both the FC-LR-MS/MS and MALDI-MS methods achieved a 1000x linear range and 
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were superior to the LC-LR-MS/MS method (Figure 5.5 and Table 5.4).  Extending the linear 
ranges can be beneficial for other quantitative applications, such as quality control of 
pharmaceutical formulations, as dilutions may not be needed to ensure the analyte’s 
concentration is within the acceptable linear range. In addition, a comparison of all five 
quantitative methods demonstrates that DESI-LR-MS/MS requires the least amount of method 
development. DESI-LR-MS/MS parameters were optimized rapidly in comparison to selection 
of a suitable MALDI matrix or chromatographic conditions for LC and FC. However, all 
alternative MS methods were much easier to develop than LC-LR-MS/MS that is limited by peak 
tailing, shifts in retention time and ion suppression from endogenous compounds. The efficacy of 
FC-LR-MS/MS, FC-HR-MS, MALDI-HR-MS, and DESI-LR-MS/MS demonstrates their 
potential benefits for quantitative analysis not realized by the industry's gold standard LC-LR-
MS/MS.  
6.1.4 Quantification of G16-3 within PAM212 cell lysate 
The ability of all methods to quantify G16-3 within PAM212 cellular lysate demonstrates 
that the extensive time and consumable usage associated with LC-LR-MS/MS is not required in 
order to achieve sensitive quantitative results. All five methods were able to accurately assess the 
post-transfection cellular concentration, 5 to 53 hours, of G16-3 within PAM212 cellular lysate; 
1.45 ± 0.06 μM. Each method was within the 15% accuracy when compared to the average 
concentration for each time point with a RSD of 15%. However, not all methods could 
reasonably monitor the cellular uptake of G16-3 by PAM212 cells at early concentrations 
because they were below the LLOQ. MALDI-HR-MS was unable to quantify the 0.25 hour time 
point, while FC-HR-MS and DESI-LR-MS/MS were unable to quantify sample prior to the 2 
hour time point. Regardless, linear uptake of the G16-3 gemini surfactant following addition of 
the transfection solution was observed during the zero to five hour period and correlated with 
LC-LR-MS/MS data. Finally, the absence of a change in concentration after the removal of the 
transfection solution at the 5 hour mark indicates the absence of metabolic activity that would 
degrade G16-3. 
6.2 Conclusion 
The development of five quantitative mass spectrometric methods to assess the 
concentration of G16-3 with PAM212 cellular lysate demonstrates the benefits alternative MS 
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methods have over LC-LR-MS/MS. While the validation of all five methods was performed 
solely for G16-3, the MS and MS/MS analysis of 29 diquaternary ammonium gemini surfactants 
ensures that each method can be tailored to other analytes. The specificity of analysis is ensured 
by the evaluation of the MS behavior and MS/MS fragmentation pattern of each diquaternary 
ammonium gemini surfactants, to confirm the precursor ion and the unique fragmentation 
pattern.9  
6.3 Future Directions 
Understanding the MS behavior of diquaternary ammonium gemini surfactants, including 
the establishment of a universal MS/MS fragmentation pathway, ensures that they can be 
differentiated from one another within a variety of matrices. Application of this knowledge to the 
development and validation of several MS quantitative methods would allow for the evaluation 
of their post transfection fate.  
6.3.1 Evaluation of the MS behavior of novel gemini surfactants 
The establishment of the universal fragmentation pathway of gemini surfactants has 
proven to be valuable as it identifies unique fragment ions for structural identification. Currently 
new diquaternary ammonium gemini surfactant molecules are being designed in order to enhance 
encapsulation efficiency, delivery, and cell viability. Such modifications include the inclusion of 
amino acid moieties within the spacer region9 or more recently the incorporation of cyclodextrin, 
to expand gemini surfactants’s use towards hydrophobic drugs.15 The use of the universal 
fragmentation pathway will ensure that the CID behavior of diquaternary ammonium gemini 
surfactants will be easier to predict and that only unique MRM transitions are utilized for 
analytical analysis. Application of the universal fragmentation pathway assisted in assessing the 
CID behavior of amino acid/di-peptide modified diquaternary ammonium gemini surfactants9 
and continues to assist in the elucidation of the CID behavior of novel diquaternary ammonium 
gemini surfactants. 
6.3.2 Quantification of diquaternary ammonium gemini surfactants 
 Assessing the post transfection fate of diquaternary ammonium gemini surfactants has 
benefited from the development of MS-based quantitative methods. I have evaluated the fate of 
gemini surfactants within the whole cellular matrix. Expansion of this work will include the 
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quantitative analysis at the sub-cellular level. The goal is to understand the effect of chemical 
modifications on sub-cellular localization or in vivo tissue distribution. Finally, extrapolation of 
the CID-MS/MS behavior of diquaternary ammonium gemini surfactants will provide a basis for 
the discovery of their metabolites through the use of either precursor ion or neutral loss scans. 
6.3.3 Sub-cellular quantitative analysis of diquaternary ammonium gemini surfactants 
An evaluation of the sub-cellular localization of the gemini surfactant G16-3 in a 
PAM212 cell line as well as the identification of any metabolites will provide information on the 
post-transfection fate of gemini surfactants. An assessment of their in vitro behavior (including 
its cellular uptake, intracellular interactions, and elimination) is important in evaluating their 
safety and toxicity profile. Previous evaluations of each gemini surfactant’s toxicity shows that 
gemini surfactants induce cytotoxicity, however, the question of how they induce toxicity was 
never identified. Application of the developed quantitative MS methods to the determination of 
the subcellular localization of diquaternary ammonium gemini surfactants allows for a more 
detailed understanding of the post transfection fate. Subcellular fractionation can be achieved 
following the sequential actions of disrupting the cellular architecture and separating the 
subcellular components.16 A basic method allows for the isolation of four main fractions, 
including the nuclear, mitochondrial, microsomal, and cytosolic fractions.17 Identification of the 
sub-cellular localization of the diquaternary ammonium gemini surfactants could address how 
their structure affects cellular toxicity. 
 
6.3.4 Assessment of the metabolites of diquaternary ammonium gemini surfactants 
Mass spectrometry can identify structural modifications through accurate and precise 
mono-isotopic mass measurement of xenobiotic metabolites during single stage MS analysis as 
well as through differences in the fragmentation patterns produced by multi stage MS
n
 analysis 
following CID.18 Single stage MS analysis can provide structural information based upon 
changes in m/z values. Metabolites may include methylation19 (14 Da difference) or  conjugation 
of glutathione,20 (i.e., 300 Da) with MS analysis providing information on the type of metabolism 
undergone by the analyte.21 Similarly, MS
n
 analysis can provide information on metabolic 
transformations,22 by monitoring the CID of analytes.22 For example, the conjugation of 
183 
 
glutathione to acetaminophen was identified by monitoring for the neutral loss of 129.042 m/z, 
loss of pyroglutamic acid from glutathione, during MS/MS analysis.23 Application of the 
developed quantitative MS methods and metabolic knowledge can provide information on both 
the type and site of metabolism based upon observed differences between their MS and MS/MS 
spectra. Lightsight software, available from AB Sciex, could be used in the identification of 
metabolites. 
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CHAPTER 7 
APPENDICES 
 
APPENDIX A 
Diquaternary ammonium gemini surfactant MS/MS fragmentation analysis 
 
CH3 N
+ N
+
CH3
CH3 CH3
CH3
CH3
G12-2
CH3 N
+ N
+
CH3
CH3
CH3
CH3
H
CH2
+
N
CH3
CH3
CH3 N
+ N
CH3
CH3
CH3
CH3
CH3
CH2
+
CH3 CH2
+
CH3
CH2
+
5
[M]
2+
2a
1a
1d/2c
Appendix A Figure 1.1 Fragmentation pattern of G12-2 
 
Appendix A Table 1 G12-2 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
227.26 285.32     72.08 143.17 
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Appendix A Figure 2.1 Fragmentation pattern of G12-3 
 
Appendix A Table 2 G12-3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
234.28 299.35 131.16   86.1 150.18   86.1         85.1 → 57.07 
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Appendix A Figure 3.1 Fragmentation pattern of G12-4 
 
Appendix A Table 3 G12-4 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4a 5 
241.28 313.39     100.11 157.19   100.11     
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Appendix A Figure 4.1 Fragmentation pattern of G12-6 
 
Appendix A Table 4 G12-6 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
255.3 341.41     128.15 171.2 87.11 128.15   214.1 212.24   85.1 → 57.07 
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Appendix A Figure 5.1 Fragmentation pattern of G12-8 
 
Appendix A Table 5 G12-8 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
269.3 369.4 201.1 199.2 156.1 185.2 101.1 156.1 310.3 214.2 212.2   85.1 → 57.07 
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Appendix A Figure 6.1 Fragmentation pattern of G12-10 
 
Appendix A Table 6 G12-10 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
283.3 397.4 229.2 227.2 184.2 199.2 115.1 184.2 352.4 214.2 212.2   85.1 → 57.07 
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Appendix A Figure 7.1 Fragmentation pattern of G12-12 
 
Appendix A Table 7 G12-12 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
297.3 425.4 257.3 255.2 212.2 213.2 129.1 212.2 380.4 214.2 212.2   85.1 → 57.07 
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Appendix A Figure 8.1 Fragmentation pattern of G12-16 
 
Appendix A Table 8 G12-16 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
325.3 481.5 313.3 311.3 268.3 241.2 157.1 268.3 436.4 214.2 212.2   85.1 → 57.07 
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Appendix A Figure 9.1 Fragmentation pattern of G16-3 
 
Appendix A Table 9 G16-3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4a 5 
290.3 355.4 131.1   86.1 178.2   86.1         85.1 → 57.07 
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Appendix A Figure 10.1 Fragmentation pattern of G16-6 
 
Appendix A Table 10 G16-6 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
311.41 379.34 173.42   128.19 199.21 87.03 128.19   270.33     85.1 → 57.07 
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Appendix A Figure 11.1 Fragmentation pattern of G16-7 
 
Appendix A Table 11 G16-7 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
318.39 411.34 187.36   144.57 206.25 94.03 144.57 352.43       85.1 → 57.07 
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Appendix A Figure 12.1 Fragmentation pattern of G18-3 
 
Appendix A Table 12 G18-3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
318.38 383.45 131.16   86.1 192.23   86.1         85.1 → 57.07 
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Appendix A Figure 13.1 Fragmentation pattern of G18-7 
 
Appendix A Table 13 G18-7 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
346.41 439.51 187.22   142.17 220.26 94.12 142.17 380.44 297.97     85.1 → 57.07 
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Appendix A Figure 14.1 Fragmentation pattern of G18:1-2 
 
Appendix A Table 14 G18:1-2 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
309.3 367.4     72.0     72.0       97.1→55.06   
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Appendix A Figure 15.1 Fragmentation pattern of G18:1-3 
 
Appendix A Table 15 G18:1-3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
316.35 381.43     86.1 191.35   86.1       97.1→55.06   
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Appendix A Figure 16.1 Fragmentation pattern of G18:1-6 
Appendix A Table 16 G18:1-6 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
337.38 423.48     128.15 212.25 211.24 128.15       97.1→55.06   
  
218 
 
  Ap
p
en
d
ix
 A
 F
ig
u
re 1
6
.2
 A
 M
S
/M
S
 sp
ectra o
f G
1
8
:1
-6
 p
ro
v
id
ed
 b
y
 an
 A
B
 S
ciex
 Q
S
T
A
R
 X
L
 q
T
o
F
-M
S
 
 
219 
 
G12-EO1
[M]
2+
2a
1a
1d/2c
CH3
CH2
+
CH3 CH2
+
CH3
CH2
+
5
1b
CH3 N
+
CH3
CH3
O
N
+
CH3
CH3
CH3
CH3 N
+
CH3
CH3
O
N
+
CH3
CH3 H
CH3 N
+
CH3
CH3
O
N
CH3
CH3
O
N
CH3
CH3
N
+
CH3
CH3
H
CH2 O
N
+
CH3
CH3 H
 
Appendix A Figure 17.1 Fragmentation pattern of G12-EO1 
 
Appendix A Table 17 G12-EO1 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
249.28 329.37 161.21   116.11 165.19   116.11         85.1 → 57.07 
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Appendix A Figure 18.1 Fragmentation pattern of G12-EO2 
 
Appendix A Table 18 G12-EO2 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
271.3 373.39 205.2   160.14 187.2 103.11 160.14 314.32       85.1 → 57.07 
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Appendix A Figure 19.1 Fragmentation pattern of G12-EO3 
 
Appendix A Table 19 G12-EO3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
293.31 417.42 249.23   204.16 209.22 125.12 204.16 346.35       85.1 → 57.07 
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Appendix A Figure 20.1 Fragmentation pattern of G12-4(OH) 
 
Appendix A Table 20 G12-4(OH) gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
249.29       116.11 165.19   116.11         85.1 → 57.07 
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Appendix A Figure 21.1 Fragmentation pattern of G12-4(OH)2 
 
Appendix A Table 21 G12-4(OH)2 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
257.28 345.23     132.11 173.19   132.11         85.1 → 57.07 
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Appendix A Figure 22.1 Fragmentation pattern of G12-2N 
 
Appendix A Table 22 G12-2N gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
255.8       129.14 171.71   129.14   214.26 212.25   85.1 → 57.07 
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Appendix A Figure 23.1 Fragmentation pattern of G12-3N 
 
Appendix A Table 23 G12-3N gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
269.72         185.72     284.32 214.26 212.25   85.1 → 57.07 
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Appendix A Figure 25.1 Fragmentation pattern of G12-3NH 
 
Appendix A Table 25 G12-3 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
262.82   188.23   143.17 178.72   143.17 271.32 214.27 212.25   85.1 → 57.07 
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Appendix A Figure 26.1 Fragmentation pattern of G12-2N2 
 
Appendix A Table 26 G12-2N2 gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
284.33 423.48     129.15 212.25   149.17         85.1 → 57.07 
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Appendix A Figure 27.1 Fragmentation pattern of G16-3NH 
Appendix A Table 27 G16-3NH gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
318.87 412.47 188.22   143.17 206.74   143.17 327.38 270.32     85.1 → 57.07 
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 Appendix A Figure 28.1 Fragmentation pattern of G18-3NH 
 
Appendix A Table 28 G18-3NH gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
346.89 439.5 188.21   143.15 220.74   143.15 397.45 297.96     85.1 → 57.07 
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Appendix A Figure 29.1 Fragmentation pattern of G18:1-3NH 
 
Appendix A Table 29 G18:1-3NH gemini surfactant fragment ions (m/z) 
[M]
2+
 1a 1b 1c 1d 2a 2b 2c 3a 3b 3c 4 5 
344.88 438.5 188.21   143.15 219.74   143.15 395.44 295.33   97.1→55.06   
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APPENDIX B 
Liquid chromatography method development 
 
 
50 ul 3 mM G12-3 Electrospray +, 95:5 MeOH:H2O w 0.1% TFA flow 0.15 ml/min, Allsphere ODS-2 , Cap 3.5, Cone 30, Temp 14
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Appendix B Figure 1 Analysis of 100 µM G16-3 on an Alltech Allsphere C18 (150x2.1 mm, 3 
µ) (A) following a 50 µL loop-injection  and gradient LC analysis (B) 
A 
B 
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Cone 30, Corona 3, Source 140, APCI 550, C4-2 5u column, Gradient of ACN (15-100%) over 30 minutes, 25 ul G3&G4
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Time0
100
%
SEPT 14 G4 AND G3 GRADIENT Scan AP+ 
255
8.01e7
15.65
446
214
14.91
425
214
16.84
480
482
17.82
508
214
17.96
512
214
18.41
525
214
19.25
549
214
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 5 10 15 20 25 30 
P
er
ce
n
ta
g
e 
o
f 
M
o
b
il
e 
P
h
a
se
 (
%
) 
Time (minutes) 
Millipore Water containing 0.1% Formic Acid 
Methanol containing 0.1% Formic Acid 
A 
B 
Appendix B Figure 2 Analysis of 100 µM G16-3 on an Vydac 214 TP C4 (50x4.6 mm, 5 µ) 
(A) following a 50 µL loop-injection  and gradient LC analysis (B) 
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Cone 30, Cap 3.50, Source 140, C4 column 50 uL G12-8 injected through injector using a 95 ACN
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Appendix B Figure 3 Analysis of 100 µM G16-3 on an Phenomenex Luna CN (240x4.6 mm, 
5 µ) (A) following a 50 µL loop-injection and gradient LC analysis (B) 
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Appendix B Figure 4 Analysis of 100 µM G16-3 on an Aglient Eclipse CN column (100 x 2.1 
mm with 3, 5 µ) (A) following a 10 µL loop-injection and gradient LC analysis (B) 
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APPENDIX C 
Development of a liquid:liquid extraction method for G16-3 
 
 
 
 
Appendix Figure C.2 FC-LR-MS/MS analysis of 0.500 µM concentration of G16-3 (m/z 
290  86 [blue] & 355 [red]) following an octanol liquid:liquid extraction from PAM212 
cell lysate. A 200 µL sample of PAM212 cell lysate was vortexed with 200 µL of octanol 
and 7.5 µL of the octanol phase was in analyzed using the FC-LR-MS/MS method. 
Appendix Figure C.1 FC-LR-MS/MS analysis of 0.500 µM concentration of G16-3 (m/z 
290  86 [blue] & 355 [red]) following a methanol protein precipitation from PAM212 
cell lysate. A 200 µL sample of PAM212 cell lysate was vortexed with 200 µL of methanol 
and 7.5 µL of the solution was in analyzed using the FC-LR-MS/MS method. 
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Appendix Figure C.4 FC-LR-MS/MS analysis of 0.500 µM concentration of G16-3 (m/z 
290  86 [blue] & 355 [red]) following a toluene liquid:liquid extraction from PAM212 
cell lysate. A 200 µL sample of PAM212 cell lysate was vortexed with 200 µL of tolune. A 
175 µL volume of the toluene phase was removed, dried down under nitrogen gas, 
reconstituted in 175 µL of methanol and 7.5 µL of the methanol phase was analyzed. 
Appendix Figure C.3 FC-LR-MS/MS analysis of 0.500 µM concentration of G16-3 (m/z 
290  86 [blue] & 355 [red]) following a hexane liquid:liquid extraction from PAM212 
cell lysate. A 200 µL sample of PAM212 cell lysate was vortexed with 200 µL of hexane. 
A 175 µL volume of the hexane phase was removed, dried down under nitrogen gas, 
reconstituted in 175 µL of methanol and 7.5 µL of the methanol phase was analyzed. 
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APPENDIX D 
Supplemental figures for chapter 5 
  
 
Millipore Water Containing 0.1% Formic 
Acid 
Methanol Containing 0.1% Formic Acid Appendix D Figure 1 Chromatographic conditions utilized for the FC-HR(LR)-MS(/MS) 
analysis of diquaternary ammonium gemini surfactants, G16-3 and G16D66-3  
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Appendix D Figure 2 Regions of the Thermo Scientific Orbitrap mass 
spectra that highlight the m/z distribution of G16-3 (A) and G16D66-3 
(B). Extracted ion chromatographs were obtained for G16-3 by selecting 
m/z of 290.331 (A) and G16D66-3 by selecting m/z of 323.538 (B). 
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Appendix D Figure 3 Fragmentation of G16D66-3 (323.589 m/z) into two ions of 343.554 m/z and 
301.507 m/z during MALDI-MS analysis. No precursor ion was observed at the expected m/z 
value for G16D66-3 ([M]2+ = m/z 323.54) 
252 
 
 
Appendix D Figure 4 During FC-LR-MS/MS analysis a low level of interference was 
observed within the PAM212 cell lysate for both G16-3 and G16D66-3 (A). The internal 
standard G16D66-3 did not interfere with the analysis of G16-3 (B). Representative 
chromatographs of the LLOQ (C), LCQ (D), MCQ (E) and HLOQ (F) peaks.  
253 
 
Appendix D Figure 5 Observed interference for both G16-3 ([M]2+ = m/z 290.33) and G16D66-3 
([M]2+ = m/z 323.54) during FC-HR-MS analysis within the PAM212 cell lysate (A).The 
internal standard G16D66-3 did not interfere with FC-MS analysis of G16-3 (B). Representative 
chromatographs of the LLOQ (C), LCQ (D), MCQ (E) and HLOQ (F) peaks.  
254 
 
Appendix D Figure 6 During DESI-LR-MS/MS analysis no interference was observed within 
the PAM212 cell lysate for either G16-3 and G16D66-3 (A). The internal standard G16D66-3 did 
not interfere with the analysis of G16-3 (B). Representative chromatographs of the LLOQ (C), 
LCQ (D), MCQ (E) and HLOQ (F) peaks.  
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Appendix D Figure 7 MALDI-HR-MS analysis of G16-3 and G16D66-3 saw no interference 
being observed within the PAM212 cell lysate for the double blank samples. The internal 
standard G16D66-3 did not interfere with the analysis of G16-3 within the blank sample. 
Representative chromatographs of the LLOQ, LCQ, MCQ and HLOQ spectrum peaks which 
exhibited smooth peak shape and isolation from neighboring peaks.  
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Appendix D Figure 8 Linear range of G16-3 within PAM212 cell lysate was assessed to be 
between 0.037-37.5 μM for FC-LR-MS/MS using a QTRAP 4000 instrument (G).  
y = 0.0106x + 0.0102 
R² = 0.9997 
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Appendix D Figure 9 Linear range of G16-3 within PAM212 cell lysate was assessed to be 
between 1.0000-500.00 μM for FC-HR-MS using an LTQ Orbitrap instrument (G). 
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Appendix D Figure 10 Linear range of G16-3 within PAM212 cell lysate was assessed to be 
between 1.000-2000 μM for DESI-LR-MS/MS using a LCQ Fleet Ion Trap MSn (G).  
Appendix D Figure 11 Linear range of G16-3 within PAM212 cell lysate was assessed to be 
between 0.037-37.5 μM for MALDI-HR-MS using a AB Sciex MALDI-ToFToF 4800 
instrument.  
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APPENDIX E 
Supplemental table for chapter 5 
 
Appendix E Table 1 Intra-day Assay of Precision and Accuracy for G16-3 using FC-LR-
MS/MS in PAM212 Cell Lysate [6 replicates for each analysis day at each concentration] 
Quality Control Analysis Day 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 1 0.0405 ± 0.0099 109.6 18.0 
 
2 0.0387 ± 0.0062 104.5 11.9 
 
3 0.0409 ± 0.0018 109.1 2.6 
LQC 1 0.986 ± 0.056 98.2 5.6 
 
2 1.02 ± 0.018 102.1 1.6 
 
3 0.983 ± 0.057 98.0 5.8 
MQC 1 10.2 ± 0.7 101.6 6.5 
 
2 10.9 ± 0.2 108.9 1.9 
 
3 10.1 ± 0.6 100.7 5.6 
LQC 1 38.1 ± 2.2 95.6 5.7 
 
2 39.7 ± 0.5 98.8 1.5 
 
3 38.7 ± 1.9 96.7 4.8 
 
Appendix E Table 2 Inter-day Assay of Precision and Accuracy for G16-3 using FC-LR-
MS/MS in PAM212 Cell Lysate [18 replicates at each concentration] 
Quality Control 
 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 
 
0.0399 ± 0.0054 107.8 10.8 
LQC 
 
0.998 ± 0.043 99.4 4.4 
MQC 
 
10.4 ± 0.5 103.7 4.7 
HQC 
 
38.9 ± 1.5 96.9 4.0 
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Appendix E Table 3 Intra-day Assay of Precision and Accuracy for G16-3 using FC-HR-MS 
in PAM212 Cell Lysate [6 replicates for each analysis day at each concentration] 
Quality Control Analysis Day 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 1 1.08 ± 0.096 89.7 8.9 
 
2 1.05 ± 0.145 104.6 13.9 
 
3 1.11 ± 0.063 110.7 5.7 
LQC 1 2.56 ± 0.11 102.3 4.5 
 
2 2.69 ± 0.30 107.5 11.5 
 
3 2.68 ± 0.21 107.3 7.8 
MQC 1 53.2 ± 1.3 106.4 2.4 
 
2 53.9 ± 1.2 107.7 2.3 
 
3 53.7 ± 2.2 107.3 4.1 
LQC 1 393 ± 21 98.3 5.3 
 
2 356 ± 27 89.0 7.6 
 
3 409 ± 16 102.2 4.0 
 
 
 
Supplemental Table 4 - Inter-day Assay of Precision and Accuracy for G16-3 using FC-HR-
MS in PAM212 Cell Lysate [18 replicates at each concentration] 
Quality Control 
 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 
 
1.08 ± 0.10 101.7 9.5 
LQC 
 
2.64 ± 0.21 105.7 7.9 
MQC 
 
53.6 ± 1.6 107.1 2.9 
HQC 
 
386 ± 21 96.5 5.6 
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Appendix E Table 5 Intra-day Assay of Precision and Accuracy for G16-3 using DESI-LR-
MS/MS in PAM212 Cell Lysate [6 replicates for each analysis day at each concentration] 
Quality Control Analysis Day 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 1 1.09 ± 0.20 108.8 17.9 
 
2 1.02 ± 0.11 102.3 10.7 
 
3 1.01 ± 0.18 97.3 18.2 
LQC 1 7.33 ± 0.73 97.8 9.9 
 
2 7.60 ± 0.57 96.6 7.4 
 
3 8.05 ± 1.08 110.3 13.4 
MQC 1 103 ± 5 103.0 4.3 
 
2 92.1 ± 13.2 92.1 14.4 
 
3 109 ± 7 108.7 6.7 
LQC 1 183 ± 19 101.7 10.1 
 
2 177 ± 6 88.5 3.6 
 
3 180 ± 8 99.0 4.6 
 
 
 
Appendix E Table 6 Inter-day Assay of Precision and Accuracy for G16-3 using DESI-LR-
MS/MS in PAM212 Cell Lysate [18 replicates at each concentration] 
Quality Control 
 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 
 
1.04 ± 0.17 102.8 15.6 
LQC 
 
7.66 ± 0.75 101.6 10.2 
MQC 
 
101 ± 10 101.5 8.5 
HQC 
 
180 ± 11 96.4 6.1 
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Appendix E Table 7 Intra-day Assay of Precision and Accuracy for G16-3 using MALDI-HR-
MS in PAM212 Cell Lysate [6 replicates for each analysis day at each concentration] 
Quality Control Analysis Day 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 1 0.445 ± 0.031 111.2 7.1 
 
2 0.395 ± 0.023 98.5 5.9 
 
3 0.410 ± 0.075 100.8 18.5 
LQC 1 27.5 ± 1.0 98.9 3.5 
 
2 26.7 ± 3.2 97.1 12.1 
 
3 30.7 ± 2.1 111.5 6.7 
MQC 1 150 ± 6 100.0 4.1 
 
2 153 ± 10. 85.4 6.5 
 
3 146 ± 6 97.6 4.2 
LQC 1 382 ± 21 99.4 5.6 
 
2 395 ± 19 97.4 4.7 
 
3 411 ± 21 107.0 5.2 
 
 
 
Appendix E Table 6 Inter-day Assay of Precision and Accuracy for G16-3 using MALDI-HR-
MS in PAM212 Cell Lysate [18 replicates at each concentration] 
Quality Control 
 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
LLQC 
 
0.414 ± 0.035 103.5 10.5 
LQC 
 
28.3 ± 2.1 102.5 7.5 
MQC 
 
150. ± 7 94.4 4.9 
HQC 
 
396 ± 21 101.3 5.2 
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Appendix E Table 9 Precision and Accuracy for 24 Hour Stability Assay (25 °C) of G16-3 in 
PAM212 Cell Lysate [6 replicates at each concentration] 
Quality Control Analysis Type 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
FC-LR-MS/MS LQC 1.07 ± 0.14 106.4 13.0 
 
MQC 10.6 ± 0.6 105.2 5.3 
 
HQC 37.8 ± 0.7 94.4 2.1 
FC-HR-MS LQC 2.34 ± 0.17 93.7 7.3 
 
MQC 53.1 ± 0.1 106.2 1.1 
 
HQC 406 ± 20 101.4 4.8 
DESI-LR-MS/MS LQC 8.06 ± 0.60 107.5 7.4 
 
MQC 96.5 ± 3.6 96.5 3.8 
 
HQC 184 ± 18 102.4 9.7 
MALDI-HR-MS LQC 27.3 ± 1.7 99.2 6.4 
 
MQC 144 ± 8 95.8 5.5 
 
HQC 374 ± 4 97.4 1.1 
 
 
 
Appendix E Table 10 Precision and Accuracy for 24 Hour Stability Assay (4 °C) of G16-3 in 
PAM212 Cell Lysate [6 replicates at each concentration] 
Quality Control Analysis Type 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
FC-HR-MS LQC 2.40 ± 0.21 96.2 8.8 
 
MQC 53.3 ± 2.3 106.6 4.3 
 
HQC 424 ± 14 105.9 3.4 
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Appendix E Table 11 Precision and Accuracy for Freeze Thaw Stability Assay of G16-3 in 
PAM212 Cell Lysate [6 replicates at each concentration] 
Quality Control Analysis Type 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
FC-LR-MS/MS LQC 1.15 ± 0.11 114.2 9.4 
 
MQC 10.9 ± 0.2 109 2 
 
HQC 38.9 ± 0.8 97.1 2 
FC-HR-MS LQC 2.60 ± 0.07 104.1 2.9 
 
MQC 53.5 ± 1.3 106.9 2.5 
 
HQC 380. ± 16 95.1 4.3 
DESI-LR-MS/MS LQC 7.36 ± 0.61 91.6 8.2 
 
MQC 95.5 ± 11.6 95.5 12.2 
 
HQC 175 ± 12 97.2 7 
MALDI-HR-MS LQC 26.2 ± 3.4 97.9 12.8 
 
MQC 142 ± 2.2 96.6 1.5 
 
HQC 384 ± 5.3 100.0 1.4 
 
 
 
Appendix E Table 12 Precision and Accuracy for 60 Day Stability (-20 °C) Assay of G16-3 in 
PAM212 Cell Lysate [6 replicates at each concentration]          
Quality Control Analysis Type 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
FC-LR-MS/MS LQC 1.01 ± 0.02 100.2 2.2 
 
MQC 10.1 ± 0.3 101 2.8 
 
HQC 41.3 ± 1.2 103.1 3 
FC-HR-MS LQC 2.53 ± 0.15 101.3 5.8 
 
MQC 52.1 ± 1.0 104.2 1.8 
 
HQC 395 ± 15 95.7 3.9 
DESI-LR-MS/MS LQC 7.21 ± 0.34 96.1 4.7 
 
MQC 106 ± 5 102.9 4.3 
 
HQC 182 ± 8 101 4.4 
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Appendix E Table 13 Precision and Accuracy for 60 Day Stability (25 °C) Assay of G16-3 in 
PAM212 Cell Lysate [6 replicates at each concentration]    
Quality Control Analysis Type 
Observed Concentration 
(mean±SD, µM) 
Accuracy Precision 
FC-LR-MS/MS LQC 1.09 ± .14 108.7 9.6 
 
MQC 10.8 ± 0.9 106.7 7.6 
 
HQC 39.2 ± 2.0 97.9 5.1 
MALDI-HR-MS LQC 27.3 ± 1.4 99.2 5.2 
 
MQC 148 ± 5 98.4 3.4 
 
HQC 410. ± 18 106.69 4.5 
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APPENDIX F 
Evaluation of fast liquid chromatography High-field asymmetric waveform ion mobility 
spectrometry tandem mass spectrometry for the quantification of G16-3 
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Appendix F Figure 1 Optimization of ESI and MS/MS parameters for G16-3 on a Thermo 
Scientific TSQ Quantum MS instrument resulted in a spray needle voltage of +5 V and collision 
energies of 5 V (m/z 290  m/z 355) and 16 V (m/z 290  m/z 86) 
266 
 
Optimized Compensation Voltage
 -60  -48  -36  -24  -12  0
 Compensation Voltage Value (V)
 0
 20
 40
 60
 80
 100
N
or
m
al
iz
ed
 In
te
ns
ity
  m/z 290.3   Optimum Setting = -51.3   Intensity = 10034475
  m/z 290.3   Optimum Setting = -50.1   Intensity = 3211461
Appendix F Figure 2 Optimization of FAIMS parameters for the analysis of G16-3 on a FAIMS 
Thermo Scientific TSQ Quantum MS instrument applied a dispersion voltage of -5000V and 
spray voltage of 4000V  in an environment of 50% helium; no dopant was utilized. 
Compensation voltages were assessed as -51 V (m/z 290  m/z 355) and -50 V (m/z 290  m/z 
86) 
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Appendix F Figure 3 Optimization of FAIMS parameters for the analysis of G16-3 on a FAIMS 
Thermo Scientific TSQ Quantum MS instrument applied a dispersion voltage of -5000V and 
spray voltage of 4200V in an environment of 50% helium; no dopant was utilized. 
Compensation voltages were assessed as -51 V (m/z 290  m/z 355) and -50 V (m/z 290  m/z 
86) 
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Appendix F Figure 4 A comparison of FC-LR-MS/MS and FC-FAIMS-LR-MS/MS analysis of 
blank PAM212 cellular lysate. The profiles and intensities of the chromatographs for both FC-
LR-MS/MS and FC-FAIMS-LR-MS/MS are similar to one another. 
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Appendix F Figure 4 A comparison of FC-LR-MS/MS and FC-FAIMS-LR-MS/MS analysis of 
PAM212 cellular lysate spiked with 200 µM G16-3. The profiles and intensities of the 
chromatographs for both FC-LR-MS/MS and FC-FAIMS-LR-MS/MS are similar to one 
another. 
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Appendix F Figure 4 A comparison of FC-LR-MS/MS and FC-FAIMS-LR-MS/MS analysis of 
PAM212 cellular lysate spiked with 200 nM G16-3. The profiles and intensities of the 
chromatographs for both FC-LR-MS/MS and FC-FAIMS-LR-MS/MS are similar to one 
another. 
